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Subarachnoid hemorrhage (SAH) stroke is associated with high rates of morbidity and mortality.  
One of the major complications of SAH is the development of delayed cerebral ischemia (DCI) 
due to vasospasm of the cerebrovasculature that typically occurs days after the hemorrhage.  
Currently, there are no established prognostic indicators of DCI and long-term outcomes in SAH 
patients.  20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs) are 
eicosanoids formed from the oxidation of arachidonic acid by cytochrome P450 (CYP) enzymes.  
20-HETE constricts cerebral arteries and contributes to cerebral ischemic injury after SAH. 
Conversely, EETs dilate the cerebrovasculature and attenuate cerebral ischemic injury.  EETs 
biological action is regulated by its metabolism to inactive DHETs.  Human polymorphisms in 
CYP eicosanoid biosynthesis/metabolism genes are reported to alter enzyme function in vitro/in 
vivo.  Thus, we hypothesized that polymorphisms in genes involved in CYP eicosanoid 
biosynthesis and metabolism will lead to increased 20-HETE or decreased EET concentrations in 
CSF resulting in the development of ischemic complications and unfavorable long-term 
functional outcomes in 363 patients with SAH.  Patients were genotyped and CYP-eicosanoid 
CSF levels were measured over 14 days after hemorrhage.  Acute outcomes assessed included 
delayed cerebral ischemia (DCI) and clinical neurological deterioration (CND) over 14 days.  
Modified Rankin Score (MRS) at 3 and 12 months were obtained for long-term outcome 
assessment. Multivariate analysis controlled for age, sex, race, and Fisher grade or Hunt & Hess 
score.  Patients with CND and unfavorable 3-month MRS had ~2.2- and 2.7-fold higher mean 
20-HETE CSF levels, respectively. Patients in high/moderate 20-HETE trajectory groups 
(35.7%) were 2.1-, 2.5-, and 2.1-fold more likely to have CND and unfavorable MRS at 3 and 12 
months.  CYP2C8*4 allele-carriers had 44% and 36% lower mean EET and DHET CSF levels 
and were 2.2- and 2.5-fold more likely to develop DCI and CND, respectively.  Multiple loss-of-
function SNPs were associated with lower CYP eicosanoid CSF levels and altered risk for 
unfavorable outcomes.  Several CYP4F2 genotype frequencies differed from Hapmap database 
indicating putative genetic markers for SAH risk.  These are the first clinical data demonstrating 
an association between genetic polymorphisms, CYP eicosanoid CSF levels, and outcomes in 
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1.1 SUBARACHNOID HEMORRHAGE (SAH) 
1.1.1 Background on stroke and SAH 
This section provides a brief discussion on the background of stroke, classification of stroke 
subtypes, brief history of hemorrhagic stroke, etiology of subarachnoid hemorrhage (SAH), and 
incidence of SAH. 
 
1.1.1.1 Background on stroke:  Stroke is a condition caused by an interruption in blood flow to 
the brain that leads to a lack of nutrients and oxygen resulting in injury to the cells in the affected 
vascular territory of the brain.  When brain cells die, function of the body parts they control is 
impaired or lost causing speech and sensory problems, memory and reasoning deficits, paralysis, 
coma, and death.1  Each year in the United States (US), approximately 795,000 people experience 
a stroke with 23% of those cases found to be recurrent strokes.2  Surprisingly, this translates to a 
stroke occurring on average every 40 seconds in the US.2  Moreover, the prevalence of stroke in 
the US from 2007-2010 was 2.8% affecting an estimated 6.8 million Americans ≥20 years of age.2  
When considered separately from cardiovascular disease (CVD), stroke ranks as the fourth leading 
cause of death in the US behind heart disease, cancer, and chronic lower respiratory diseases.2, 3  
In the United States, stroke accounts for 1 of every 19 deaths and stroke related death are estimated 
to occur every 4 minutes on average.2  Also, stroke is a leading cause of serious long-term disability 
in the US and is associated with direct and indirect costs of $38.6 billion each year.2   
1.1.1.2 Stroke subtypes:  Stroke is typically classified into major subtypes based on its etiology.  
Strokes caused by occlusion of a blood vessel are referred to as “ischemic” while those caused by 
the rupture of a blood vessel are referred to as “hemorrhagic”.  Hemorrhagic strokes are further 
classified into intracerebral hemorrhage, which is characterized by bleeds in the brain parenchyma, 
and SAH, which is characterized by bleeds into the subarachnoid cavity between the arachnoid 
membrane and pia matter. Ischemic strokes are the most common type accounting for 87% of all 
strokes with the remaining 10% and 3% of strokes accounted for by intracranial hemorrhage and 
subarachnoid hemorrhage (SAH), respectively.2, 4  Although hemorrhagic strokes are less common 
than ischemic strokes, the mortality rates and cost associated with hemorrhagic stroke are much 
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higher.  For example, the 30-day mortality rate was recently reported to be 8-12% in ischemic 
stroke and 37-44% in hemorrhagic stroke.2  Furthermore, SAH accounts for 25% of all fatalities 
related to stroke5 and 25% of potential years lost to life due to stroke6.  A study of stroke patients 
in the US in 1990 reported a lifetime cost of $91,000 for ischemic stroke, $124,000 for 
intracerebral hemorrhage, and $228,000 for subarachnoid hemorrhage.7  Based on the high 
mortality rates and costs associated with SAH, it has been the focus of many clinical studies and 
reviews in recent years. 
1.1.1.3 Brief history of hemorrhagic stroke:  A brief description of some key historical events 
in the diagnosis and treatment of SAH has been previously described.8  Amazingly, ancient 
Egyptian writings provide the first known documentation of an intracranial aneurysm (IA).8  Many 
years later in 1679, there was a documented association of IAs and cerebral hemorrhages.9  In the 
1760s, the first documented report of an unruptured IA was published10 and IAs were suggested 
to be the source of cerebral hemorrhages11.  The first documented account of an IA rupture was 
noted in 181412 and the first description of neurological deterioration occurring days after a stroke 
was published in 1859.13  Autopsy of this patient showed a ruptured middle cerebral artery which 
was suggested to be the cause of the stroke and subsequent neurological symptoms.13  In the 1930s, 
clinical angiograms were developed which aided in the diagnosis and treatment of hemorrhagic 
stroke.14 Also, the direct treatment of aneurysms using surgical methods such as clip repair was 
performed.15  In the 1940s, ruptured IAs were associated with cerebral infarction.16   
Since the 1950s, many of the major accomplishments in the diagnosis and treatment of 
SAH have focused on neurovascular complications and their relationship to outcomes.  Prior to 
1950, the first description of cerebral vasospasm was made in 1925 after rabbit cortical arties were 
observed to contract after mechanical stimulation.17  In the 1940s, blood breakdown products were 
proposed as vasoactive agents in the brain.18, 19  In the 1950s, cerebral vasospasm in SAH patients 
was determined by cerebral angiograms.20, 21  In the 1960s, angiographic vasospasm was associated 
with ischemic lesions, worse outcomes, and reduced cerebral blood flow (CBF).22, 23  Also, it was 
proposed to delay the timing of surgical treatment in order to reduce the risk of vasospasm that 
was observed in the first 10 days after SAH.24  However, larger studies published in 1976 indicated 
a reduced risk of vasospasm and mortality in patients undergoing surgery within 48 hours.25  In 
addition, serial angiograms showed that the onset, peak, and subsidence of vasospasm occurred 3, 
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6 to 8, and 12 days after SAH, respectively, and that mortality was related to the presence and 
severity of vasospasm.26  Katada et al.27 and Taemae et al.28 published the first association between 
the size of the blood clot and the incidence of angiographic vasospasm in the late 1970s.   In 1980, 
the Fisher et al. proposed a formal classification of SAH based on the size and location of blood 
after noting that severe angiographic vasospasm was almost invariably present in patients with 
subarachnoid clots larger than 5 × 3 mm or layers of blood ≥1 mm in vertical cisterns and fissures.29  
Subsequent studies confirmed these findings and determined that thick subarachnoid clot 
completely filling any cistern/fissure was an independent predictor of delayed ischemic 
neurological deficits (DIND).30  Thus, many of the major accomplishments in the diagnosis and 
treatment of SAH in the second half of the 20th century have focused on neurovascular 
complications and their relationship to outcomes.   
1.1.1.4 Etiology of SAH:  SAH can be classified into three major groups based on its etiology, 
which is usually determined by the pattern of blood on a computed tomography (CT) scan or other 
imaging technology.  Previous studies have reported that 75% of SAH cases are due to ruptured 
IA.31  The exact means by which IAs form and rupture is unknown, but hypertension and smoking-
induced vascular changes are thought to play a major role.32  IAs commonly occur at the 
bifurcation of the cerebral arteries at the base of the brain which implies a hemodynamic effect to 
the vessel wall.32  More specifically, the incidence of IAs are highest on the anterior 
communicating artery (30%), posterior communicating artery (25%), middle cerebral artery 
(20%), internal carotid artery (7.5%), vertebrobasilar tip (7%), and other locations (10.5%).33  
Histological studies of intracranial arteries commonly report structural defects in the vasculature, 
such as a thin tunica media and internal elastic membrane, which may account for their 
susceptibility to formation from shear stress.32  Fortunately, most IA are small and an estimated 
50-80% of IA do not rupture during a person’s lifetime.33  The rate of rupture of IAs depends on 
multiple factors including the location, size, morphology, and previous history of SAH.34, 35  No 
identifiable cause is determined in about 20% of SAH cases, which are often classified as 
idiopathic (spontaneous) or perimesencephalic.5  Perimesencephalic SAH is characterized by 
blood which is confined to the cisterns around the midbrain and is rarely due to ruptured 
aneurysms.36, 37  Also, perimesencephalic SAH typically follows a relatively benign clinical course 
with the major complication being hydrocephalus.37  The remaining 5% of SAH cases are due to 
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other causes such as arterio-venous malformations of the brain or spine, mycotic aneurysm, 
intracranial arterial dissection, cerebral trauma, tumors, bleeding diseases, and sympathomimetic 
drugs.5, 31  In summary, most SAH cases are due to a ruptured IA in the arteries at the base of the 
brain. For the purpose of simplicity, the term SAH will refer to aneurysmal SAH in the remainder 
of this document.   
 
Figure 1-1: SAH etiology 
 
1.1.1.5 Incidence of SAH:  In the US, SAH accounts for 3-5% of all strokes and affects 
approximately 10-15 per 100,000 or approximately 30,000 people each year.38-41  Because an 
estimated 12-15% of individuals that suffer from SAH die before hospital admission, the true 
incidence of SAH may even be higher.42, 43  A number of studies have reported that the incidence 
of SAH worldwide has not changed significantly over the past 40 years.44-48  However, a recent 
study reports a slight decrease in the incidence of SAH in regions other than Japan, South and 
Central America, and Finland from 1950 to 2005.49  Thus, despite medical advances over the past 
40 years, the incidence of SAH remains relatively constant and continues to be a major cause of 
stroke worldwide.    
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1.1.2 Risk factors for intracranial aneurysms and SAH 
This section highlights the risk factors for IAs and SAH including modifiable and non-modifiable 
risk factors and includes a discussion of genetic disorders and genes associated with the 
pathogenesis of IAs and SAH.  The end of this section includes a table which summarizes these 
risk factors (Table 1-1: Risk factors for intracranial aneurysm/SAH). 
 
1.1.2.1 Non-modifiable risk factors:  There are multiple risk factors associated with SAH, but 
many are not modifiable.  For example, the incidence of SAH is most common in age 40-60 
(median ≥50) and increases with age.50  Also, the risk of SAH is 1.4 to 1.6-fold higher in women 
than men.49, 51  This sex difference may be attributed to hormonal factors as some studies have 
reported a lower risk for SAH with pre-menopausal women52-55 and older age at onset of menarche 
or at birth of first child56.  Interestingly, some studies suggest that the incidence of SAH is 
influenced by seasonal effects with higher risk of SAH in winter57 and spring58, but conflicting 
results are reported59. Furthermore, race and regional differences are suggested to have a major 
impact on the risk for SAH.  In the United States, Black Americans are at higher risk than white 
Americans.60  Likewise, Maori and Pacific people are at higher risk than white New Zealanders.61  
Worldwide, the age-adjusted annual incidence of SAH varies 10-fold between different 
countries.62  For instance, the incidence of SAH in China and Finland was reported as 2.0 and 22.5 
cases per 100,000 individuals, respectively.62  In addition, the age-adjusted incidence rate of SAH 
in low- to middle-income countries was found to be almost double that of high-income countries.44  
These data indicate that older age, female sex, seasonal factors, regional differences, race/ethnicity, 
and economic factors are considered non-modifiable risk factors for SAH.   
1.1.2.3 Familial history:  Another important risk factor for SAH is previous or familial history of 
ruptured or unruptured IA.  Although the presence of an unruptured IA is relatively common 
occurring in 1-6% of the adult population63-65, a greater incidence of IA is reported in families of 
individuals with ruptured or unruptured IA.  To illustrate, four epidemiological studies of familial 
IAs reveal that 7-20% of SAH patients had 1st or 2nd degree relatives with IA.66-70  In individuals 
with ruptured or unruptured IA, the frequency of IA in 1st degree relatives was almost 5-times 
higher than observed in controls.69  In addition, multiple IA are observed in about 25% of 
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individuals with SAH and the formation rate of new aneurysms is reported to be 1-2% per year.71-
77  In addition to presenting an increased risk for IA, previous or familial history of ruptured or 
unruptured IA increase the risk for SAH as well.  For example, SAH patients were almost twice 
as likely to have a 1st degree relative affected by SAH compared to controls.78  Likewise, the 
incidence of SAH in 1st degree relatives of SAH patients is 4-fold higher than the expected 
incidence of SAH in the same population.79  Furthermore, studies suggest that 1st degree relatives 
of SAH patients are at a 3 to 7-fold higher risk for SAH compared to 2nd degree relatives.79  These 
studies suggest there is a higher risk of SAH in individuals with previous or familial history of 
ruptured or unruptured IA, yet screening and surgical treatment of unruptured aneurysms in this 
population remains controversial.51, 80 
1.1.2.3 Rare genetic disorders:  In additional to familial risk factors, certain rare inherited genetic 
disorders have been previously associated with SAH.  Schievink81 and others82, 83 provide excellent 
reviews on this topic and focus on disorders involved connective tissue and structural support of 
the vasculature such as Autosomal Dominant Polycystic Kidney Disease (ADPKD)84, Ehlers-
Danlos syndrome Type IV85, Marfan syndrome86, Pseudoxantoma Elasticum87, and 
Neurofibromatosis88.  To illustrate, ADPKD results from a mutation in one of the polycystin genes 
(PKD1 and PKD2) which are integral membrane spanning proteins involved in interactions with 
the extracellular matrix.89  The disease is characterized by renal cysts, renal failure and vascular 
pathology.90  Moreover, individuals with ADPKD show a 4- and 5-fold greater risk of IAs and 
SAH, respectively,91 and the average age of SAH in this group is 41 years, a decade earlier than 
sporadic cases.92-94  However, a risk-benefit analysis failed to show any benefit of screening and 
treatment of unruptured aneurysms in ADPKD patients.90  These findings suggests that connective 
tissue disorders and other rare genetic disorders affecting the cerebral vasculature may play an 
important role in the formation and rupture of IAs, but the identification, screening, and treatment 
of these patients may have limited clinical utility in reducing the risk for SAH.   
1.1.2.4 Candidate genes:  Based on the previously established heritable risk factors for IA and 
SAH, many studies investigated the relationship between genetics and IA.  Linkage studies of 
families with IA have failed to identify any genetic modes of transmission and suggest that the 
genetics of IA are complex involving multiple genes.95  Nevertheless, these linkage analyses in 
combination with genome wide association studies (GWAS) and candidate gene association 
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studies have identified multiple chromosomal regions that may contain one or more susceptibility 
genes for IA.83  Candidate genes identified thus far are involved in diverse biological processes 
such as inflammation, structural support, remodeling of the extracellular matrix, regulation of 
blood pressure, and lipid metabolism.  For example, collagen and elastin provide much of the 
content of the vascular extracellular matrix and contribute to the structural integrity and elasticity 
of the vessels.96, 97  Endoglin is a glycoprotein highly expressed on endothelial surfaces and serves 
an important role in the formation of blood vessels.98  Also, matrix metallopeptidase-9 (MMP-9) 
is involved in the breakdown of extracellular matrices in various tissues.99  Together, these proteins 
play an important role in the formation and maintenance of the cerebral vasculature.  By the same 
token, genetic studies have reported an association between the IA formation and polymorphisms 
in collagen type I (COL1A2)100, collagen type III (COL3A1)101, elastin (ELN)95, 102, endoglin 
(ENG)103, and MMP-9104 genes.  Similarly, endothelial nitric oxide synthase (eNOS) and 
angiotensin converting enzyme (ACE) play an important role in regulating blood pressure and 
vascular reactivity and have been associated with the incidence of IA in multiple studies.105-110  
Likewise, polymorphisms in genes involved in inflammation, such as interleukin 1- (IL-1)111, 
-1 antichymotrypsin (SERPINA3)112, and heme oxygenase 1 (HO-1)113, have been associated 
with IA.  Also, lipid metabolism genes such apolipoprotein A (APOA) have been identified as 
candidate genes for IA.114  Although multiple IA candidate genes have been identified, many of 
the genetic markers were not further studied or the findings could not be replicated in the same or 
different populations.83  Furthermore, many of these studies involved patients with unruptured IA 
and not SAH.  Thus, there are currently no genetic markers that identify an increased risk for SAH 
in diverse populations.   
1.1.2.5 Modifiable risk factors:  On the other hand, there are multiple potentially modifiable risk 
factors associated with SAH.  CVDs, such as hypertension53-55, 115, 116 and cerebrovascular 
disease53-55, but not diabetes117, are associated with increased risk for SAH.  In addition, SAH has 
been associated with smoking and heavy alcohol use115, 116  Some studies suggest that the use of 
sympathomimetic drugs including phenylpropanolamine118 and cocaine119, 120 increase the risk for 
SAH, especially in younger patients120.  Furthermore, some dietary factors have been proposed as 
SAH risk factors.  For instance, greater vegetable consumption121 and yogurt122 are associated with 
decreased and increased risk for SAH, respectively, while high consumption of coffee and tea123 
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was not reported to affect SAH risk.  Although there are other modifiable risk factors for SAH that 
have been identified, a recent review suggests that the most important modifiable risk factors for 
SAH include hypertension, smoking and excessive alcohol intake, each conferring a 2- to 3-fold 
increase in risk.124  Furthermore, avoiding tobacco and alcohol misuse and treating high blood 
pressure with antihypertensive agents has been shown to reduce the risk of SAH.125  In summary, 
there are multiple modifiable risk factors for SAH, but avoiding tobacco and alcohol misuse and 





Table 1-1: Risk factors for intracranial aneurysm/SAH 
Category Risk Factor High-Risk Group 
Demographic factors 
Age  Older age50 
Sex Female49, 51 
Race/ethnicity non-Caucasian60, 61 
Heritable factors 
Family history of IA/SAH 1st/2nd Degree Relatives with IA/SAH66-70, 78, 79 
Connective tissue disorders 
Autosomal Dominant Polycystic Kidney Disease84 




Variants in genes involved in 
vascular structure/remodeling 
Collagen Type I (COL1A2)100  
Collagen Type III (COL3A1)101 
Elastin (ELN)95, 102 
Endoglin (ENG)103 
Matrix Metallopeptidase-9 (MMP-9)104 
Variants in genes regulating 
blood pressure 
Endothelial Nitric Oxide Synthase (eNOS)105-107  
Angiotensin Converting Enzyme (ACE)108-110 
Variants in genes involved in 
inflammation 
Interleukin 1- (IL-1)111 
-1 Antichymotrypsin (SERPINA3)112 
Heme Oxygenase-1 (HO-1)113 
Modifiable risk factors 
Lifestyle 
Smoking / tobacco use115, 116124 
Heavy alcohol use115, 116124 
Sympathomimetic drugs (cocaine)118-120 
Diet (low vegetable consumption/yogurt)121, 122 
Medical conditions 
Hypertension53-55, 115, 116, 124 
Cerebrovascular disease53-55 
Other factors 
Regional differences Varies per country62  
Economic factors Low income countries44 




1.1.3 Clinical course and management of SAH 
This section highlights the typical symptoms present on admission and the most common 
intracranial and systemic complications associated with SAH in the clinic.  In addition, this section 
discusses the American Heart Association (AHA) guidelines for the diagnosis, monitoring, and 
treatment of patients with SAH.   
 
1.1.3.1 Clinical presentation:  Clinical symptoms of SAH have been previously described but are 
of limited use in the diagnosis of SAH.  The most common symptom of SAH is a sudden onset of 
a very severe headache also known as a “thunderclap” headache, which may be the only symptom 
in up to 1/3 of SAH patients.126  About 10% of patients with SAH report a sentinel leak that occurs 
days to weeks before the SAH and results in similar headache symptoms.127-129  However, others 
argue that headaches due to sentinel leaks are rare and do not help in SAH diagnosis.130  Other 
common symptoms include a disturbance in consciousness, vomiting, or neck stiffness.126  A 
smaller percentage of patients show a retinal or vitreous hemorrhage in the eye131 or other 
neurological deficits including motor defects, aphasia, seizures, visual troubles, and amnesia.126  
In the first few days after SAH, psychiatric manifestations are common including depression 
(45%), apathy (42%), denial (21%) and catastrophic reaction (17%).132  However, no clinical 
feature is sufficiently reliable to make a diagnosis126 and SAH is frequently misdiagnosed.133, 134 
1.1.3.2 Acute intracranial complications:  SAH is associated with numerous medical 
complications that typically develop over different time periods after the hemorrhage.  In the first 
24 hours after SAH, the primary cause of death is usually attributed to a rise in intracranial pressure 
(ICP) due to the large volume of bleed in the subarachnoid space and blockage of cerebrospinal 
fluid (CSF) drainage.5  A sufficient increase in ICP can lead to decreased cerebral perfusion 
pressure (CPP), global cerebral ischemia, edema, and ultimately death.5, 135-137  Extensive cerebral 
ischemic injury is well documented in the individuals who die within the first 24 hours after 
SAH.138-144  For individuals that survive the SAH, the most important immediate concern is the 
risk of an aneurysm rebleed.  Although ruptured IAs tend to heal in survivors of SAH, the risk of 
rebleed is significant, especially early after SAH, if the IA is not treated surgically.  To illustrate, 
the cumulative incidence of rebleeding in SAH patients with untreated IA is 2-4% within 24 
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hours33, 145-147, 15-20% within two weeks33, and 35-40% within a month148 After a month, the risk 
of rebleeding decreases gradually from 1–2%/day to 3%/year5  Rebleeding is more frequent in 
patients with poor clinical presentation and large IA.5, 149  Surgical treatment of IA significantly 
reduces the risk of IA rebleeds, but also presents additional risks and complications sometimes 
leading to additional morbidity and mortality.51, 139, 150, 151  Hydrocephalus occurs in ~20-30% of 
SAH patients typically within 48 hours after SAH and is highly correlated with poor neurologic 
grade.152, 153  When hydrocephalus leads to clinical complications, it can be treated with CSF 
diversion using external ventricular drains or lumbar drains.5   In summary, the most common 
acute intracranial complications after SAH are increased ICP, IA rebleed, and hydrocephalus.   
1.1.3.3 Delayed intracranial complications:  In the time period following the first day after SAH, 
the most important complications are the development of cerebral vasospasm and delayed cerebral 
ischemia (DCI).  Cerebral vasospasm describes the abnormal constriction of large cerebral arteries 
and is often associated with radiographic or CBF evidence of diminished perfusion in the distal 
territory of the affected artery.154  The gold standard for assessment of cerebral vasospasm is 
cerebral angiography.150  Angiographic vasospasm occurs in 30-70% of SAH patients and typically 
develops at 3-5 days, reaches maximum constriction at 5-14 days, and gradually resolves over 2-
4 weeks after the hemorrhage.155, 156  Approximately 50% of patients that develop vasospasm also 
develop DCI.156-158  In general, DCI describes the delayed onset of a mismatch between CBF and 
the metabolic oxygen requirement within a given cerebral region resulting in ischemic neuronal 
damage.159  The definitions and terms used to describe DCI in the clinic vary greatly, but typically 
include radiographic evidence of vasospasm with clinical features of cerebral ischemia after 
exclusion of factors not related to vasospasm.160  Clinical features of cerebral ischemia that occur 
in the absence of vasospasm are commonly referred to as clinical neurological deterioration 
(CND), neurological deficits, or delayed ischemic neurological deficits (DIND) whereas those that 
occur in the presence of vasospasm are commonly called DCI or symptomatic vasospasm.160   
Conversely, asymptomatic vasospasm is commonly used to refer to the condition when there are 
no clinical features of cerebral ischemia, but vasospasm is detected.160  However, it is important 
to note that these terms are often used interchangeably in the literature.160  In patients that survive 
SAH, 50-70% develop angiographic vasospasm, 25-50% develop symptoms of DCI, and 30-50% 
show radiological signs of infarction attributed to vasospasm.161  Since cerebral vasospasm and 
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DCI typically develop days after SAH and may be reversible, these complications serve as a target 
for aggressive preventive and treatment strategies.153 
1.1.3.4 Systemic complications:  In addition to the commonly observed intracranial 
complications after SAH, it is common for patients to develop systemic complications, especially 
in the first few days after the hemorrhage.153, 162  Patients with SAH commonly develop cardiac 
dysfunction (75%), fever (54%), anemia (36%), hypertension (27%), hypotension (18%), 
pneumonia (20%), and pulmonary edema (14%).153, 163, 164  A recent study reported that 79% 
patients developed at least one systemic complication after SAH.165-167  In the Cooperative 
Aneurysm Study, 23% of deaths were attributed to systemic complications with half of those due 
to pulmonary complications.168  Although prevention and treatment of systemic complications 
might improve outcome after SAH169, clinicians are often challenged by the potential adverse 
effects of these interventions on the intracranial complications.170  Also, therapies aimed at 
reducing intracranial complications can increase the frequency and severity of systemic 
complications.153, 171, 172  Despite the varied and frequent systemic complications that develop after 
SAH, the prevention and treatment of intracranial complications continues to be the focus in the 
management of SAH.150  
1.1.3.5 Diagnosis, monitoring, and treatment:  The prevention, diagnosis, and treatment of SAH 
is the topic of numerous studies and reviews.  Recently, the American Heart Association (AHA) 
performed a comprehensive review of the clinical evidence in this topic and provided guidelines 
in the management of SAH patients.125  It should be noted that the evaluation of the clinical data 
is not fully comprehensive and the guidelines note some of the areas in which there is a lack of 
quality information.  The guidelines are categorized into Class I, II, and III based on the size of 
the treatment effect and Level A, B, and C as an estimate of certainty of the treatment effect.  For 
instance, Class I guidelines are those in which “there is significant evidence for and/or general 
agreement that the procedure or treatment is useful and effective”.  Level A and B guidelines are 
categorized based on evaluations from multiple populations and limited populations, respectively.  
The paragraph below summarizes some of the key Class 1 recommendations for the management 
of SAH.  All recommendations are categorized as Class 1B unless specified otherwise. 
According to the 2012 AHA guidelines for the management of SAH125, “a high level of 
suspicion for SAH should exist in patients with acute onset of severe headache”.  The acute 
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diagnosis of SAH should be performed using non-contrast CT, which can be followed by a 
lumbar puncture if the CT is non-diagnostic.  The detection of the aneurysm should be performed 
using 3-dimensional digital substraction angiography (DSA) and the initial clinical severity of 
SAH should be determined using of simple validated scales such as Hunt and Hess (Table 1-6: 
Hunt and Hess Scale) and World Federation of Neurological Surgeons (Table 1-8: World 
Federation of Neurologic Surgeons Scale).  The urgent diagnosis of SAH is emphasized because 
delays in CT scan allow SAH blood to degrade thus increasing the possibility of a normal CT 
scan.  For example, modern CT scanners failed to detect blood in approximately 2-7% of SAH 
cases within 12-24 hours.173, 174  Within 10 days, SAH blood is almost completely dissolved and 
the sensitivity to detect SAH using CT declines rapidly.31  Once the SAH is confirmed, urgent 
treatment of patients is suggested to avoid aneurysm rebleeding.  Proper CBF and hemodynamics 
should be maintained through the control of blood pressure and cerebral perfusion pressure 
(CPP) and by the maintenance of euvolemia and normal circulating blood volume.   Acute 
hydrocephalus should be prevented by cerebrospinal fluid diversion via external ventricular 
drainage or lumbar drainage.  Chronic SAH-induced hydrocephalus should be treated with 
permanent CSF diversion (Class IC).  Oral nimodipine should be administered to all SAH 
patients as it has been shown to improve neurological outcomes but not cerebral vasospasm 
(Class IA).  For patients that develop DCI, the induction of hypertension is recommended unless 
blood pressure is elevated at baseline or cardiac status precludes it.  The ruptured aneurysm 
should be treated by surgical clipping or endovascular coiling followed by cerebrovascular 
imaging to verify proper obliteration of the aneurysm.  If both surgical methods are amenable, 
endovascular coiling is preferred over surgical clipping.  Also, “the determination of aneurysm 
treatment, as judged by both experienced cerebrovascular surgeons and endovascular specialists, 
should be a multidisciplinary decision based on characteristics of the patient and the aneurysm” 
(Class IC).  Low-volume hospitals (<10 SAH patients per year should consider transferring SAH 
patients to high-volume centers (<35 SAH cases per year) with experienced cerebrovascular 






1.1.4 Pathophysiology of SAH 
This section describes the mechanisms of acute and delayed injury including oxidative stress, 
inflammation, acute cerebral ischemia, microvascular dysregulation, microthrombosis, delayed 
vasospasm, and DCI.  Figures at the end of this section summarize the primary mechanisms leading 
to cellular death and injury (Figure 1-2: Primary mechanisms of injury after SAH) and key 
regulators of cerebrovascular tone (Figure 1-3: Key regulators of cerebrovascular tone after SAH) 
after SAH. 
 
1.1.4.1 Mechanisms of acute injury:  During SAH, blood is released into the subarachnoid space 
at arterial pressure and spreads diffusely over the surface of the brain bathing pial arteries with 
fresh blood.175   The proposed etiologies of acute mortality include direct neural destruction from 
the force of the hemorrhage and cerebral ischemia secondary to acute elevations in ICP.176  Rise 
in ICP due to blood in subarachnoid space and impeded CSF drainage can lead to 
cerebrovascular dysfunction and vascular engorgement 177 with subsequent cerebral edema 178.  
In additional to the mechanical causes of the rise in ICP, the development of global cerebral edema 
is a processes that occurs at the cellular level.179  As ICP rises to levels approximating the mean 
arterial pressure, the cerebral perfusion pressure approaches zero resulting in a loss of CBF as 
further described in Section 1.2.2.  Changes in CBF can also occur in the absence of increased ICP 
when cerebral metabolism is altered.180  This process can lead to cerebral ischemia when the CBF 
fails to meet the metabolic requirements of the tissues.159  Also, decreased availability of nitric 
oxide (NO) 181, 182, acute vasoconstriction183, 184, and microvascular platelet aggregation185 have 
been shown to play an important role in the development of acute cerebral ischemia after SAH.  
Ultimately, cerebral ischemia results in energy failure in neurons and glia and initiates the cascade 
of events leading to cytotoxic edema.186  Cerebral ischemia also leads to apoptosis in the cells that 
constitute the blood brain barrier (BBB).187  For example, cell death in astrocytes and endothelial 
cells leads to the diffusion of serum from the vascular lumen into cerebral tissues (vasogenic 
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edema). Numerous intracellular second messenger cascades involving caspases, hypoxia-
inducible factor 1 (HIF-1), vascular endothelial growth factor (VEGF), and matrix 
metalloproteinases (MMPs) have been implicated in apoptosis of cells in the 
cerebrovasculature leading to disrupted BBB.179, 188  These studies only highlight the complex 
mechanisms involved in the pathogenesis of acute cerebral ischemia. 
SAH also induces acute brain injury through oxidative stress and inflammation.  
Preclinical189 and clinical190, 191 evidence shows that oxidative stress significantly contributes 
to brain injury after SAH.  The largest source of oxidative stress after SAH are superoxide 
anions released from ischemic mitochondria and free radicals produced from the breakdown 
of hemoglobin.179, 189, 192  The free radicals presented by these reactive oxygen species (ROS) 
directly damage various brain tissues through the promotion of lipid peroxidation, protein 
breakdown, and DNA damage.186  There are several antioxidants in the brain that protect 
tissues against ROS including superoxide dismutases, glutathione peroxidases, and catalase.  
However, these protective mechanisms are down-regulated or showed reduced antioxidant 
capabilities after SAH.189, 190, 193  Also, SAH induces inflammation the secretion of cytokines 
from leukocytes and erythrocytes in the bleed.  These oxidative and inflammatory mechanisms 
ultimately result in neuronal apoptosis, endothelial injury, and breakdown of the BBB after 
SAH.  Collectively, cerebral ischemia, cerebral edema, oxidative stress, and inflammation 
following SAH ultimately contribute to cell death and cerebral infarction which have been 
related to the initial bleed and poor outcomes.194-196 
1.1.4.2 Mechanisms of delayed injury:  The most notable pathogenic mechanisms of DCI are 
attributed to the development of cerebral vasospasm, altered microvascular regulation of CBF, and 
thromboembolism after SAH.  The pathogenesis of vasospasm has been the subject of numerous 
reviews.197-200  The exact cause of vasospasm remains unclear but its development is directly 
correlated with large bleeds, clots, and the time cerebral arteries are exposed to blood.201  
Kozniewska et al. provides an excellent review on the putative mechanisms involved in the 
pathophysiology of acute and delayed vasospasm.200  In the first few hours after SAH, activated 
platelets and mechanically damaged red blood cells (RBC) release numerous plasmogens 
including the vasoconstrictors thromboxane A2 (TXA2), serotonin, adenosine triphosphate (ATP), 
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and platelet-derived growth factor (PDGF).200  Also, hemoglobin (Hb) scavenges the vasodilator 
NO,  which relaxes vascular smooth muscle cells (VSMC) directly by stimulation of cyclic 
guanosine monophosphate (cGMP) production202 and indirectly by decreasing the synthesis of the 
vasoconstrictors endothelin-1 (ET-1)203 and 20-hydroxyeicosatetraenoic acid (20-HETE)204.  After 
a few days, RBCs undergo phagocytosis and lysis releasing oxyhemoglobin (oxyHb) and other 
break down products.205  OxyHb scavenges NO to a greater extent than Hb leading to enhanced 
vasoconstrictive responses200, especially in the presence of elevated levels of vasoconstrictors such 
as ET-1, TXA2, and serotonin (5-HT) levels.
206, 207  Furthermore, vasospastic arteries showed 
upregulation of the endothelin receptor ETB and serotonin receptor 5-HT1B leading to increased 
contractile responses to ET-1 and 5-HT.208, 209  The metabolism of Hb also produces bilirubin 
oxidation products (BOXes), which contribute to vasoconstriction.210  Increased levels of BOXes 
were observed in patients with vasospasm and the timing of the increase correlates well with the 
onset of vasospasm.210 The lysis of RBCs leads to the formation of oxidative stress and 
inflammation, which have been associated with cellular apoptosis, vascular remodeling, and DCI.  
Other established pathophysiological mechanisms involved in vasospasm focus on endothelial 
dysfunction and increased contractility of VSMC.211  Endothelial dysfunction involves damage to 
the endothelium and reduced production of vasodilators such as NO and increased production of 
vasoconstrictor such as ET-1.212, 213 The increased vasoconstrictive response of VSMC has been 
noted after SAH200, 212, 213 and is attributed to a decrease in the number of potassium (K+) 
channels214 or activation of signal transduction mechanisms such as protein kinase C (PKC) and 
Rho kinase that alter calcium (Ca+2) sensitivity.206  Furthermore, SAH has been shown to induce 
some degree of vascular remodeling, which has been implicated in the development and 
maintenance of cerebral vasospasm.215  Collectively, these studies describe the most notable 
mechanisms associated with acute and delayed vasospasm and may serve as therapeutic targets to 
improve outcomes after SAH.   
On the other hand, some evidence suggests that cerebral vasospasm plays a limited role in 
the development of DCI after SAH.216  Despite the associations between the development of 
vasospasm and DCI, the incidence, location, severity, and temporal relationship between 
angiographic vasospasm and DCI does not correlate well.216, 217  The time course for DCI generally 
parallels that of cerebral vasospasm, but reductions in CBF often occur before vasospasm can be 
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visualized.218  One contributing factor is that cerebral vasospasm is measured large cerebral 
arteries219-221, but the microvasculature plays a predominant role in regulating CBF regulation222, 
223, especially after SAH 224.  Direct evidence of microvascular vasospasm in humans after SAH 
was shown using MRI225 and orthogonal polarization spectral imaging226.  Clinical studies 
investigating the treatment of vasospasm provide additional evidence that vasospasm plays a 
limited role in the development of DCI and outcomes after SAH.  To illustrate, nimodipine 
improves outcomes without affecting angiographic vasospasm216 and treatment of angiographic 
vasospasm often fails to improve outcomes216.  Together, these studies emphasize the importance 
of microvascular regulation of CBF on outcomes after SAH and note the limitations of the current 
monitoring and treatment methods.   
Furthermore, growing evidence suggests that microthrombosis in cerebral arteries 
contributes to the development of cerebral infarction after SAH.  First of all, many patients show 
a diffuse pattern and small size of infarcts after SAH, which indicates pathophysiological 
mechanisms other than vasospasm.227  Secondly, clinical studies of SAH have noted that clinical 
signs of ischemia often do not correlate with pathological evidence of ischemia.150, 228  In a study 
of 29 patients that died a mean of 8 days after SAH, clinical ischemia was noted in 48% of patients, 
but pathological evidence of ischemia was seen in 93% of patients.228  In this study, thrombi in 
small cerebral blood vessels were commonly detected in patients with clinical or radiological signs 
of DCI.228  Also, transcranial Doppler ultrasound (TCD) commonly shows signals of 
thromboembolism in SAH patients.229  Other studies note a relationship between microthrombi 
and vasospasm in patients who died after SAH.230  In addition, experimental SAH shows that 
microcirculatory thrombosis occurs acutely after SAH, which supports the clinical findings.185  
Yet, despite the preclinical and clinical evidence that thromboembolism plays a role in the 
pathophysiology of SAH, clinical studies report a lack of a beneficial effect of antiplatelet and 





Figure 1-2: Primary mechanisms of injury after SAH 





Figure 1-3: Key regulators of cerebrovascular tone after SAH 
RBC, red blood cells; Hb/oxyHb, hemoglobin/oxyhemoglobin; AngII, angiotensin II; Thr, thrombin; 5-HT, serotonin; 
ATP, adenosine triphosphate; AA, arachidonic acid; HO, hemooxygenase; CYP, cytochrome P450; COX, 
cyclooxygenase; TXS, thromboxane synthase; PTGIS, prostacyclin synthase, ROS, reactive oxygen species; BOXes, 
bilirubin oxidation products; NO, nitric oxide; TXA2, thromboxane A2; PGI2, prostacyclin; 20-HETE, 20-
hydroxyeicosatetraenoic acid,  EETs, epoxyeicosatrienoic acids 
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1.1.5 SAH outcomes 
This section notes the morbidity and mortality rates and trends in the US and/or worldwide. 
 
1.1.5.1 Mortality:  SAH presents an unusually high risk of death.  Approximately 10-20% of 
individuals that suffer SAH die before reaching the hospital.42, 43  Among those reaching the 
hospital, approximately 20% are comatose and need immediate respiratory support42, 232, 10% die 
within 24 hours31, and 25% die within 2 weeks140.  Population-based studies report 30-day 
mortality rates of 40-44%.46, 60, 233  Mortality rates at 6 months are similar to those at 12 months 
and range from 38-77%.234  Case fatality rates are estimated to be approximately 50%.138  Although 
SAH accounts for only 3-5% of all strokes, SAH accounts for 25% of all fatalities related to 
stroke.5  Also, SAH accounts for 25% of potential years lost to stroke due to the relatively young 
age of onset and the relatively worse outcomes when compared to ischemic stroke.6  These data 
demonstrate that the SAH is considered a very serious condition associated with an extremely high 
mortality.   
Despite the relatively high mortality rates of SAH worldwide44, many studies report a 
decreasing trend over time.5  In the US, epidemiological studies of SAH patients have reported 21 
to 30-day mortality rates of 57% from 1945 to 197446, 42% from 1975 to 198446, 45% in 1988139, 
and 26-33% from 1993 to 200340, 235.  One study estimates that the mortality rate of SAH decreased 
approximately 1% per year in the US from 1979 to 1994.6  Worldwide, the mortality rates of SAH 
vary greatly with values ranging from 8-67%.236  The large variability may be due in part to 
inconsistent measurement criteria for some studies, which did not account for deaths that occur 
before hospital admission.236  In a meta-analysis of population-based studies, SAH fatality rates 
decreased worldwide by 17% from 1973 to 2002.237  High income countries showed lower fatality 
rates (25-35%) compared to low to medium income countries (40-48%).44  In addition, regional 
differences in mortality rates have been noted with median values in the US, Europe, and Japan 
reported to be 32%, 44%, and 27%, respectively.236 Taken together, these studies suggest that the 
mortality rate of SAH is decreasing world-wide, especially in high income countries. 
1.1.5.2 Morbidity:  For individuals that survive SAH, many suffer from neuropsychological and 
physical deficits that impact their quality of life.  Less than 1/3 of SAH survivors regain their 
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previous occupation and report no effect on their lifestyle at 18 months.5, 238, 239  Approximately 
1/3 of SAH survivors are left with physical disabilities or cognitive impairments, which leaves 
them dependent.138, 240  Recovery to an independent state does not ensure good outcomes because 
reductions in quality of life are commonly reported in these patients.239  Although cognitive 
function tends to improve over the first year after SAH,241 global cognitive impairment is still 
present in ~20% of patients at 1 year.242  In addition, some studies report that SAH patients 
commonly suffer from neuroendocrinal dysfunction and sleep disorders.243, 244  Overall, 
approximately 2/3 of SAH survivors report a reduced quality of life.240, 245  Many of these 
individuals do not return to work, retire early, and are unable to function at the same intellectual 
level as before the rupture.246-249  When both morbidity and mortality data are considered, death or 
dependence occurs in almost 70% of patients.250  In summary, multiple studies have demonstrated 
that SAH continues to be associated with significant morbidity and mortality. 
There is lack of population-based studies investigating long-term outcomes after SAH.  
One population-based study of 2155 SAH reports very modest improvements in outcome after 
SAH during the last few decades.138  In this study, the proportion of patients who remained 
independent after SAH increased 1.5% per year from 1977 to 1990.138  Another study of 8739 
patients reported that 8-20% suffer from persistent dependence.236  The International Subarachnoid 
Aneurysm Trial reports 12% of patients with significant lifestyle restrictions and 6.5% are left 
functionally dependent at 1 year.150  A recent study of SAH patients in Australia and New Zealand 
reported a high proportion of SAH patients with a diminished level of health related quality of life 
measurements such as incomplete recovery at 1 year (46%), ongoing memory problems (50%), 
mood abnormalities in (39%), speech problems (14%), and self-care (10%).240  These data suggest 
that despite advancements in the treatment of SAH and its subsequent complications, a large 
percentage of SAH patients continue to suffer from deficits in cognitive, functional, or quality of 
life indicators.   
1.1.5.3 Assessment of Outcomes:  Long-term outcomes after SAH can be measured using a wide 
variety of methods involving cognitive, physical, and quality of life assessments.  The Glasgow 
Outcome Score (GOS) (Table 1-2: Glasgow Outcome Scale) is a commonly used method to 
measure disability after stroke in the clinic because of its simple scale and history of use.251  
However, several limitations of the GOS scale have been noted including categories that do not 
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provide information on specific deficits, lack of sensitivity to detect small but clinically relevant 
changes in outcome, and poor inter-rater reliability.252   Currently, the Modified Rankin Scale 
(MRS) and Barthel Index are the most commonly used scales for measuring the degree of disability 
or dependence in the daily activities of people who have suffered a stroke.253  Recent studies 
reported that the MRS is more sensitive method for assessing disability when compared to the 
Barthel Index.254  Also, the validation of the MRS scale has been demonstrated through its 
relationships to physiological indicators such as stroke type, lesion size, perfusion and neurological 
impairment.255  Thus, MRS is a validated and clinically useful method to measure the disability or 
dependence as a long-term outcomes in SAH patients.   
 
Table 1-2: Glasgow Outcome Scale 
 
 




2 Persistent vegetative state Unable to interact with environment; unresponsive
3 Severe disability Able to follow commands/ unable to live independently
4 Moderate disability Able to live independently; unable to return to work or school
5 Good recovery Able to return to work or school
Score Category Description
0 No symptoms NA
1 No significant disability
Able to perform all usual duties and activities 
despite symptoms
2 Slight disability
Unable to perform all previous activities but able 
to look after own affairs without assistance
3 Moderate disability
Requires some help, but able to walk without 
assistance
4 Moderately severe disability
Unable to walk without assistance and unable to 
attend to own bodily needs without assistance
5 Severe disability




Table 1-4: Barthel Index 
 
 
1.1.6 Prognostic factors of long-term outcomes 
This section highlights some of the key prognostic factors of long-term outcomes after SAH 
including factors related to the patient demographics, hospital, hemorrhage, and CBF regulation.  
This section also notes the inter-relation of these prognostic factors and highlights the most 




Needs help cutting, spreading butter, etc., or requires modified diet 5
Independent 10
Dependent 0
Independent (or in shower) 5
Needs to help with personal care 0
Independent face/hair/teeth/shaving (implements provided) 5
Dependent 0
Needs help but can do about half unaided 5
Independent (including buttons, zips, laces, etc.) 10
Incontinent (or needs to be given enemas) 0
Occasional accident 5
Continent 10




Needs some help, but can do something alone 5
Independent (on and off, dressing, wiping) 10
Unable, no sitting balance 0
Major help (one or two people, physical), can sit 5
Minor help (verbal or physical) 10
Independent 15
Immobile or < 50 yards 0
Wheelchair independent, including corners, > 50 yards 5
Walks with help of one person (verbal or physical) > 50 yards 10
Independent (but may use any aid; for example, stick) > 50 yards 15
Unable 0
Needs help (verbal, physical, carrying aid) 5
Independent 10
Toilet Use
Transfers (bed to 
chair and back)











1.1.6.1 Patient demographics:  Patient demographic factors have been shown to influence 
outcomes after SAH.  Numerous studies report that older patients have worse outcomes than young 
patients, especially in those over 60 years of age.46, 250, 256-258  To illustrate, Nieuwkamp et al. 
reported that only 1 of 6 patients older than 75 years of age leave the hospital alive and 
independent.259  Conversely, a study of young SAH patients (<40 years of age) by Ogungbo et al. 
reported that age does not affect outcomes at discharge and that moderate and severe disability 
groups continued to improve and achieve good recovery at 6 months after SAH.260  Likewise, sex 
and race have been associated with differences in outcome after SAH.  For example, higher 
mortality rates have been reported in women compared to men6, 43, 46 and in American minorities 
compared to white Americans.261  Also, some studies report that socio-economic status can 
influence outcomes after SAH.  For instance, Jakovljevic et al. reported that low socio-economic 
status was associated with worse outcomes in SAH in a large population-based Finnish stroke 
incidence study.262  In summary, demographic factors such as older age, female sex, and low socio-
economic status are prognostic factors of SAH outcomes.    
1.1.6.2 Hospital/institution:  Other factors related to the hospital/institution have been shown to 
affect outcomes after SAH.  These factors include the availability of endovascular services263, 
volume of SAH patients treated235, 263-265 and the type of facility in which the patient is first 
evaluated266.  As expected, treatment in these institutions can significantly affect outcome.  Many 
studies report that early treatment can improve outcome.173, 174, 267, 268  Also, conservative or 
aggressive treatment in patients with poor clinical grade can reduce mortality rates from ~90% to 
~50% and significantly improve favorable outcomes in survivors.248, 269, 270  Recently, AHA 
published treatment strategies and guidelines that have been shown to dramatically impact 
outcomes in SAH patients.150  These guidelines highlight the importance the hospital/institution 
and treatment on outcomes. 
1.1.6.3 Aneurysm and hemorrhage:  Undoubtedly, factors related to the ruptured aneurysm and 
subsequent severity of bleed are important predictors of outcome after SAH.  Aneurysm factors 
such as size, location, and morphology may affect prognosis by presenting surgical complications 
or post-operative complications related to the bleed.271, 272  Surgical treatment of aneurysms usually 
involves the obliteration of the aneurysm using clips or coils and significantly reduces the risk of 
aneurysm rebleeds, but surgery can lead to additional morbidity and mortality sometimes without 
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improvements in the patient’s condition.139, 151  On the other hand, untreated IA are at high risk for 
rebleeding with a 30-day cumulative risk of 30-60%.139, 154  Aneurysm rebleeding, especially early 
after SAH273, is a major predictor of poor outcome and is associated with mortality rates of ~70-
80% and severe functional and neuropsychological deficits.145, 250, 274-277. Over the last few decades, 
the severity and location of the bleed, commonly measured using a CT scan and categorized using 
clinical grading scales such as the Fisher scale (Table 1-5: Fisher Scale), have shown to be one of 
the most important prognostic indicators of outcomes after SAH.234, 278  Larger bleeds have been 
consistently associated with numerous clinical complications and ultimately worse outcomes.234  
Also, the presence of parenchymal, ventricular and subarachnoid clots results in poor clinical 
outcome.250, 274, 279-281  The severity and location of the bleed is also highly associated with the 
severity of clinical presentation, which is also important prognostic indicator of outcomes.278  
Various grading scales have been used to evaluate the severity of clinical presentation including 
the Hunt and Hess (HH) Scale (Table 1-6: Hunt and Hess Scale), World Federation of Neurological 
Surgeons Scale (WFNSS) (Table 1-8: World Federation of Neurologic Surgeons Scale), and 
Glasgow Coma Scale (GCS) (Table 1-7: Glasgow Coma Scale).278  Scores on the HH46, 274, 282, 283, 
WFNSS284, 285 and the GCS 246, 274, 280, 285, 286 have predicted outcomes in diverse populations of 
SAH patients whether assessed on admission or during the clinical course.  Collectively, these 
studies suggest that aneurysm factors, large bleeds, and poor clinical presentation are important 
prognostic indicators of outcome after SAH.   
 
Table 1-5: Fisher Scale 
 
IVH, intraventricular hemorrhage 
Grade Criteria
1 No hemorrhage evident
2 SAH < 1mm thick
3 SAH > 1mm thick
4 SAH of any thickness with IVH or parenchymal extension
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Table 1-6: Hunt and Hess Scale 
 
 
Table 1-7: Glasgow Coma Scale 
 
 
Table 1-8: World Federation of Neurologic Surgeons Scale 
 
 
1.1.6.4 CBF dysregulation:  Numerous hemodynamic factors are associated with outcomes after 
SAH.  In the first few days after SAH, worse outcomes are expected in patients with increased 
ICP135-137, decreased CPP135-137, vasospasm183, 184 and cerebral ischemia137, 180, 182, 184, 287, 288 
Likewise, continuous measurement of cerebrovascular autoregulation using the pressure reactivity 
index were associated with outcomes after SAH.289  However, Barth et al. reported that pressure-, 
oxygen-, and flow-related autoregulatory indices were not associated with outcomes.290  A few 
days after SAH, hemodynamic factors such as cerebral vasospasm and DCI often lead to cerebral 
infarction and are leading cause of morbidity and mortality after acute SAH.171, 291  In a review of 
106 studies (3,327 patients), DCI was associated with a mortality rate of 30% and permanent 
Grade Criteria
1 Asymptomatic, mild headache, slight nuchal rigidity
2
Moderate to severe headache, nuchal rigidity, no 
neurologic deficit other than cranial nerve palsy
3 Drowsiness / confusion, mild focal neurologic deficit
4 Stupor, moderate-severe hemiparesis
5 Coma, decerebrate posturing
Response 1 2 3 4 5 6
















Grade Glasgow Coma Score  Motor Deficit
1 15 Absent
2 13 - 14 Absent
3 13 - 14 Present
4 7 - 12 Present or Absent
5 3 - 6 Present or Absent
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deficits in 34%.292  Another study reported that patients with DCI are 6-fold more likely to suffer 
from moderate to severe neuropsychological deficits when compared to patients that do not 
develop DCI.293  Cerebral vasospasm is generally associated with DCI, and to a lesser extent 
cerebral infarction, but demonstrates poor ability to predict outcomes when compared to DCI or 
cerebral infarction.294-298  When multiple secondary insults were evaluated together, the number of 
these potentially avoidable events after SAH were found to be important predictors of outcome.299  
Other clinical complications associated with worse outcomes include global cerebral edema150, 
hydrocephalus286, cardiac dysfunction300, hyperglycemia150, fever150, anemia150, pneumonia150, 
sepsis150, pulmonary edema300, epilepsy301.  In addition, comorbidities such as untreated and 
treated hypertension, atrial fibrillation, congestive heart failure, coronary artery disease, and renal 
disease have been shown to affect outcomes.235  Collectively, these studies suggest that 
hemodynamic factors, clinical complications, comorbidities, and secondary insults after SAH are 
predictors of outcome. 
1.1.6.5 Inter-relation and clinical relevance:  Although numerous prognostic factors of 
outcomes after SAH have been identified, studies note the inter-relation of these factors and the 
limitations of the individual predictors.245, 302  For example, older patients are more likely to be 
admitted with poor clinical grade SAH and to develop medical complications that may lead to 
worse outcomes.259  Likewise, the aneurysm size and severity of clinical presentation are closely 
associated with aneurysm rebleeding.149  Multivariate analysis can be used to address the issue of 
the inter-relation of these factors and to identify the primary determinants of outcomes.  Using 
multivariate analyses, Hijdra et al. argued that the three most important prognostic indicators for 
outcomes are age, severity of clinical presentation (Table 1-6: Hunt and Hess Scale), and the 
severity and location of the bleed (Table 1-5: Fisher Scale).250, 280  Of these 3 prognostic factors, 
the severity of clinical presentation, particularly the level of consciousness, was the most important 
determinant280, but the mechanisms of this relationship remain unclear.198  Other studies report 
additional individual prognostic factors of outcome using multivariate analyses, but the severity 
of clinical presentation and/or the severity and location of the bleed are consistently noted 
determinants in these studies as well.169, 274, 303, 304  Clinical grading scales are commonly used to 
assess the severity of bleed and clinical presentation and to predict outcomes, but their predictive 
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ability is limited and none have achieved universal acceptance.245, 278 Currently, there are no widely 
accepted prognostic indicators of long-term outcomes after SAH.   
 
1.1.7 Prognostic factors of acute outcomes 
This section highlights some of the key methods used for the diagnosis and prediction of acute 
ischemic complications such as CND and DCI.  These methods include clinical grading scales, 
radiographic monitoring modalities, physiological indicators, biochemical markers, and genetic 
markers. 
 
1.1.7.1 Diagnosis and management of DCI:  The prediction, prevention, diagnosis, and treatment 
of acute outcomes such as CND and DCI has become a major focus in the management of SAH 
because it occurs in a high percentage of patients, leads to significant morbidity and mortality, and 
develops days after SAH potentially providing a time window for therapeutic intervention.  As 
previously mentioned in Section 1.1.3, the development of DCI in SAH patients is a complex 
process in which the pathological processes involved are not fully understood and the clinical 
diagnosis is difficult. Vergouwen et al. recently provided a thorough review of the various terms 
used in the literature to describe DCI in SAH patients and the problems presented by the variety 
of these terms.305  One of the primary problems in defining and measuring DCI in the clinic is that 
the clinical features of cerebral ischemia are difficult to categorize and diagnose, especially in 
patients who are comatose or sedated.  Also, clinical features of DCI require the exclusion of other 
causes, such as rebleeding, surgery, infection, and hydrocephalus, which may be unrelated to 
cerebral vasospasm.  In order for consistent comparison across studies, many clinicians use clinical 
grading scales, radiographic methods, and/or physiological indicators to diagnose or predict acute 
ischemic complications after SAH.306 
1.1.7.2 Clinical grading scales:  The clinical condition of SAH patients is commonly evaluated 
using the HH (Table 1-6: Hunt and Hess Scale), Fisher (Table 1-5: Fisher Scale), GCS (Table 1-7: 
Glasgow Coma Scale), and WFNS (Table 1-8: World Federation of Neurologic Surgeons Scale) 
scales.  These scales have been used to categorize the severity of SAH and predict outcomes, but 
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have been shown to have poor inter-rater reliability and limited success in predicting DCI.278, 307, 
308  The Fisher Scale is the most commonly used clinical grading method used to predict vasospasm 
after SAH.278  Disadvantages of the Fisher Scale includes scoring criteria developed using old 
imaging technology, unclear and subjective classifications, and exclusion of certain characteristics 
of the bleed such as clot density and clearance rate.278 As a result of these limitations, clinical 
grading scales have not approached universal acceptance as predictors of acute ischemic 
complications after SAH.   
1.1.7.3 Radiographic monitoring modalities:  Radiographic monitoring modalities such as CT 
scan and magnetic resonance image (MRI) have been reported as useful tools for monitoring for 
DCI after SAH.  Cerebral angiography is reported to be the gold standard for assessing cerebral 
vasospasm after SAH.291  Despite the accurate identification of the presence of vasospasm, 
angiography has shown limited ability to accurately diagnose or predict DCI.309-311  In addition, 
these radiographic monitoring methods are expensive, invasive, and cannot be applied regularly at 
the patient bed-side.  These factors limit the utility of radiographic methods to be used to monitor 
or predict the onset of acute ischemic complications in SAH patients. 
1.1.7.4 Physiological Indicators of DCI:  Numerous studies have investigated physiological 
indicators of DCI using transcranial Doppler ultrasonography (TCD), electroencephalography 
(EEG), brain tissue oxygen monitoring, and cerebral microdialysis, while a few recent studies have 
evaluated and near-infrared spectroscopy (NIRS) and thermal diffusion cerebral blood flow (TD-
CBF).306  Limitations of these methods to predict DCI include cost, invasive procedures, inability 
to continuously monitor patients at bed-side, and studies with small number of patients.306 The use 
of TCD to measure the velocities of RBCs in large cerebral arteries and has been previously 
associated with the development of radiographic evidence of vasospasm.312-314 Although this 
method is cheap, non-invasive and bedside technology, significant inter-patient variability is 
observed because it is highly operator dependent and temporal windows are inadequate in some 
populations.314-316  Thus, there are currently no clinically relevant physiological measurements that 
can be used to predict the onset of acute ischemic complications in SAH patients.   
1.1.7.5 Biochemical markers:  Due to the limitations of the clinical grading scales, radiographic 
methods, and physiological measurements to predict DCI, many researchers have investigated the 
ability of certain biomarkers to predict or indicate the onset of acute ischemic complications.  A 
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biomarker can be defined as a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention.263  Potential advantages presented by biomarkers include the ability to 
elucidate the pathogenic mechanisms, identify early indicators of complications, and evaluate the 
temporal effects of the biomarker levels over the clinical course of SAH injury.  A recent review 
by Rodriguez-Rodriguez et al. identified numerous biochemicals involved in inflammation, 
oxidative stress, tissue injury, and vascular pathology as potential biomarkers of vasospasm and 
outcome after SAH.317  Lad et al. evaluated proteomic CSF biomarkers after SAH and identified 
the most promising vasospasm biomarkers to be ET-1, interleukin-6, and thrombin activity 
markers and outcome biomarkers to be cytokines and neurofilaments.318  Ducruet et al. 
summarized the relationships between gene variants with various outcomes after SAH, but noted 
study limitations such as small cohorts and inconsistent results.319  Currently, there are no widely 
accepted genetic or biochemical markers of DCI or long-term outcomes after SAH.   
1.1.7.6 Genetic Markers:  Other studies have investigated the relationship between genetic 
markers, DCI, and outcomes in SAH patients.  Advantages of using genetic markers to predict 
DCI include consistent genotyping results, inexpensive methods, and the ability to apply the 
predictive tool at any time before or after the injury.  Most of these genetic studies have focused 
on candidate genes that have been shown to impact CBF or recovery after SAH.   
Nitric Oxide:  NO plays a critical role in the regulation of cerebrovascular tone under basal 
conditions320 and after SAH321-324.  The eNOS gene regulates NO synthesis in the endothelium of 
the cerebral vasculature325, 326 and thus serves as a candidate gene for genetic studies in SAH 
patients.  Multiple studies investigated the role of the eNOS promoter polymorphism -786T>C 
(rs2070744) on acute and long-term outcomes in patients with SAH.  In SAH patients classified 
as Fisher grade 3, carriers of the variant C allele were more likely to develop acute complications 
such as asymptomatic or symptomatic vasospasm when compared to patients with the TT 
genotype.327  In this study, vasospasm was determined using TCD or angiography and was 
considered symptomatic if the vasospasm occurred in the presence of DIND.  Likewise, Starke et 
al. reported that patients with the variant CT genotype showed an approximate 3.5-fold increase 
in the incidence of cerebrovascular complication, such as angiographic vasospasm, DIND, and 
angiographic vasospasm with DIND, whereas no significant association was observed with 
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genotype and infarct on CT or MRI scan.328  Other studies reported that the -786T>C gene variants 
were associated with outcomes in SAH patients only after controlling for important clinical 
covariates in a multivariate analysis. For example, Ko et al. reported that the variant genotype or 
allele was not associated with angiographic vasospasm or infarct on CT scan in a univariate 
model.329  But, the presence of the homozygous variant CC genotype was associated with a 3-fold 
increase in risk of angiographic vasospasm after adjustment for age, sex, race/ethnicity, Hunt-Hess 
grade, and Fisher group.  In a another study, the presence of the variant C allele was not associated 
with DIND, but predicted an approximate 4-fold increase in risk for poor outcomes as determined 
by GOS after controlling for age and sex.330  Alexander et al. used a tagging SNP approach to 
characterize the genetic variability of the eNOS gene in SAH patients and reported that 
angiographic vasospasm was not associated with any of the individual tagging SNP alleles, but 
was associated with the combination of three tagging SNP variants (rs1799983, rs1800779, 
rs3918188).331  In addition, the carriers of the variant allele in rs1799983 was associated with 
worse long-term functional outcomes as measured by GOS and MRS at 6 months.331  Taken 
together, these results suggest that the -786T>C promoter polymorphism and other eNOS variants 
may be associated with worse acute and long-term outcomes after SAH. 
Apolipoprotein E:  Apolipoprotein E (APOE) plays an important role in the pathological events 
after SAH 332 including the impairment of vascular endothelium function 333, 334.  There are multiple 
studies investigating the relationship between APOE gene variants and acute and long-term 
outcomes after SAH in humans.  The APOE 4 (rs429358) gene variant has been extensively 
studies in SAH patients, but results are conflicting.  For example, Gallek et al. reported that the 
APOE 4 allele was associated with worse functional outcomes, as determined by GOS and MRS 
scores at 3 and 6 months, after controlling for age, race, HH grade, and Fisher grade.335  On the 
other hand, other studies reported that the APOE 4 was not associated with cerebral infarction336, 
functional outcomes as determined by GOS and MRS at 3 months336 and GOS at 16 months, or 
neuropsychological outcomes at 16 months.337  Although there are some conflicting results 
regarding the relationship of the APOE 4 polymorphism and outcomes after SAH, a meta-analysis 
reported that the APOE 4 allele was associated with a 2-fold increase in incidence of DCI and 
2.6-fold increase in incidence of poor outcomes.338  Another study investigated the relationship of 
promoter polymorphisms on the APOE gene and reported that patients with the variant -291T 
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allele were almost 4-times more likely to develop the concomitant presence of TCD vasospasm 
with DIND in both univariate and multivariate analyses after controlling for age, sex, blood 
pressure, blood lipid, Hunt and Hess grade, and Fisher grade.339  These results suggest that the 4 
and -291T promoter variants on APOE gene may be associated with worse acute and long-term 
outcomes in SAH patients. 
Other candidate genes:  Other studies have investigated the relationship between certain 
candidate gene polymorphisms and outcomes in SAH patients, but there are inconsistent results or 
a lack of studies to verify the findings.  For example, Vergouwen et al. reported that the -675 
5G>4G (rs1799889) allele on Plasminogen Activator Inhibitor-1 (PAI-1) gene was associated with 
a 3.3-fold increase in relative risk for DCI and a trend for worse functional outcomes as determined 
by GOS at 3 months.340  On the other hand, Ladenvall et al. reported that the -675 5G>4G allele 
was not associated with functional outcomes as determined by GOS at 1 year.341  One study 
reported that the 6178G>T (rs335364374) allele on Ryanodine Receptor 1 (RYR1) was associated 
with a 6-fold increase in risk for symptomatic vasospasm, which was defined as the combined 
presence of DIND along with cerebral vasospasm as determined by TCD, angiography, or CT 
scan.342  Another study reported that the patient homozygous for the 1080C>T variant on 
Cystathionine -synthase (CBS) gene were at increased risk for DCI, but not angiographic 
vasospasm, after controlling for admission hypertension.343  In this study, DCI was defined as the 
presence of DIND or infarct on CT or MR imaging.  Also, carriers of the variant Val66Met allele 
(rs6265) on the Brain Derived Neurotropic Factor (BDNF) gene were 4- and 8-fold more likely to 
show worse functional outcomes as measured by GOS both before and after controlling for patient 
age, clinical condition, and radiological severity of the bleeding, respectively.344  In addition, a 
Catechol-O-methyltransferase (COMT) gene variant was associated with TCD vasospasm early 
after SAH both before and after controlling for clinical covariates.345  In SAH patients classified 
as Fisher Grade 3, carriers of the variant 2 subunit on the haptoglobin (Hp) gene showed a 23-
fold increase in risk for TCD vasospasm.346  Furthermore, Ruigrok et al. genotyped SAH patients 
for variants on multiple candidate genes previously associated with outcomes in animal models of 
cerebral ischemia.347  In this study, the presence of the -863C>A allele on Tumor Necrosis Factor-
 (TNF-) predicted 2.3-fold increase in risk for worse outcomes as determined by GOS at 3 
months after controlling for sex, age, clinical condition on admission, amount of blood on CT scan, 
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rebleeding, and DCI.347  In summary, there are a few studies that report an association between 
genetic polymorphisms in the PAI-1, RYR1, CBS, BDNF, COMT, Hp, and TNF- genes and 
altered acute and long-term outcomes in SAH patients, but results need to be confirmed in 
additional studies.  One common element of the genes and biomarkers associated with 
complications after SAH is that several of these pathways are involved in the regulation of CBF.  
Therefore, a thorough understanding of the cerebral circulatory system, CBF regulation, and 
mechanisms of autoregulation is beneficial to understand the impact of these potential prognostic 
factors on outcomes after SAH.   
 
1.2 CEREBRAL BLOOD FLOW 
 
1.2.1 Cerebral circulatory system 
1.2.1.1 Regulation of CBF in microcirculation and macrocirculation:  The cerebral circulation 
can be broadly categorized into two groups based on the size of the arteries:  macrocirculation and 
microcirculation.  In the macrocirculation, blood enters the brain through the internal carotid 
arteries and vertebral arteries and then flows through large arteries in the subarachnoid space.  
These large arteries include the Circle of Willis at the base of the brain and pial arteries that course 
the surface of the brain.  Blood then flows through arteries that penetrate the cerebral parenchyma 
into smaller arteries, arterioles, and finally capillaries before returning to the circulatory system 
through the venous system.  There is a notable difference in the relative contribution of the 
macrocirculation and microcirculation to the regulation of CBF.   Large arteries play a major role 
in the regulation of CBF and contribute significantly to the total cerebrovascular resistance (CVR).  
For instance, large pial arteries in cats and monkeys comprised of the majority (60%) of the total 
CVR, but differences in species were noted.348  Small arteries, arterioles, and capillaries in the 
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microcirculation also significantly contribute to the regulation of CBF, but primarily through 
metabolic control and neurovascular coupling.349  These studies demonstrate that both the 
macrocirculation and microcirculation are important contributors of CBF regulation.   
1.2.1.2 Morphology and function of microcirculation and macrocirculation:  There are also 
notable differences in the morphology and thus function of cerebral arteries in the microcirculation 
and macrocirculation.   The general morphology of cerebral arteries has been reviewed by Lee et 
al.96  The artery is comprised of three primary layers: intima, media, and adventitia.  These layers 
are separated by a thin layer of elastic tissue called the elastic lamina.  The intima is the innermost 
(luminal) layer and is comprised of a single layer of endothelial cells that rest on a protein rich 
layer called the basal lamina.  The media contains a thick layer of smooth muscle cells, elastic 
fibers, and collagen fibers.  The outermost layer is the adventitia contains fibroblasts, elastic fibers, 
collagen fibers, and nerve fibers that innervate VSMC.  However, there are significant differences 
morphology and thus function of the cerebral arteries in the various vessel types.  For instance, 
capillaries contain only endothelial cells and a basement membrane and regulation of CBF through 
these vessels is controlled by pericytes.  Capillary endothelial cells are connected by tight junctions 
that form the BBB, which controls the exchange of materials between the blood and brain through 
anatomical, physiochemical, and biochemical mechanisms.  Smaller arteries and capillaries are 
surrounded by astrocytic end feet that couple neuronal and vascular activity.350 Astrocytes 
contribute to the integrity of the BBB, provide structural support to neurons, uptake metabolic by-
products of nerve activity, and recycle neurotransmitters.351, 352  Also, large cerebral arteries 
contain small blood vessels in the adventitia layer that supply nutrients to outer regions of the 
vessel wall and extrinsic perivascular nerves that can stimulate the VSMC in the media layer.  The 
varied morphology of the cerebral vasculature emphasizes the specialized function of these 
vessels.   
 
1.2.2 CBF regulation 
The adult brain weighs 2% of the total body weight, but consumes 20% of the oxygen produced 
by the body at resting state.  Overall CBF in the brain is ~50ml/100g/min with higher perfusion in 
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grey matter (70ml/100g/min) and lower perfusion in white matter (20ml/100g/min). 353  The 
mechanisms involved in the regulation of CBF are numerous and complex.  However, the 
following paragraph will briefly discuss factors involved in the regulation to CBF including 
myogenic, metabolic, and neurogenic mechanisms. 
Cerebral autoregulation is the process in which the cerebrovasculature maintains a constant 
CBF in the face of changing CPP by altering CVR.353  CPP is usually not measured directly but is 
calculated from the difference between mean arterial blood pressure (MABP) and intracranial 
pressure (ICP). 
Equation 1-1: CBF as a function of CPP 
 
CBF, cerebral blood flow; CPP, cerebral perfusion pressure; CVR, cerebrovascular resistance; MABP, mean arterial 
blood pressure; ICP, intracranial pressure 
MABP is commonly used as an index of CPP because it is usually higher than ICP.  However, in 
patients with SAH, ICP often rises to levels approaching MABP resulting in loss of perfusion and 
cerebral ischemia.354   In normal brain, CBF undergoes autoregulation at MABP from 70 to 120 
mmHg to ensure adequate oxygen delivery to the brain.353    Below 70 mmHg, cerebral vasodilation 
is maximal and CBF decreases as transmural pressure decreases. Above 120 mmHg, 
vasoconstriction is maximal and CBF increases as transmural pressure increases.353  Loss of 
autoregulation can lead to damage in the structure of the arteries, perfusion insufficient to meet 
metabolic demands, altered cerebral blood volume and ICP, and tissue damage in the brain.353  
Loss of cerebral autoregulation is seen in SAH and other pathophysiological states.353  Thus, 
cerebral autoregulation is a complex process to maintain CBF in the face of dynamic changes in 
hemodynamics in order to prevent cerebral injury.   
 
1.2.3 Mechanisms of cerebral autoregulation 
1.2.3.1 Myogenic, metabolic, and neurogenic processes:  The primary paradigms associated 
with the autoregulation of CBF include myogenic, metabolic, and neurogenic processes.  
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Myogenic response refers to the constriction that occurs in arteries in the face of increasing arterial 
pressure.  Large cerebral arteries on the Circle of Willis and pial arteries on the surface of the brain 
are sensitive to myogenic regulation.355  The cellular mechanisms of pressure-induced myogenic 
tone have not been clearly elucidated, but the response is associated with activation of mechano-
sensitive nonselective cation channels (stretch receptors), activation of phospholipase C (PLC), 
release of AA from membrane, inhibition of KCa+2 channels, and Ca
2+ entry through voltage-
sensitive channels of VSMC.351, 356, 357  Metabolic regulation, also referred to as functional 
hyperemia or neurovascular coupling, refers to the process by which neuronal activity leads to 
dynamic changes in regional CBF.  During neuronal activity, regional CBF is regulated to meet 
the metabolic demand for glucose and oxygen levels in active regions of the brain and to remove 
metabolic products.352  Metabolic regulation of CBF occurs rapidly (within a few seconds) through 
a complex process involving the neurovascular unit.352  Astrocytes play a key role in neurovascular 
coupling through cell signaling events and astrocytic endfeet processes.351, 352  Neurovascular 
coupling is controlled by several metabolic factors including potassium, CO2, O2, pH, and 
adenosine and vasoactive substances such as NO and EETs.352  Regulation of CBF by metabolic 
processes usually occurs at the level of small precapillary arterioles.355   Furthermore, CBF in large 
arteries are subject to neurogenic regulation by extrinsic perivascular nerve.355  This process 
appears to protect the brain against large fluctuations in blood pressure, but is reported to play a 
minor role in cerebral autoregulation compared to myogenic and metabolic regulation.355, 358  Thus, 
the primary mechanisms involved in autoregulation of CBF are myogenic response and metabolic 
regulation.   
1.2.3.1 Endothelial derived factors: It is also important to highlight the critical role of the 
vascular endothelium in the development and maintenance of cerebrovascular tone.  Numerous 
vasodilator and vasoconstrictor substances are synthesized and release in the endothelium of 
cerebral arteries.  Well-known endothelium-derived constricting factors (EDCF) include 
endothelin 1 (ET-1), thromboxane A2 (TXA2), and prostaglandin F2 (PGF2).
359  The production 
of ET-1 is catalyzed by endothelin converting enzymes (ECE) and can be stimulated by 
angiotensin II, vasopressin or thrombin.359  Well-known constrictors derived from endothelium 
include NO, prostaglandin I2 (PGI2), prostaglandin E2 (PGE2), and endothelium-derived relaxing 
factors (EDRF).359  EDRF is a general term used to describe factors hyperpolarize VSMC through 
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activation of K+ channels and include CO, K+, hydrogen peroxide (H2O2), NO, and EETs.
356, 360  
Release of EDRF can be stimulated by numerous plasmogens, hormones, and mechanical 
stimuli.359  Endothelial dysfunction is plays a pivotal role in the pathogenesis of many 
cerebrovascular disease including SAH.361  Also, the imbalance between vasoconstrictive and 
vasodilatory factors is thought to contribute to the development of cerebral vasospasm.159  These 
findings demonstrate the vascular endothelial factors contribute to regulation of cerebrovascular 
tone and pathophysiology of cerebrovascular disease. 
 
1.3 EICOSANOIDS AND CYP METABOLISM 
1.3.1 Eicosanoids 
 
This section highlights the important role of arachidonic acid metabolites, also known as 
eicosanoids, in the pathogenesis of numerous disorders.  This section notes that arachidonic acid 
metabolites of the cyclooxgenase and lipooxygenase pathway are implicated in the development 
of DCI after SAH, but have shown limited clinical utility.  Conversely, eicosanoids derived from 
the cytochrome P450 pathway have not been studied as extensively.   
 
1.3.1.1 Eicosanoid Biosynthesis and Clinical Relevance:  Eicosanoids are important signaling 
molecules derived from the oxidation of either -3 or -6 essential fatty acids.  Arachidonic acid 
(AA) is a polyunsaturated -6 essential fatty acid that is typically stored in the sn-2 position of 
phospholipid membranes and comprises approximately 5–15% of total fatty acids in most tissue 
phospholipids.362  AA is released primarily through the activation of cytosolic phospholipase A2 
(cPLA2) in response to a variety of physiological, pharmacological, and pathological stimuli.
363  
Free AA can be oxidized by several enzymes to produce multiple groups of eicosanoids that play 
an important role in cell signaling and regulation pathways.364  The enzymatic oxidation of AA 
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occurs through three major pathways: cyclooxgenase (COX), lipooxygenase (LOX), and 
cytochrome P450 (CYP) (Figure 1-4: Eicosanoid synthesis from arachidonic acid).365  The 
oxidation of AA by COX and LOX forms multiple families of eicosanoids including 
prostaglandins (PGs), prostacyclin (PGI2), thromboxane (TXA2), leukotrienes (LTs), lipoxins 
(LPs), and others.  These eicosanoids are widely recognized as pathologic mediators of CVD, 
cancer, pain, fever, inflammation, and other disorders366-368 and thus serve as targets for numerous 
pharmacotherapies.   
 
 
Figure 1-4: Eicosanoid synthesis from arachidonic acid 
(Permission for use of figure granted by Jafar Sadik Bhasha Shaik) 
 
1.3.1.2 Role of Eicosanoids in CBF Regulation:  It is well established that eicosanoids derived 
from COX enzymes, and to a lesser extent LOX enzymes, contribute to the regulation of CBF and 
development of DCI.369  For example, alterations in the levels of multiple eicosanoids were 
observed in various experimental models of DCI.370-374  Studies have shown that the cerebral 
vasculature constricts in vitro and in vivo in response to a variety of these eicosanoids.375, 376  Also, 
administration of prostacyclin and non-steroidal anti-inflammatory drugs (NSAIDs) have been 
shown to prevent or reverse vasospasm in experimental models of SAH.377-381  These studies 
indicate that eicosanoids are likely to contribute to the development of DCI and pathogenesis of 
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SAH in humans.  However, treatment of SAH patients with agents targeting the COX and LOX 
pathway has been limited due to either lack of clinical efficacy or unwanted side effects primarily 
affecting hemostasis.382-384   On the other hand, eicosanoids formed from the oxidation of AA by 
CYP enzymes have not been studied as extensively.  However, recent evidence demonstrates that 
eicosanoids of the CYP pathway of AA metabolism are formed in various tissues, exert diverse 
biological effects, and contribute to the overall pathogenesis of several disease states including 
SAH.  
 
1.3.2 Cytochrome P450 (CYP) enzymes 
This section describes the relevant background on CYP enzymes and their mechanism of action.  
 
1.3.2.1 Background on CYPs:  Cytochromes P450 (CYPs) constitute a superfamily of heme-
containing proteins that play an important role in the metabolism of a large variety of xenobiotics 
and endogenous compounds.385, 386   CYPs are bound to membranes in the endoplasmic reticulum 
or in the inner mitochondrial membrane.385  The name for CYPs was derived from the unique 
spectral properties of these of enzymes that absorb light at 450nm after reduction by carbon 
monoxide (CO).385  The oxidation of a substrate by CYPs involves the splitting of molecular 
oxygen and the transfer of one oxygen atom to the substrate and the other oxygen atom to form a 
water molecule.385, 387  Based on their mechanism of action, CYPs are also referred to as 
monooxygenase, mixed function oxidase, and hydroxylase enzymes.385  The catalytic activity for 
CYPs requires the flavoprotein cytochrome P450 reductase for the transfer of electrons from 
nicotinamide adenine dinucleotide phosphate (NADPH) to CYPs.385, 387  CYPs can also complex 
with cytochrome b5 to alter catalytic activity.
385, 387 
1.3.2.2 CYP catalytic cycle:  Details of the CYP catalytic cycle are described by Danielson et al. 
and summarized in Figure 1-5: CYP catalytic cycle.385  First, the substrate binds to the CYP that 
is linked to a heme group made of a protoporphyrin IX complex with iron at the center.  Before 
binding of the substrate, the iron is in the Fe+3 state and binds water above the plane of the 
protoporphyrin IX complex.  Binding of the substrate releases water bound to Fe+3 and facilitates 
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the transfer of an electron from NADPH-CYP reductase to reduce Fe+3 to Fe+2.  Next, the 
CYP/substrate complex binds and reacts with molecular oxygen to produce an unstable ferrous 
dioxygen-bound complex (Fe+3 -O2∙) that accepts the transfer of a second electron from NADPH-
CYP reductase to form Fe+3-O2-.  The reduced complex is protonated twice to form of the reactive 
ferryl heme ([Fe-O]+3), and the release of a water molecule.  Finally, the oxygen atom of the ferryl 
species is transferred to the substrate and the substrate is released leaving the enzyme in its original 
Fe+3 state bound to water.   
 
Figure 1-5: CYP catalytic cycle 
 
1.4 CYP EICOSANOID BIOSYNTHESIS AND ELIMINATATION 
This section highlights the key enzymes responsible for the formation and elimination of 
eicosanoids derived from the CYP pathway of AA metabolism.  It also discusses the nomenclature 
for CYP eicosanoids and the regio- and stereo-selectivity of their isomers.  Furthermore, the 
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relevant elimination pathways of these CYP eicosanoids are discussed.   
 
1.4.1 CYP eicosanoid formation 
1.4.1.1 CYP eicosanoid regioisomers: CYPs can metabolize AA by hydroxylation, 
epoxidation, or allylic oxidation reactions.  The nomenclature of these CYP eicosanoids is based 
on the site of oxidation. Hydroxylation or allylic oxidation of AA leads to the formation of 
hydroxyeicosatetraenoic acids (HETEs) while epoxidation of AA forms epoxyeicosatrienoic acids 
(EETs).  The hydroxylation of AA can occur at the terminal carbon to form 20-
hydroxyeicosatetraenoic acid (20-HETE)388-395 or subterminal positions to form 16-, 17-, 18-, or 
19-HETE.396, 397  Allylic oxidation of AA leads to the formation of 7-, 10-, 11-, 12- 13-, and 15-
HETE.398  Epoxidation of AA can occur at one of the four double bonds of AA leading to the 
formation of 5,6-, 8,9-, 11,12-, or 14,15-EET.391, 392, 397, 399-404  EET isomers occur as R- or S-
enantiomers and the regio- and stereo-selectivity of EET formation can vary among mammalian 
species and tissue.356  Numerous studies have reported that 20-HETE and EETs are the major 
products produced by the CYP mediated metabolism of AA.356  Thus, 20-HETE and EETs are the 
major CYP eicosanoid products.   
1.4.1.2 20-HETE and EET synthesis:  Numerous human CYP isoforms have been implicated in 
the formation of 20-HETE including CYP4F2, CYP4A11, CYP2E1, CYP2C18, CYP2C19, 
CYPF12, CYP1A1, CYP1B2, CYP1B1, and CYP4FB3.388-395  But, it has been established that 
CYP4F2 and CYP4A11 are the key human CYP isoforms responsible for the formation of 20-
HETE.356  20-HETE is formed in tissues various tissues including liver, kidney, heart, lung, brain 
and vasculature.356  Human enzymes responsible for the formation of EETs include CYP2C8, 
CYP2C9, CYP2J2, CYP2C18, CYP2B6, CYP1A2, CYP1A1, and CYP1B2391, 392, 397, 399-404, but 
CYP2J2, CYP2C8, and CYP2C9 are primary isoforms responsible for EET synthesis.356  EETs 
are formed in various tissues including liver, kidney, heart, lung, brain, pancreas, gastrointestinal 
tract, and vasculature.356, 405  In brain, EETs are primarily formed by neurons, astrocytes, and 
endothelial cells and can be released from the membranes of red blood cells while 20-HETE is 
primarily synthesized in vascular smooth muscle cells (VSMC) and to a lesser extent white blood 
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cells.356, 406, 407  Together, these data demonstrate that CYP eicosanoids are formed in various 
tissues from the metabolism of AA and the key human CYP enzymes responsible for the formation 
of 20-HETE are CYP4F2 and CYP4A11 while EETs are primarily formed by CYP2J2, CYP2C8, 
and CYP2C9. 
1.4.2 CYP eicosanoid elimination   
Once formed, EETs can be further elimination in a number of pathways.  The primary pathway of 
EET elimination is metabolism by soluble epoxide hydrolase (SEH) to their corresponding diols 
known as dihydroxyeicosatrienoic acids (DHETs).  This process appears to be stereoselective with 
the preferred substrate of 14,15-EET > 11,12-EET > 8,9-EET and negligible metabolism of 5,6-
EET.408  EETs and to a lesser extent DHETs409 can also be incorporated into the sn-2 position of 
phospholipid membranes through esterification by coenzyme A (CoA)410, 411 and SEH is proposed 
to regulate this process.412  Like AA, these membrane stores of EETs and DHETs can be released 
through activation of cPLA2.
413  EETs are reported to be highly bound to fatty acid binding proteins 
thus limiting free concentrations in the plasma.414, 415  DHETs exhibit protein binding but to a 
lesser extent than EETs.415  Other minor pathways of elimination include -oxidation, glutathione 
conjugation, and metabolism by CYPs.414  Thus, can bind to proteins or be incorporated into lipid 
membranes, but the primary elimination pathway of EETs is metabolism by SEH to form DHETs.   
The primary pathways of 20-HETE eliminated have not been clearly elucidated.416  Porcine 
coronary endothelial cells have been shown to metabolize 20-HETE to 20-carboxy-aracidonic acid 
(20-COOH-AA).417 Likewise, cerebral arteries converted 20-HETE to 20-COOH-AA418, 419 with 
catalysis by alcohol dehydrogenase.419  On the other hand, mouse brain endothelial cells and rat 
seminal vesicles converted 20-HETE to 20-OH-PGE2 and 20-hydroxy-PGF2, respectively.418, 420  
In human tissues, 20-HETE was metabolized by COX and LOX enzymes in platelets to form a 
series of novel metabolites formed by COX.421  Also, a glucuronide conjugation of 20-HETE was 
reported in urine.422, 423  Like EETs, 20-HETE is highly bound to plasma proteins and is avidly 
incorporated into lipid membranes through esterification.356  20-HETE also reported to undergo -
oxidation.356  Taken together, these studies report a series of 20-HETE metabolites and elimination 
pathways, but none have been identified as the primary pathway of elimination.   
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1.5 CYP EICOSANOID ENZYMES 
 
1.5.1 Expression of CYP eicosanoid enzymes 
This section highlights relevant information on the CYP family, gene location, protein expression, 
tissue localization, and mammalian orthologues for CYP eicosanoid enzymes.   
 
1.5.1.1 CYP4A11 expression:  In mammals, six CYP4 gene subfamilies have been identified 
CYP4A, CYP4B, CYP4F, CYP4V, CYP4X, and CYP4Z 424-427  In humans, the CYP4A family 
consists of two isoforms CYP4A11 and 4A22, which are located in the CYP4 ABZX gene cluster 
at 1p33 425.  CYP4A22 shares 97% nucleotide identity and 94% amino acid identity with CYP4A11 
but expression in human tissues is much lower than CYP4A11.428, 429  CYP4A11 is primarily 
expressed in human liver and kidney.  To illustrate, CYP4A11 is the predominant microsomal 
CYP4A enzyme in human liver and kidney microsomes428, 429 and is highly expressed in liver 
parenchymal cells390, kidney proximal tubule cells 390, 430 and to a lesser extent in the thick 
ascending limb and collecting duct of the kidney430.  The CYP4A isoforms capable of producing 
20-HETE in rats include CYP4a1, CYP4a2, CYP4a3, and CYP4a8, which are highly expressed in 
tissues such as liver, kidney, testes, or muscle.356, 425 Likewise, the CYP4A isoforms capable of 
producing 20-HETE in mice include CYP4a10, CYP4a12, and CYP4a14, which are highly 
expressed in tissues such as liver and kidney.356, 425  These data suggest that CYP4A enzymes are 
highly expressed in liver and kidney and to a lesser extent other tissues in mammalian species. 
1.5.1.2 CYP4F2 expression:  In humans, the CYP4F gene subfamily consists of CYP4F2, 
CYP4F3, CYP4F8, CYP4F11, CYP4F12, and CYP4F22 genes, which are located at chromosome 
19p13 as part of a large gene cluster.396, 431-434  These CYP4F genes have very similar structures 
and splicing sites.435  It has been proposed that the CYP4F subfamily is the result of a gene 
duplication process resulting in multiple CYP4F genes with high amino acid homology and 
different catalytic specificity.436  Of the CYP4F enzymes expressed in humans, CYP4F2 is the 
predominant enzyme responsible for the metabolism of fatty acids (-hydrolase).425  CYP4F2 is 
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expressed in significant and highly variable levels in liver and kidney425, 437 CYP4F2 is expressed 
to a lesser extent in skin, several other tissues and tumors, but not in myeloid cells in humans.435  
The CYP4F isoforms response for 20-HETE formation in rats include CYP4f1, CYP4f4, CYP4f5, 
and CYP4f6 enzymes, which are highly expressed in liver, kidney, brain, gastrointestinal tract, 
and lung.356, 425  Likewise, the CYP4F isoforms response for 20-HETE formation in mice include 
CYP4f13, CYP4f14, CYP4f15, CYP4f16, CYP4f18, which are highly expressed in liver, kidney, 
brain, and leukocytes.356, 425  These data suggest that CYP4F enzymes are highly expressed in liver 
and kidney and to a lesser extent other tissues in mammalian species. 
1.5.1.3 CYP2J2 expression:  CYP2J2 is the only isoform of the CYP2J subfamily of enzymes in 
humans438. CYP2J2 gene was mapped on the short arm of human chromosome 1438, the genomic 
region spans approximately 40 kb439.  The gene encodes a protein with a molecular mass of 57.7 
kd and consists of 502 amino acids.401  CYP2J2 is the only human CYP known to be expressed at 
high levels in heart particularly in cardiac myocytes and endothelial cells in coronary arteries.401, 
440  To illustrate, mRNA levels for CYP2J2 were 10 time higher than CYP2C8/9.441  CYP2J2 is 
also expressed to a lesser extent in human liver, intestine, lung, kidney, vasculature, and other 
tissues 399, 401, 442, 443  In the liver and intestine, CYP2J2 constitutes 1 to 2% of total P450 content.444  
In addition, CYP2J2 showed selective distribution in different brain regions.445, 446  Although 
CYP2J2 is widely distributed in human tissues, the pattern of distribution and expression does not 
seem to correlate with that of CYP2C8/9 and SEH.447  In other mammalian species, CYP2J 
isoforms responsible for EET formation include CYP2j3 and CYP2j4 in the rat, CYP2j5 and 
CYP2j6 in the mouse, and CYP2j1 in the rabbit and sequence homology ranges from 69% to 
94%.448  These CYP2J enzymes are widely expressed in various tissues, but high expression of 
CYP2j1 is reported in rabbit small intestine, CYP2j3 in the rat heart and liver, CYP2j4 in rat brain, 
heart, lung, intestine, kidney, and liver, CYP2j5 in mouse kidney, and CYP2j6 in mouse 
intestine.356, 448  These data suggest that CYP2J2 plays an important role in the human heart and 
coronary arteries while CYP2J enzymes in other species are widely distributed among various 
tissues. 
1.5.1.4 CYP2C9 expression:  In humans, the CYP2C subfamily consists of CYP2C8, CYP2C9, 
CYP2C18, and CYP2C19.  The CYP2C8 and CYP2C9 genes are in close proximity on 
chromosome 10q24 located in a CYP2C gene cluster also containing CYP2C18 and CYP2C19 
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genes449-451. Given the close proximity of CYP2C8 and CYP2C9, some degree of linkage 
disequilibrium has been reported in these genes.451-453.  The CYP2C enzymes are found 
predominantly in the liver and comprise 8-35% of the total CYP content.454, 455  CYP2C8 accounts 
for 7% of CYP content in the liver, and is expressed to a lesser extent in the kidney, adrenal gland, 
mammary gland, brain, ovary, uterus, and duodenum.449, 456-458  CYP2C9 accounts for 19% of CYP 
content in the liver and, among all CYP isoforms, levels are only exceeded by CYP3A4.459-461 In 
extrahepatic tissues, CYP2C8/9 are expressed in a wide variety of tissues such as kidney, lung, 
vasculature, gastrointestinal tract, skin, and prostate.447  In one study, tissue-specific patterns of 
CYP2C9 were very similar to those of SEH.447  CYP2C enzymes have also been detected in rat 
brain astrocytes.462  In other mammalian species, CYP2C isoforms responsible for EET synthesis 
include CYP2c11, CYP2c12, CYP2c23, and CYP2c24 in the rat and CYP2c29, CYP2c38, 
CYP2c39, CYP2c40 and CYP2c44 in the mouse and show similar patterns of expression as those 
described in humans.356, 391, 463-466 These data suggest that CYP2C8/9 plays an important role in 
both hepatic and extrahepatic tissues in mammalian species.   
1.5.1.5 SEH Expression:  Soluble epoxide hydrolase (SEH) is part of the epoxide hydrolase 
family of enzymes that are found in all living organisms.413, 467 SEH was first identified in insects 
while studying the metabolism of a terpenoid epoxide that mimicked the insect juvenile 
hormone.468  The term SEH was based on its localization in the soluble and peroxisomal fractions 
of the cell.469, 470   In the following 30 years, the gene, protein, and catalytic mechanisms were 
characterized and studied.471-474  In humans, SEH is the product of the EPXH2 gene located on 
chromosome 8p21-p12.471, 475, 476  The active form of the human SEH protein is a homodimer with 
each monomer consisting of 555 amino acids and a molecular mass of 62.5 kDa.475, 477 The SEH 
enzyme is widely distributed in mammalian tissues and the expression and specific activity of SEH 
is reported to be highest in the liver, followed by the kidney, with lesser activity in other 
extrahepatic tissues.414  For example, studies of various human tissue homogenates have reported 
that the highest levels of SEH activity are found in liver and kidney.478  Enayetallah et al. also 
observed SEH in high levels in liver and kidney but also identified SEH in many other organs 
including adrenals, pancreatic islets, pituitary gland, lymphoid tissues, muscles, vascular smooth 
muscle cells, and epithelial cells in the skin, prostatic ducts, and the gastrointestinal tract.447  In 
this study, the tissue specific-patterns of SEH expression seemed to correlate well with those of 
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CYP2C9.  In human brain tissues, SEH was found mainly in the neuronal cell bodies, 
oligodendrocytes, astrocytes, and VSMC and the specific activity of SEH in the various brain 
regions was approximately 10-fold less than that of the liver.479  Other studies of Enayetallah et al. 
identified SEH in different subcellular compartment in an array of human tissues.480  SEH 
expression was present in both cytosolic and peroxisomal in human hepatocytes and renal proximal 
tubules and was found exclusively in the cytosol of pancreatic islet cells, intestinal epithelium, 
anterior pituitary cells, adrenal gland, endometrium, lymphoid follicles, prostate ductal epithelium, 
alveolar wall, and blood vessels.480  Collectively, these data suggest that SEH is found in a wide 
array of human tissues with the highest levels and activity in the liver and kidney.   
1.5.2 Gene regulation of CYP eicosanoid enzymes 
This section contains information on activators and repressors of CYP eicosanoid genes and 
highlights mechanisms involved in this process. 
 
1.5.2.1 CYP411 gene regulation:  There are several agents that induce expression of the CYP4A 
subfamily of enzymes.  CYP4A enzymes are induced in several mammalian species by 
hypolipidemic drugs such as fibrates.481-483   This response is likely mediated through PPARα, 
which plays a central role in lipid homeostasis through gene regulation.484-486 The induction of 
CYP4A enzymes does not necessarily diminish the activation of PPARα because a number of ω-
hydroxylated fatty acid metabolites are also PPARα agonists.487-489  Caloric restriction and fasting 
are thought to elevate PPARα responsive genes in the liver in response to the increased release of 
fatty acids from adipocytes.490 491  Also, statins have been shown to induce CYP4A gene 
expression in rat liver and rat hepatocytes492 through activation of the transcription factor, sterol 
regulatory element-binding protein 2 (SREBP-2)493.  In contrast, statin induction of CYP4A11 
mRNA was not seen in primary human hepatocytes.494  In addition, androgens such as 5-
dihydrotestosterone (DHT) have been shown induce CYP4A enzymes in the renal vasculature of 
rodents495, which led to increase blood pressure,496, 497 especially in males498.  This effect was 
accompanied by a down regulation of CYP2C enzymes responsible for the synthesis of EETs495 
and an increase in the 20-HETE to EET ratio in the renal vasculature.497  Furthermore, a high fat 
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diet has been shown to down regulate the expression of CYP4A and CYP2C enzymes, reduce the 
formation of 20-HETE and EETs in renal tubules, and lead to hypertension in rats.498  These effects 
can be reversed by administration of fibrates such as clofibrate and fenofibrate.499, 500  On the other 
hand, the retinoic acid receptor (RAR) agonist all trans-retinoic acid is reported to suppress 
CYP4A11 expression in a human hepatoma cell line.501  Taken together, these studies suggest that 
CYP4A enzymes in mammals are induced by hypolipidemic drugs, PPAR agonists, statins, 
androgens, and starvation and suppressed by a high fat diet and RAR agonists with some variable 
responses among species and sex.  
1.5.2.2 CYP4F2 gene regulation:  Expression of CYP4F2 is reported to be under the control of 
several nuclear hormone receptors and transcription factors.  For example, CYP4F2 gene 
expression can be induced by retinoic acid in HepG2 cells through an RAR/retinoid X receptor 
(RXR) heterodimer response element.502  Also, CYP4F2 gene expression can be induced in Hep2G 
cells by saturated fatty acids and repressed by PPARα agonists such as clofibrate and Wy14643.503  
In contrast, CYP4A11 expression in a human hepatoma cell line is repressed by all trans-retinoic 
acid501 and induced by hypolipidemic drugs through PPAR504.  Statins can also induce CYP4F2 
expression in human hepatocytes and HepG2 cells through SREBP activation, which are a 
transcription factors that play an important role in lipid and sterol homeostasis.494  Several 
transcription factor binding sites, such as NF-Y, C/EBP, CREB and Sp1, have been shown to 
contribute to SREBP binding and to efficient target gene transactivation.494  In addition, direct 
repeat elements (DR-1 and DR-2) in the 5′ promoter and intron 1 have been shown to cooperate in 
gene transcription.503  Taken together, these data suggest that CYP4F2 expression is induced by 
activators of the nuclear receptors RAR/RXR and PPAR, transcription factors such as SREBP 
and SP1, and other regulatory elements in the promoter region. 
1.5.2.3 CYP2J2 gene regulation:  The regulatory mechanisms of CYP2J enzymes have not been 
well studied.  CYP2J2 is alternatively spliced in a tissue-specific fashion that may serve as a 
mechanism to regulate gene expression or activity.448  Also, the promoter region contains four 
binding site consensus sequences for the SP1 transcription factor.505 Some studies have shown that 
activator protein-1 (AP-1), a multiprotein transcription factor complex, down regulates CYP2J2 in 
liver cells.506  AP-1 activity is activated by stress stimuli such as hypoxia, cytokines, growth 
factors, carcinogens and UV irradiation and activates signaling pathways regulate cell survival and 
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apoptosis.506  In addition, metabolites of CYP2J enzymes are reported to activate the nuclear 
receptor PPAR in vitro and in vivo.507  CYP2J has also been induced with agents such as 
phenobarbital, β-naphthoflavone, clofibrate, and acetone.401, 448  CYP2J protein levels do not 
appear to change in selected animal models of disease, including salt-sensitive hypertension, 
oxygen-induced lung injury, and cardiac ischemia/reperfusion.448  Furthermore, CYP2J may be 
regulated by nutrition508 and age448.  These data suggest that CYP2J gene expression is activated 
by PPAR agonists and repressed by stress stimuli through the activation of AP-1. 
1.5.2.4 CYP2C8/9 gene regulation:  CYP2C8/9 gene expression is regulated by multiple nuclear 
receptors and transcription factors.509, 510  Transcription of CYP2C8/9 is regulated by the nuclear 
receptors constitutive androstane receptor (CAR)/pregnane X receptor (PXR), glucocorticoid 
receptor (GR), and hepatocyte nuclear factor- (HNF-.454, 511-513 Recent studies have identified 
other nuclear receptors and transcriptional factors including HNF4α, HNF3γ, C/EBPα, and RORs 
that regulate the constitutive expression of CYP2C genes in liver.454, 514  CYP2C8 protein and 
mRNA levels are not affected by sex and age.515  Some studies report correlations in the mRNA 
expression of 2C8, 2C9, 2C19, and 3A4 due to common regulatory pathways.515  In vitro studies 
report that CYP2C8 expression is induced strongly by the antibiotic rifampin and to a lesser extent 
by the glucocorticoid steroid dexamethasone and barbiturate phenobarbital.512, 516, 517  Clinical 
studies report that rifampin decreases the plasma exposure of major CYP2C8 substrates such as 
rosiglitazone518, 519, pioglitazone520, and repaglinide521, 522.  Similarly, CYP2C9 is strongly induced 
by rifampin but can also be moderately induced by secobarbital.517, 523 In clinical studies, treatment 
with rifampicin has been shown consistently to increase the clearance of drugs eliminated by 
CYP2C9. Also, the clearance of losartan, phenytoin, tolbutamide and S-warfarin is approximately 
doubled in healthy volunteers or patients treated with rifampicin.524, 525  Induction of CYP2C8/9 is 
of concern because it can lead to drug-drug interactions, drug tolerance, or altered drug disposition 
and response.454  In summary, CYP2C8/9 gene expression is regulated by multiple nuclear 
receptors and transcription factors including CAR/PXR, GR, and HNF- and induction of these 
enzymes by rifampin or other agents may lead to clinically relevant changes in pharmacotherapy. 
1.5.2.5 SEH gene regulation:  The expression of SEH is regulated by multiple processes. SEH 
contains a TATA-less promoter with a GC-rich region and SP-1 binding site that appears to be 
involved in the basal expression of EPHX2.526 SP-1 transcription factor has been shown to induce 
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SEH expression through demethylation in HepG2 cells.527  In addition, PPAR agonists have been 
noted to induce SEH expression in rodents.528-530  Also, SEH expression has been linked to 
hormonal stimuli.  For example, angiotensin II is reported to upregulate SEH expression in human 
endothelial cells through activation of AP-1531 and increase SEH protein levels and catalytic 
activity in rat renal cortical tissue 532  Sex hormones are also suggested to affect SEH expression 
in rodents.  In mice, males show 55% and 28% higher SEH activities in liver and kidney, 
respectively, in comparison to females529 and ovariectomy increases SEH activities in liver and 
kidney529.  Furthermore, inflammatory stimuli have been shown to affect SEH expression.413 531  
Cigarette smoke transiently reduces SEH activity in the human lung 533 and exposure to gamma 
radiation increases the levels of EPHX2 mRNAs through NFkB induction in human cell lines 534  
It has also been shown that SEH activity can be affected by post-translational modification through 
tyrosine nitration of the protein.535  These data provide evidence that SEH gene expression is 
induced by SP-1 transcription factor, PPAR agonists, male sex, and reduced by smoking and 
tyrosine nitration of the protein.   
1.5.3 Substrates for CYP eicosanoid enzymes 
This section summarizes notable substrates that have been previously reported to be metabolized 
by CYP eicosanoid enzymes.  It includes a discussion of the individual contribution of each 
enzyme to the formation or elimination of CYP eicosanoids and highlights their role in the 
metabolism of other endogenous compounds and drugs.  
 
1.5.3.1 CYP4A11 substrates:  The CYP4A family of enzymes is generally known for the 
metabolism of medium chain (C10-C16) and long chain (C16-C26) fatty acids primarily by 
oxidation of the terminal () carbon and to a lesser extent the -1 carbon.536  CYP4A11 catalyzes 
the ω-hydroxylation of lauric acid, palmitic acid, and AA in human kidney537, human liver538, and 
in cells expressing the recombinant protein388, 539.  In these studies, the -hydrolase activity of 
CYP4A11 was greatest toward lauric acid (C12) followed by palmitic acid (C16), and then 
arachidonic acid (C20).  In human liver microsomes, CYP4A11 is responsible for 85% and 13% 
of the -hydrolase activity towards lauric acid538 and AA389, respectively.  Although CYP4A11 
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seems to play a minor role in the metabolism of long chain fatty acids in the liver, its effects in the 
kidney seem more apparent.  In human kidneys, CYP4A11 is the predominant isoform responsible 
for the -hydroxylation of arachidonic acid to form 20-HETE.540  In other mammalian species, the 
CYP4A subfamily have been shown to catalyze the  or -1 hydroxylation of lauric acid, 
palmitic acid, AA, or prostaglandins in liver, kidney, or in vitro.541-543  Taken together, these 
studies demonstrate that CYP4A enzymes play an important role in the metabolism of fatty acids 
in the liver and kidney.   
1.5.3.2 CYP4F2 substrates:  The CYP4F family of enzymes is generally known for the 
metabolism of long chain (C16-C26) fatty acids and lipids primarily by oxidation of the terminal 
() carbon and to a lesser extent the -1 carbon.536, 544  CYP4F2 has been reported to be responsible 
for the metabolism of AA and its metabolites such as prostaglandins E1 and A1, lipotoxins A4 and 
B1, 5-, 8-, and 12-HETE, prostanoids, leukotriene B4, and anandamide.426, 463, 481, 545  In human 
liver, CYP4F2 is the primary -hydroxylase enzymes responsible for the metabolism of the pro-
inflammatory leukotriene B4 and arachidonic acid.435, 544  For example, CYP4F2 content in human 
liver microsomes has been significantly correlated with leukotriene B4 and AA hydroxylase 
activities (r>0.63).437  Although CYPF2 and CYP4A11 are reported to -hydroxylate arachidonic 
acid in the liver, CYP4F2 has been shown to be the principle enzyme responsible for 20-HETE 
formation in human liver microsomes.546  In addition, CYP4F2 is reported to -hydroxylate AA 
in the proximal tubules of the human kidney to form 20-HETE.390  Likewise, CYP4F2 catalyzes 
the ω-hydroxylation of phytanic acid (C20), oleic acid (C18), stearic acid (C18), palmitic acid 
(C16), α- and γ-tocopherols (vitamin E), but not lauric acid (C12).544, 547, 548  In addition to 
metabolizing endogenous fatty acids and lipids, CYP4F2 is also responsible for the metabolism of 
xenobiotics.  For example, CYP4F2 is a primary vitamin K1 oxidase in the liver that limits 
excessive accumulation of vitamin K.549  Likewise, CYP4F2 is a major human liver microsomal 
enzymes responsible for the O-demethylation of the anti-parasitic drug pafuramidine (DB289)550.  
Furthermore, CYP4F2 is the predominant enzyme responsible for the hydroxylation of the 
immunomodulating drug fingolimod.551, 552  In summary, CYP4F2 is a major enzyme involved in 
the metabolism of long chain fatty acids, lipids, vitamin K, pafuramidine, and fingolimod. 
1.5.3.3 CYP2J2 substrates:  Like CYP2C8 and CYP2C9, CYP2J2 is an epoxygenase that 
catalyzes epoxide formation at the site of a carbon-carbon double bond.505  There are multiple 
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xenobiotics that are readily metabolized by CYP2J2.448  A recent study investigating 139 marketed 
drugs and compounds reported that CYP2J2 can metabolize numerous structurally diverse 
compounds such as albendazole, amiodarone, cyclosporine A, danazol, mesoridazine, 
nabumetone, tamoxifen, and thioridazine.553  Many of these substrates were also metabolized by 
CYP3A4, but there were differences in regioselectivity.553  Also, CYP2J2 metabolism of large 
compounds was more restricted to a single site.553  Endogenous substrates of CYP2J include fatty 
acids such as AA and linoleic acid.439, 505  CYP2J2 catalyzed the metabolism of AA to four 
regioisomeric epoxyeicosatrienoic acids (EETs): 14,15-EET; 11,12-EET; 5,6-EET and 8,9-
EET.401, 463  In this study, 14,15-EET was the primary metabolite and the epoxidation was highly 
stereoselective for 14(R),15(S)-EET whereas 11,12-EET; 5,6-EET and 8,9-EET seemed to be less 
selective for specific enantiomers.401 The regio- and stereo-selective product profile of CYP2J 
enzymes was different from that of other known AA epoxygenases such as CYP2C enzymes.397, 
402, 554-556 In addition, AA and ebastine strongly inhibited the metabolism of astemizole in 
microsomes from human small intestines and by recombinant CYP2J2.557  Furthermore, CYP2J 
enzymes oxidized other endogenous substrates such as testosterone, but showed low activity 
toward some fatty acids such as prostaglandins and lauric acid.448  In summary, CYP2J2 
metabolizes numerous structurally diverse drugs and compounds and serves as a primary enzyme 
involved in the stereo and regio-selective epoxidation of AA and other fatty acids. 
1.5.3.4 CYP2C8/9 substrates:  The CYP2C8 and CYP2C9 are major phase I metabolizing 
enzymes that play an integral role in the biotransformation of structurally diverse xenobiotics and 
endogenous compounds.558  It has been estimated that CYP2C8 and CYP2C9 are responsible for 
the metabolic clearance of up to 5% and 15%-20%, respectively, of all drugs undergoing Phase I 
metabolism 458, 559, 560  Over 100 marketed drugs are metabolized by CYP2C9 including many with 
a narrow therapeutic index such as warfarin and phenytoin.460  CYP2C9 metabolizes many 
structurally diverse drugs such as the NSAIDs diclofenac, hypoglycemic agent tolbutamide, 
angiotensin II blocker lostartan, and sulphonylurea tolbutamide.517  Likewise, the CYP2C8 
substrate-binding cavity is reported to accommodate large and/or structurally unrelated 
compounds, such as paclitaxel, amiodarone, cerivastatin, and sorafenib.517, 561, 562  Although 
CYP2C8 and CYP2C9 show 70% sequence homology, CYP2C8 shares more common substrates 
with CYP3A4 than it does with CYP2C9.458  CYP2C9 also plays a role in the metabolism of 
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several endogenous compounds such as linoleic acid, AA, serotonin, steroids, melatonin, and 
retinoids.460, 563, 564  CYP2C8 also metabolizes endogenous compounds such as retinoids and 
AA.510  For example, CYP2C8/9 have been shown to metabolize AA to form various region- and 
stereo-isomers of EETs in hepatic and extrahepatic tissues.400, 405, 463, 565  In summary, CYP2C8/9 
play an important role in the metabolism of many structurally diverse drugs and endogenous 
compounds. 
1.5.3.5 SEH substrates:  SEH has not been reported to be a major metabolizing enzyme for any 
marketed drugs.  However, SEH plays an important role in defense and detoxification in multiple 
species by converting potentially harmful epoxide-containing compounds into diols, which are less 
reactive and easier to excrete.566  SEH of mouse, rat, and human have similar molecular weight 
and immunoreactivity567, but SEH of primate and non-primate species differ in substrate 
specificity.566  Saturated and unsaturated fatty acid epoxides, including linoleic and AA epoxides, 
are excellent SEH substrates.568-573  For example, SEH is the primary metabolizing enzyme of 
EETs, which have been established as lipid mediators with important biological functions 574  
Recently, it has been discovered that SEH is a bi-functional enzyme that possesses an N-terminal 
phosphatase activity in addition to its C-terminal epoxide hydrolase activity.575, 576  It has been 
suggested that endogenous substrates of the N-terminal phosphatase domain include 
phosphorylated lipid metabolites such as isoprenoid phosphates.577  Some phosphorylated lipid 
metabolites are precursors in the biosynthesis of cholesterol576-578 and isoprenoid phosphates are 
known to play a role in isoprenylation of small G-proteins and cell signaling579.  Interestingly, 
endogenous substrates of the C-terminal domain, such as fatty acid epoxides, are found in the 
cytosol488, 580, 581, while endogenous substrates of the N-terminal domain, such as isoprenoid 
phosphates, are found in the peroxisomes and/or the cytosol579, 582.  Collectively, these data suggest 
that SEH plays multiple diverse roles in lipid metabolism and cellular signaling in various tissues 




1.5.4 Inhibitors of CYP eicosanoid enzymes 
This section summarizes some of the key small molecules that have been used to inhibit the 
enzymes involved in CYP eicosanoid biosynthesis.  These inhibitors have been used in preclinical 
and/or clinical studies investigating the function of these enzymes in various diseases.  
 
1.5.4.1 Inhibitors of 20-HETE Pathway:  Numerous -hydroxylase inhibitors and 20-HETE 
antagonists have been developed over the last few decades.  Mechanism based inhibitors of 
CYP4F2 and CYP4A11 include 1-aminobenzotriazole (ABT)583, 17-octadecynoic acid (17-
ODYA)584, 585, 10-undecynoic acid (10-UDYA)584, 585, and 10-undecynyl sulfate (10-SUYS)586.  
Competitive and non-competitive inhibitors of 20-HETE synthesis include N-methylsulfonyl-
12,12-dibromododec-11-enamide (DDMS)587, N-hydroxy-N`-(4-butyl-2-methylphenyl)-
formamidine (HET0016)588, and N-(3-Chloro-4-morpholin-4-yl) phenyl-N`-hydroxyimido 
formamide (TS-011)589.  There are a few 20-HETE antagonists including the stable structural 20-
HETE analogs 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid (20-HEDE)587,  and 20-hydroxyeicosa-
6(Z),15(Z)-dienoic acid (WIT002)590.  Also, 20-HETE agonists include 4-amino-N-(20-hydroxy-
eicosa-5(Z),14(Z)-dienoyl) benzenesulfonamide (ABSA) and 20-hydroxyeicosa-5(Z),14(Z)-
dienoic acid (WIT003).590  These compounds have been used in preclinical studies to investigate 
the role of 20-HETE in the regulation of cerebral blood flow or cerebrovascular response.  Among 
the -hydrolase inhibitors, TS-011 demonstrates superior sensitivity and selectivity and thus 
appears to be one of the most promising agents for clinical development.589  In addition, CYP4F2 
-hydroxylase activity has been shown to be inhibited by some dietary agents.  Sesamin has been 
shown to inhibit CYP4F2 -hydroxylase activity towards tocopherols (vitamin E) in rat and 
human liver microsomes591 and dietary sesamin has been shown to elevate vitamin E levels in 
vivo592-594  Likewise, ketaconozole has been shown to inhibit fingolimod metabolism by CYP4F2 
in human liver microsomes595, but showed minimal effects on the pharmacokinetics of fingolimod 
in humans551.  In summary, numerous selective -hydroxylase inhibitors and 20-HETE 
antagonists have been used in preclinical studies to help elucidate the mechanisms involved in the 
pathogenesis of various diseases and demonstrate potential for future clinical studies.  
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1.5.4.2 Inhibitors of EET Synthesis:  A few epoxygenase inhibitors have been used in preclinical 
studies investigating the role of CYP eicosanoids in various disease models.  For example, 
miconazole596, 17-ODYA596, and N-methylsulfonyl-6-(2-propargyloxyphenyl) hexamide (MS-
PPOH) 597 have been used to investigate the role of EETs in the regulation of cerebral blood flow 
in vivo.  However, some authors have noted that 17-ODYA is not specific and equally inhibits 
epoxygenase and -hydroxylase activity, thus presenting limitations of its use.598  In addition, 
there are numerous selective, competitive and mechanism-based inhibitors of epoxygenase 
enzymes that have been previously reported in other studies.599  For example, derivatives of 
ebastine and terfenadine have been shown to be high affinity inhibitors of CYP2J2600 and the 
metabolism of astemizole in human small intestinal microsomes and recombinant CYP2J2 
microsomes was inhibited by -naphthoflavone, ketoconazole, troglitazone, tranylcypromine, 
ebastine and terfenadine601.  The Department of Medicine at Indiana University provides an 
excellent table summarizing CYP2C8 and CYP2C9 inhibitors and clinically relevant drug 
interactions.517  This table and other studies report that CYP2C8 is strongly inhibited by the 
hypolipidemic drug gemfibrozil and moderately inhibited by the antibiotic trimethoprim.509, 517, 602-
605  CYP2C9 is strongly and moderately inhibited by fluconazole and amiodarone, respectively.517, 
524  Clinical studies reported altered anticoagulant effect of warfarin in patients coadministered 
with amiodarone.606, 607  In summary, numerous inhibitors of epoxygenase enzymes exist, but few 
have been used in the investigation of CYP eicosanoids in disease.   
1.5.4.3 Inhibitors of EET metabolism:  Based on the numerous biological functions associated 
with EETs and their rapid metabolism observed in vivo608, multiple inhibitors of SEH were 
developed to elevate EETs levels and augment their beneficial biological effects.  Shen et al. 
provides an excellent review that summarizes the history of the development of these inhibitors 
and their use in various studies and clinical investigations.609  In this review, it is noted that several 
pharmaceutical companies and academic institutions were involved in the development of SEH 
inhibitors as a potential therapeutic treatment for hypertension, atherosclerosis, pulmonary 
diseases, diabetes, pain, inflammation, immunological disorders and other indications.  
Pharmaceutical companies involved in the development of these SEH inhibitors were Arête 
Therapeutics, Astellas, Boehringer Ingelheim, GlaxoSmithKline, Merck, Roche, Taisho, 
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Dainippon Sumitomo, and Takeda while the primary academic institutions involved included 
University of California Davis, Columbia University, Chinese Academy of Sciences, and Shanghai 
Institute of Biological Sciences.  Over the years, numerous type of SEH inhibitors were developed 
in order to improve its potency, solubility, pharmacokinetic properties, and selectivity.  The major 
inhibitor chemotypes include urea, amide, carbamate, thioester, carbonate, ester, thiourea, 
thioamide, amidine, guanadine, heterocycles, aminoheterocycles, aminoheteroaryls, chalcone 
oxides, acyl hydrazones, chalcone oxides and trans-3-phenylglycidols.609  The most common SEH 
inhibitor used in preclinical models of ischemic and hemorrhagic stroke include 12-(3-Adamantan-
1-yl-ureido)-dodecanoic acid (AUDA) and 12-(3-Adamantan-1-yl-ureido)-dodecanoic acid butyl 
ester (AUDA-BE).  The therapeutic utility of some of these agents have been investigated in 
clinical trials, however there are currently no approved SEH inhibitors on the market.   
1.6 ROLE OF CYP EICOSANOIDS IN THE CEREBROVASCULATURE 
1.6.1 Role of CYP eicosanoids in pathogenesis of aneurysms 
This section will highlight the key cellular signaling pathways and cellular responses activated by 
CYP eicosanoids with a focus on those involved in vascular homeostasis and intracranial aneurysm 
formation or rupture.  
 
1.6.1.1 Cellular action and signaling pathways:  20-HETE and EETs produce diverse array of 
biological actions in a variety of tissues and cells, but function primarily in the cardiovascular and 
renal systems.  Roman et al. provides an excellent review on the role of CYP eicosanoids in 
cardiovascular function.581  EETs are reported to dilate renal and cerebral arteries, promote 
angiogenesis, mitogenesis, and fibrinolysis, and inhibit inflammation, apoptosis, and platelet 
aggregation.581  The cellular actions of EETs are mediated through numerous intracellular 
signaling mechanisms such as 3,’5’-cyclic monophosphate (cAMP), phosphokinase A (PKA), 
phosphatidylinositol 3-kinase (PI-3K), protein kinase B (PKB/Akt), mitogen-activated protein 
kinase (MAPK), IB kinase (IK), I-kappa-B-alpha (IB, epidermal growth factor receptor 
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(EGFR), and Src kinase in various cell types.581  The predominant intracellular signaling pathways 
appear to be species- and cell-dependent.356  Evidence suggests that the cellular actions of EETs is 
mediated through a G-protein coupled receptor (GPCR), but so far only putative receptors have 
been proposed.581  The cellular actions of 20-HETE appear to counterbalance those of EETs.  20-
HETE constricts renal and cerebral arteries and promotes angiogenesis, inflammation, apoptosis, 
and platelet aggregation.356  20-HETE is reported to activate a wide array of intracellular signaling 
pathways and 20-HETE receptor has not been identified.356   Although DHETs have been reported 
to constrict coronary arteries610 and activate PPAR, the preponderance of studies report that 
DHETs do not affect cerebrovascular tone611 and cellular function581 and thus are considered 
inactive metabolites.  Based on the biological actions and cellular mechanisms of 20-HETE and 
EETs, their role in CVD and other disorders has been an intense area of focus in recent years.   
1.6.1.2 Hypertension and vascular remodeling:  Recent evidence suggests that CYP eicosanoids 
may play a role in the formation and rupture of IA.  Previous studies report a strong link between 
hypertension and vascular remodeling with the formation and rupture of IA.124, 612  Growing 
evidence demonstrates that 20-HETE and EETs are key regulators of blood pressure and play an 
important role in the development of hypertension.356, 613  Also, a recent review by Imig et. al. 
suggests that CYP eicosanoids impact vascular homeostasis and remodeling.355  In vitro studies 
report that EETs exhibit proliferative, migratory, angiogenic, fibrinolytic, anti-apoptotic, anti-
inflammatory, and anti-platelet aggregation effects in vascular endothelial cells and inhibit 
migration and apoptosis in VSMC.355  20-HETE is involved in vascular remodeling and 
microvessel formation by stimulating proliferation, migration, and mitogenesis in VSMC and 
proliferation and angiogenesis in microvascular endothelial cells.355  Collectively, these findings 
suggest that CYP eicosanoids play an important role in hypertension and vascular homeostasis and 
may contribute to the pathogenesis of IA and risk of rupture.   
1.6.2 CYP eicosanoid regulation of cerebrovascular tone 
This section will discuss the responses in cerebrovascular tone to exogenous administration of the 




1.6.2.1 Response of isolated vessels:  The role of CYP eicosanoids in the regulation of CBF has 
been a topic of intense area of study in the last two decades.  Previous studies demonstrated that 
CYP eicosanoids regulate cerebrovascular tone in vitro.  In these studies, cerebral arteries were 
dissected from the brain, mounted on glass micropipettes with sutures, pressurized in a perfusion 
chamber, bathed in a physiological saline solution, and exposed to pharmacological agents as 
previously described.590  The internal diameters of the vessels were measured with a video system.  
Harder et al reported that exogenous addition of 20-HETE at 0.1-10nM constricted isolated cat 
pial arteries in a dose-dependent manner by ~4-13%.614  Lange et al. studied the effects of higher 
concentrations of 20-HETE (1-1000nM) on isolated cat pial arteries and reported a dose-dependent 
constriction of 6-29% that reached a maximum at 2-5 min after application of 20-HETE.615  In 
studies of isolated cat microvascular cerebral arteries, exogenous addition of 20-HETE at 10-
100nM led to a dose-dependent constriction of ~9-14% that reached a maximum at 2-5 min after 
application.616    In rats, isolated pial and basilar arteries were constricted in a dose-dependent 
manner by 9-26% after exogenous addition of 20-HETE and 20-HETE agonists ABSA and 
WIT003 at 10-1000nM.590  In contrast, administration of the 20-HETE antagonist WIT002 at 10-
1000nM did not constrict these arteries but it attenuated the vasoconstrictor responses following 
administration of 20-HETE and 5-hydroxytryptamine.590  In a similar study by Gebrehedin et al.587, 
20-HETE (10-1000nM) constricted isolated rat pial arteries in a dose-dependent manner by 12-
25%, which was attenuated by the administration of 20-HETE antagonist 20-HEDE (1uM).  It is 
important to note that the vasoconstrictive properties of 20-HETE are as potent or greater than 
those of well-established endogenous regulators such as ET-1.617 Collectively, these studies 
demonstrate that 20-HETE constricts cerebral arteries in a dose- and time-dependent manner with 
a potency comparable to the primary endogenous regulators of cerebrovascular tone.   
Similar methods were used to investigate the effect of EETs on the tone of isolated cerebral 
arteries.  Isolated cat cerebral arteries pre-constricted with serotonin were dilated in a dose-
dependent manner ~50-110%, 60-109%, and 30-51% by exogenous addition of 11,12-EET, 8,9-
EET, and 5,6-EET at 1-50uM, respectively.611  Half-maximal dilation (EC50) was observed at 2-
4uM for all three EET regioisomers.611 The effects of EETs were transient with a maximum effect 
observed at 3 min and a returned to baseline at 5 min after EET administration.611   These results 
were consistent with previous studies, which report a short half-life of EETs in aqueous 
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solution.618, 619  Other studies report similar vasodilator responses in cerebral arteries and other 
vascular beds in response to exposure to EETs.356  These findings demonstrate that EETs dilate 
cerebral arteries in an isomer- and time-dependent manner both in vitro and in vivo.   
1.6.2.2 Mechanisms of vascular response:  Numerous studies have elucidated some of the key 
mechanisms involved in the regulation of cerebrovascular tone by CYP eicosanoids.  In isolated 
cerebral arteries and smooth muscle cells, 20-HETE activates numerous intracellular signaling 
pathways involved in vasoconstriction including PKC, Ras, tyrosine kinase, and mitogen-activated 
protein (MAP).620  Also, 20-HETE activates rho-kinase pathways that increase the sensitivity of 
cerebral arteries to calcium.621  In addition, 20-HETE promotes vasoconstriction through the 
activation of various ion channels.  In some studies, 20-HETE constricts cerebral arteries through 
activation of L-type Ca+2 channels leading to a rise in intracellular Ca
+2 levels.616  Likewise, 20-
HETE activates transient receptor potential channel 6 (TRPC6) promoting vasoconstriction 
through Ca+2-dependent622 and Ca+2-independent 623 mechanisms.  Also, 20-HETE promotes 
vasoconstriction by inhibition of large-conductance Ca+2-activated potassium channels (KCa+2 
channels) through its phosphorylation by activation of PKC.615, 624   Conversely, EETs are reported 
to dilate cerebral arteries by the activation of KCa+2 channels and inhibition of L-type Ca
+2 channels 
on smooth muscle cells through a putative GPCR.625  Other studies suggest that EET mediated 
dilation of cerebral arteries occurs in an autocrine manner on endothelial cells by the activation of 
transient receptor potential (TRP) channel V4, C3, or C6.625  Activation of these receptors 
promotes Ca+2 influx, activation of small conductance (SK) and intermediate (IK) conductance K+ 
channels, hyperpolarization, and release of K+ ions from endothelial cells.  K+ ions then stimulate 
inward rectifying (Kir) K+ channels and Na+/K+ ATPase, thus hyperpolarizing and relaxing the 
VSMC.  These studies are helpful to elucidate the mechanisms involved in the regulation of 
cerebrovascular tone and CBF by CYP eicosanoids.   
1.6.3 20-HETE regulation of CBF 
This section will highlight some of the key studies investigating the role of 20-HETE on the 
regulation of CBF, cerebral ischemic injury, myogenic response, and cerebral vasospasm.  This 
section will also provide evidence that 20-HETE mediates the response to well-known regulators 
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of CBF and cerebrovascular tone. 
 
1.6.3.1 20-HETE regulation of baseline CBF:  Studies have investigated the effects of 20-HETE 
on baseline CBF and cerebral ischemic injury.  Direct injection of 20-HETE (8 mg/kg) into the 
internal carotid artery in rats reduced baseline CBF for 2 hours and led to a large ischemic 
infarct.589  Also, intracisternal administration of the 20-HETE agonist WIT003 (1.5 nmol) reduced 
baseline CBF by 20% while the 20-HETE antagonist WIT002 (1.5 nmol) and 20-HETE agonist 
ABSA did not affect baseline CBF.590  These studies suggest that 20-HETE is a key regulator of 
CBF and may play a role in cerebral ischemic injury.  
1.6.3.2 Role of 20-HETE in myogenic response:  As mentioned in Section 1.2.3, the myogenic 
response plays a key role in the autoregulation of CBF.358  The similarities between the 
mechanisms involved in myogenic response and vasoconstriction by 20-HETE led to the 
hypothesis that 20-HETE mediates the myogenic response of cerebral arteries and autoregulation 
of CBF.  Gebremedhin et al. investigated the role of 20-HETE in the myogenic response of isolated 
rat pial arteries and reported that 20-HETE concentrations in cerebral arteries increased 6-fold 
when the intravascular pressure was increased from 20 to 140 mm Hg.587  The addition of the CYP 
inhibitor DDMS (10uM) and 20-HETE antagonist 20-HEDE (1uM) eliminated the myogenic 
response of these cerebral arteries.587  Extending this research into preclinical animal models, 
Harder et al. demonstrated that inhibitors and antagonists of 20-HETE attenuated the 
autoregulation of CBF after elevations of arterial pressure.356, 587, 614  These studies suggest that 20-
HETE significantly contributes to the myogenic response of cerebral arteries in isolated vessels 
and preclinical animal models.  
1.6.3.3 Role of 20-HETE in cerebral vasospasm:  Extending these findings to models of SAH, 
a few studies investigated the role of 20-HETE in the development of acute and delayed 
vasospasm.  In a rat model of SAH, 20-HETE levels in CSF increased seven-fold and the 20-HETE 
synthesis inhibitors 17-ODYA and HET0016 attenuated this increase in 20-HETE levels.626  Pre-
treatment of rats with these CYP4A/4F (-hydrolase) inhibitors attenuated the acute reduction in 
CBF that returned to control within 120 minutes after induction of SAH.626  In similar studies by 
Yu et al., 20-HETE levels in CSF increased 4-fold after SAH in rats, but levels were not impacted 
by the administration of the 20-HETE antagonist WIT002 (1.5 nmol) and the 20-HETE agonist 
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ABSA (1.5 nmol).  On the other hand, WIT002 attenuated the acute reduction in CBF while the 
20-HETE agonist ABSA exacerbated the acute fall in CBF following SAH.590  Similar studies 
using the 20-HETE synthesis inhibitor TS-011 in SAH models revealed similar results.589  Taken 
together, these data suggest that 20-HETE levels increase after SAH and contribute to the 
subsequent acute reduction in CBF.   
A few studies investigated the role of 20-HETE in the development of delayed vasospasm 
after SAH.  Roman et al.620 studied a dual hemorrhage model of SAH in dogs involving an injection 
of blood into the cisterna magna followed by a second injection of blood 4 days later.  At day 7 
after the initial injection of blood, 20-HETE levels in CSF increased 8-fold and the basilar arteries 
constricted to 58% of control.  Administration of the 20-HETE synthesis inhibitor TS-011 (0.1 
mg/kg i.v.) at day 7 reversed the delayed vasospasm in this model.620  Using a similar dual 
hemorrhage model of SAH in rats involving an intracerebroventricular (icv) injection of blood 
followed by a second injection of blood two days later, Takeuchi et al.627 reported that the large 
arteries at the base of the brain constricted by 30% and CBF reduced to 67% after the first injection 
of blood, but CBF levels returned to control after 24 hours.  The second injection of blood led to 
a sustained constriction of these arteries by 30%.  Administration of TS-011 (0.1 mg/kg i.v.) five 
days after the second injection of blood reversed the vasospasm and the CBF returned to control 
values.  These studies demonstrate that 20-HETE plays a key role in the development of delayed 
vasospasm after SAH. 
Although some mechanisms involved in the regulation of cerebrovascular tone by 20-
HETE have been elucidated, it is unclear if these mechanisms are involved in cerebral vasospasm 
after SAH.  Recently, Roman et al. proposed a hypothesis summarizing the role of 20-HETE in 
mediating these biphasic changes in cerebrovascular tone after SAH.620  In the acute phase of SAH, 
20-HETE levels are increased primarily through scavenging of NO and CO by Hb and release 
from membranes through the activation of cPLA2 by ischemia or other stimuli.  Previous studies 
have shown that NO and CO inhibit 20-HETE synthesis enzymes.204, 628  In the secondary phase 
of SAH, 20-HETE levels are increased through the upregulation of CYP4A/4F enzymes or 
dissolving of blood clots.  However, this area continues to be an area of intense research focus and 
discussion.   
1.6.3.4 20-HETE mediates response to vascular regulators:  Growing evidence suggests that 
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20-HETE affects the vasoconstrictor response of well-known regulators of cerebrovascular tone 
and CBF (Figure 1-3: Key regulators of cerebrovascular tone after SAH).  In cerebral arteries, 20-
HETE synthesis is stimulated by angiotensin II, ET-1, 5-HT, and ATP620, all of which have been 
implicated in the pathophysiology of cerebral vasospasm after SAH.200  In addition, administration 
of 20-HETE synthesis inhibitors HET016 and 17-ODYA attenuated the vasoconstrictor response 
of 5-HT and was reversed with the co-administration of the 20-HETE agonist WIT003.590, 629  
These findings suggest that the vasoconstrictor effects of 5-HT on cerebral arteries is mediated in 
part by 20-HETE.  It has been well established that NO is a key regulator of CBF and plays an 
import role in the development of cerebral vasospasm after SAH.630   NO dilates cerebral arteries 
through the stimulation of guanylyl cyclase (GC) and subsequent formation of cyclic guanosine 
monophosphate (cGMP) or through cGMP-independent mechanisms.  Other investigators showed 
that NO binds to CYP4A enzymes and inhibits the formation of 20-HETE thereby affecting the 
cerebral vasodilator response to NO in a cGMP-independent manner both in vitro and in vivo.204  
Moreover, recent evidence suggests that 20-HETE mediates CBF regulation by pericytes and 20-
HETE inhibition by NO facilitates prostaglandin E2 mediated dilation.
631  Taken together, these 
studies suggest that 20-HETE mediates the vasoconstrictor response of certain key regulators of 
cerebrovascular tone and CBF.   
1.6.4 EET regulation of CBF 
This section will highlight some of the key studies investigating the role of EETs on the regulation 
of CBF, cerebral ischemic injury, and neurovascular coupling.   
 
1.6.4.1 Role of EETs in regulation of CBF: Extending the findings from isolated arteries to 
preclinical animal models, Ellis et al. investigated the effect of EETs on cerebrovascular tone of 
cat and rabbit pial arteries in vivo using a cranial window technique.632  In this study, administration 
of 5,6-EET at 15 g/ml led to a rapid dilation of cat pial arteries by 31% followed by a return to 
baseline after 5 min.632  Likewise, rabbit pial arteries were dilated in dose dependent manner by 
14,15-EET, 11,12-EET, and 8,9-EET, and 5,6-EET at 15 g/ml to a maximal dilation of 2%, 5%, 
8%, and 23%, respectively.632  Alkayed et al. reported that that EET synthesis inhibition by 
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miconazole (20uM for 30min) reduced baseline CBF by 30% in rats.633.  These studies suggest 
that EETs play a role in the normal regulation of CBF in preclinical animal models.   
1.6.4.2 Role of EETs in neurovascular coupling:  Growing evidence suggests that EETs 
significantly contribute to the regulation of CBF in response to neuronal activity.352, 634, 635  As 
discussed in Section 1.4.1, EETs are formed in multiple cell types in the neurovascular unit, 
including neurons, astrocytes, and endothelial cells.356  In astrocytes, EETs can be released from 
the phospholipid membranes of astrocytic foot processes in response to excitatory amino acids 
such as glutamate.633  Glutamate has also been shown to upregulate CYP2C enzymes responsible 
for EET synthesis in rats.462  Moreover, the functional hyperemic response to whisker stimulation 
in anesthetized rats is attenuated by inhibition of EETs formation.351  Conversely, Liu et al. 
reported that 20-HETE has little impact on the functional hyperemic response to whisker barrel 
stimulation in rats, unless neuronal nitric oxide synthase (nNOS) was inhibited.636  More recent 
studies show that individual administration of an EET synthesis inhibitor, EET antagonist, 
metabotropic glutamate receptor (mGluR) antagonist, and adenosine A2B receptor antagonist, 
block the functional hyperemic response to whisker stimulation in rats by ~50%, but co-
administration of an EET synthesis inhibitor or EET antagonist with mGluR antagonist or 
adenosine A2B receptor antagonist had no additional effect on the hyperemic response.  These data 
suggest that the synthesis and release of EETs in models of functional hyperemia may be linked 
to pathways involving adenosine and glutamate.  Furthermore, EETs released from astrocytes 
promote angiogenesis and through mitogenesis of capillary endothelium, which is blocked by 
inhibition of EET formation by 17-ODYA.637  These findings suggest that EETs contribute to 
angiogenesis, a process related to flow-metabolism coupling.  Taken together, these studies 
suggest that EETs, but not 20-HETE, are key mediators in the regulation of CBF by neurovascular 
coupling. 
1.6.4.3 Role of EETs in cerebral ischemic injury:  The role of EETs in preclinical models of 
SAH has not yet been reported, but investigators report that EETs are an important regulator of 
CBF and injury resulting from temporary focal ischemia.  In a temporary focal ischemia model in 
mice, administration of the SEH inhibitor AUDA-BE (10mg/kg i.p.) decreased infarct size by 40% 
when administered 1 hour before reperfusion and by 52% when administered 2 hours after 
reperfusion.638  This response was reversed with the administration of the EET synthesis inhibitor 
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MS-PPOH (0.5 mg/200mL over 24 hr).  Likewise, gene deletion of EPHX2 gene, which codes for 
SEH, or administration of 14,15-EET (1g over 24 hours) reduced infarct size in mice by 56% and 
68%, respectively, in the temporary focal ischemia model.639  Also, CBF was higher during the 
occlusion in SEH knockout mice.  In vitro studies of cerebral ischemia demonstrate that EETs 
protect astrocytes against ischemic cell death640.  Also, variants in the EPHX2 gene, which codes 
for SEH, have been shown to affect SEH activity and neuronal survival after ischemic injury.641  
These studies provide evidence that EETs alter CBF and cerebral ischemic injury in vitro and in 
preclinical animal models and warrant further investigation in humans.   
1.7 CLINICAL STUDIES OF CYP EICOSANOID LEVELS IN STROKE 
1.7.1 CYP eicosanoid levels SAH patients:  
To date, there are only a few studies that measure CYP-eicosanoid levels in plasma or CSF from 
patients with SAH.  Previously, our laboratory measured 20-HETE levels in fresh CSF from four 
patients with SAH using HPLC-MS and reported values ranging from ~0.1-2.9 ng/ml in two 
patients with DCI and levels below the detection limit for the majority of samples in two patients 
without DCI.642  Then, our lab used UPLC-MS/MS to measure CYP-eicosanoid levels in fresh 
CSF from seven patients with SAH and reported 20-HETE and 8,9-DHET levels ranging from 
~0.2-5.0 ng/ml and ~0.2-2.0 ng/ml, respectively.643  More recently, our group measured 20-HETE 
levels in fresh CSF from 108 patients with SAH using HPLC-MS644 and reported values ranging 
from 0.1-30.2 ng/ml (mean ~1.4 ng/ml).  In this study, detectable 20-HETE levels were associated 
with the severity of hemorrhage and DCI, but not angiographic vasospasm.  Roman et. al measured 
20-HETE in CSF from nine SAH patients with DCI and 13 healthy controls using HPLC-MS/MS 
and reported mean concentrations of ~0.11 ng/ml and non-detectable (<0.02 ng/ml) levels in 
control samples.620  Plasma 20-HETE levels (~0.28 ng/ml) were not different than control levels.  
These data demonstrate the ability to measure CYP eicosanoids in CSF from SAH patients and 




1.7.2 CYP eicosanoid levels in ischemic stroke patients:   
Only one study has measured CYP eicosanoid levels in ischemic stroke (IS) patients.  Ward et al. 
measured CYP eicosanoids in plasma and CSF from 44 patients with acute IS (<96 hours) and 44 
healthy age- and sex-matched controls.645   Stroke patients had elevated plasma 20-HETE (0.62 ± 
0.05 ng/ml), EETs (24.96 ± 1.07 ng/ml) compared with and DHET (31.25 ± 1.55 ng/ml) compared 
with controls (0.36 ± 0.05 ng/ml, 11.33 ± 1.07 ng/ml, and 22.93 ± 1.55 ng/ml, respectively).  In a 
subset of 14 patients, 20-HETE levels (0.22 ± 0.05 ng/ml) and EET levels (16.47 ± 3.2 ng/ml) 
were decreased at 30 days after the stroke when compared to values at day 0 (0.45 ± 0.07 ng/ml 
and 25.87 ± 3.4 ng/ml, respectively).  In another subset of 24 patients with lesion size and CBF 
data, there was a significant positive correlation between lesion size and plasma 20-HETE 
(r=0.44), but not EET and DHET, levels.  There were no associations between CBF and CYP 
eicosanoid levels. Furthermore, 20-HETE levels were also associated with greater neurological 
impairment, unfavorable functional outcomes, and reduced cognitive function.  These data show 
that CYP eicosanoid levels are increase acutely in stroke patients and decline within a month and 
that 20-HETE was associated with lesion size and functional indices, but not CBF.  
1.8 STUDIES OF HUMAN GENE VARIANTS IN CYP EICOSANOID PATHWAY 
1.8.1 In vitro studies of substrate metabolism:   
This section will identify candidate gene polymorphisms reported to alter transcriptional activity, 
protein expression, or enzymatic activity in vitro.  Tables at the end of Section 1.8 summarize key 
findings from this section.   
 
1.8.1.1 CYP4A11 in vitro metabolism:  The effect of a few polymorphisms in the promoter and 
coding regions of CYP4A11 have been evaluated in vitro.  One such polymorphism is the -
825A>G transition found in the promoter region of the CYP4A11 gene.  Sugimoto et al. 
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demonstrated that when the variant -825G/G construct was expressed in human renal proximal 
tubule epithelial cells, the luciferase expression was reduced ~30% compared to the WT construct 
implying reduced transcriptional expression of CYP4A11.646  In the same study, probes containing 
the variant -825G/G construct stimulated DNA binding of nuclear extracts in a gel mobility shift 
assay.  Combined with the results from the luciferase assay, these results suggest that the -825G/G 
binding factor may serve as a transcriptional repressor of CYP4A11.  Conversely, the -296C>T 
polymorphism did not to affect transcriptional activity of CYP4A11 in vitro.647  Gene 
polymorphisms in the coding region of CYP4A11 have also been explored.  Gainer et al. showed 
that cells expressing the 434Ser (8590T>C) polymorphism in the coding region of CYP4A11 
showed reduced arachidonic acid and lauric acid metabolizing activity compared to the 433Phe 
(WT) protein.540  The kinetic parameters Vmax and Km were reduced to 41% and 68% of WT values 
for AA metabolism and 35% and 46% of WT values for lauric acid metabolism, respectively.  
These studies demonstrate that the CYP4A11 -825G and 434Ser polymorphisms are associated 
with reduced translational activity and enzymatic activity, respectively, resulting a moderate loss-
of-function in vitro.  
1.8.1.2 CYP4F2 in vitro metabolism:  There are a few polymorphisms in regulatory region of 
CYP4F2 that have been associated with altered transcriptional activity when expressed in vitro.  
Lui et al. evaluated the promoter activity of c.-48G>C (g.421G>C) and showed increased promoter 
activity of the construct containing the g.-421C polymorphism compared to g.421G (WT) 
constructs.648  Also, a gel retardation assay showed Myb binding to the WT protein but not the 
construct with the variant g.421C allele.  Combined with the results from the reporter assay, these 
results suggest that Myb may repress expression of CYP4F2 and the g.421G polymorphism may 
result in loss of Myb binding and thus increased expression of CYP4F2.  In another study, Lui et 
al. evaluated the transcriptional activity of the CYP4F2 regulatory region in HEK293 cells using 
reporter constructs of two haplotypes for CYP4F2.649  In the haplotype analysis, The Haplotype I 
construct contained the WT alleles c.-91T, c.-48G (g.421G), c.-13T, and c.+34T while the 
Haplotype II construct contained the variant alleles c.-91C, c.-48C (g.421C), c.-13C, and c.+34G.  
Haplotype I (WT) construct showed higher basal transcription and LPS-stimulated activity than 
the variant Haplotype II construct.  Other constructs containing the variant -91C allele in the 
presence and absence of the -48C allele showed lower transcriptional activity than -91T (WT) 
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construct whereas the variant -48C allele did not affect transcriptional activity in the presence and 
absence of the variant -91C allele.  Also, electrophoretic mobility shift assays with nuclear extracts 
show that NF-kB binding site existed at position c.-91 and the variant -91C allele altered its binding 
pattern.  Combined with the previous results, these data suggest that NF-kB binding to the c.-91 
site on CYP4F2 increases expression and the variant -91C allele attenuates this effect.  
Collectively, these data suggest that the CYP4F2 regulatory region containing the variant -91C 
allele and/or the variant alleles present in Haplotype II result in a moderate reduction in basal and 
LPS-stimulated transcriptional activity whereas the variant -48G allele has been reported to 
increase or have no effect on transcriptional activity of CYP4F2.     
Other CYP4F2 polymorphisms are reported to alter enzymatic activity and protein levels 
when expressed in vitro.  Bardowell et al. showed that cells expressing the variant 12Gly (*2) and 
433Met (*3) alleles increased and decreased enzymatic activity towards both vitamin E and AA 
when compared to the 12Trp and 433Val (WT) constructs, respectively.650  Specifically, the 
variant *2 allele showed a 2.5-fold and 1.9-fold increase in specific activity towards vitamin E and 
AA, respectively.  On the other hand, the variant *3 allele resulted in 34% and 80% lower specific 
activity towards vitamin E and AA, respectively.  Likewise, constructs with both variant *2 and 
*3 alleles showed resulted in 40% and 78% lower specific activity towards vitamin E and AA, 
respectively.  Conversely, other in vitro studies expressing the variant *3 and *2/*3 alleles showed 
a 34-44% decrease in 20-HETE production whereas the construct with the variant *2 allele did not 
show any difference when compared to controls.651  None of these variant constructs affected the 
-hydroxylation of leukotriene B4.  Also, McDonald et al. reported that human liver microsomes 
from patients with the *1/*3 and *3/*3 genotypes had 64% and 22% of the CYP4F2 protein content 
and 52% and 25% of vitamin K1 oxidation compared to samples from patients with the *1/*1 
(WT) genotype.549  No association was observed between transcriptional activity of CYP4F2 in 
human liver microsomes and the variant *3 allele.  Taken together, these data suggest that the 
variant CYP4F2*3 allele results in decreased -hydroxylase enzyme activity towards vitamin E 
and AA in vitro and lower protein levels but no change to mRNA expression of CYP4F2 in human 
liver microsomes.  On the other hand, the variant CYP4F2*2 allele increased -hydroxylase 
enzyme activity towards vitamin E in vitro, but the reported effect on -hydroxylase enzyme 
activity towards AA is inconsistent. 
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1.8.1.3 CYP2J2 in vitro metabolism:  There are numerous polymorphisms in CYP2J2 that have 
been reported to alter enzymatic activity, transcriptional activity, or protein levels when expressed 
in vitro.  For example, in vitro expression of CYP2J2 constructs containing the variant 143Ala 
(*2), 158Cys (*3), 192Asn (*4), and 404Tyr (*6) alleles showed reduced activity to metabolize 
fatty acids such as AA or linoleic acid when compared to WT constructs (143Thr, 158Arg, 192Ile, 
and 404Asp).439  Specifically, constructs with the variant *2, *3, *4, and *6 alleles metabolized 
AA to 59%, 41%, 30%, and 5% of WT (*1 allele) values, respectively.  Likewise, the variant *2, 
*3, and *6 alleles metabolized linoleic acid to 58%, 50%, and 10% of WT values, respectively, 
but the variant *4 allele did not alter CYP2J2 activity toward linoleic acid.  Other in vitro studies 
report reduced transcriptional activity of cells expressing the variant c.-50T (*7) polymorphism in 
the promoter region of CYP2J2.505, 652, 653 Human cardiac tissue653 and bovine aortic endothelial 
cells505, 652 expressing the *7 polymorphism construct reduced transcriptional activity to 38% and 
48-50% of values seen in WT constructs, respectively.  Speiker et al. proposed that the reduced 
transcriptional activity is due to the disruption of a Sp1 transcription factor binding site.505  In 
addition, human liver microsomes from patients harboring the *7 variant allele showed reduced 
CYP2J2 protein levels.654  Another study reported that in vitro expression of a construct containing 
the 186Gly (*8) polymorphism showed almost complete loss of enzyme activity toward astemizole 
and ebastine metabolism and no carbon monoxide (CO) binding to the heme moiety indicating the 
lack of a functional heme moiety.655  In the same study, structural models predicted that the 186 
residue is near the heme moiety and the *8 polymorphism may suppress the normal docking of 
heme into its binding site. Furthermore, in vitro expression of a CYP2J2 construct containing the 
115Leu (*10) polymorphism showed reduced enzyme activity towards terfenidine, loss of heme 
binding, and altered protein folding.656  Collectively, these data suggest that the *2, *3, *4, *7, and 
*10 polymorphisms result in a moderate loss in enzyme activity while the *6 and *8 
polymorphisms demonstrate almost complete loss-of-function in vitro. 
1.8.1.4 CYP2C8 in vitro metabolism:  CYP2C8 is one of the most extensively studied CYP 
isoforms with respect to the effect of polymorphic variants on enzyme activity.  Multiple in vitro 
studies showed that constructs expressing the CYP2C8*3 (139Lys/399Arg) polymorphisms did 
not affect protein expression when compared to WT CYP2C8 protein.657-659  When the single 
399Arg polymorphism was expressed in Hep 2G cells, CYP2C8 protein levels were reduced to 
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40% of WT values, but introduction of the 139Lys polymorphism to form the *3 construct restored 
protein levels to WT values.659  Interestingly, the mRNA levels in cells expressing the 399Arg 
polymorphism were not significantly different than WT suggesting that the lower protein levels 
associated with this polymorphism may not be due to altered transduction, but may be due to 
instability of the protein as previously suggested with CYP2D6*10.660, 661  In human liver samples, 
CYP2C8 protein levels and mRNA expression in individuals with the *3 allele were not different 
than WT.515, 662  These data suggest that CYP2C8 mRNA expression and protein levels are not 
affected by the *3 polymorphism.   
On the other hand, multiple in vitro studies report that *3 allele affects the CYP2C8-
mediated metabolism of endogenous substrates such as AA and drugs such as paclitaxel and 
amiodarone.  For example, Smith et al. reported that constructs expressing the *3 polymorphism 
showed 4-fold lower 14,15-EET formation from AA metabolism compared to WT constructs.663  
Kinetic parameters reported showed that Km, Vmax, and CLint were 247%, 80%, and 32% of WT 
values, respectively.  A similar study reported that the *3 polymorphism was associated with a 
2.2- , 2.7- , and 2.4-fold reduction in activity towards AA metabolism to form 11,12-EET, 14,15-
EET, and total EETs, respectively.664  Furthermore, incubations of human liver microsomes from 
patients with the *3/*3 and *1/*3 genotype and AA showed a 34% decrease and no difference in 
the formation of EETs and DHETs when compared to those with the WT genotype.  Similarly, 
constructs expressing the *3, 139Lys and 399Arg polymorphisms are associated with reduced 
metabolism of several drugs including drugs including paclitaxel657-659, 662, 664 and amiodarone657.  
On the other hand, a few studies suggest that the *3 polymorphism did not affect amiodarone and 
paclitaxel metabolism by CYP2C8.658, 665  Collectively, these studies suggest that the CYP2C8*3 
polymorphism may be associated with lower in vitro metabolism of AA, paclitaxel, and 
amiodarone.   
Similar studies investigated the effect of the *4 polymorphism on CYP2C8 mRNA and 
protein expression.  One study reported that yeast cells transfected with the *4 polymorphism 
expressed protein levels ~20% of WT values.657  Likewise, human liver samples genotyped for a 
haplotype containing the *4 allele showed reduced protein levels compared to values in WT 
samples.665  Conversely, other studies report that human liver microsomes and liver samples from 
patients with the *4 allele showed no difference in mRNA or protein levels of CYP2C8.515, 662  
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These conflicting results regarding the effect of the CYP2C8*4 variant on CYP2C8 mRNA and 
protein expression warrants further investigation.   
The CYP2C8*4 polymorphism has also been shown to affect the in vitro metabolism of 
AA and several drugs.  For example, E. Coli expressing the *4 polymorphism showed 5-fold lower 
14,15-EET formation from AA metabolism when compared to WT values.663  Kinetic parameters 
reported showed that Km, Vmax, and CLint was 67%, 21%, and 30% of WT values, respectively. 
Similarly, the CYP2C8*4 polymorphism is associated with reduced in vitro metabolism of several 
drugs including drugs including paclitaxel657, 662, 666, nifedipine657, and amiodarone657, 667.  One 
study reported that paclitaxel metabolism by human liver samples was not affected by the *4 allele, 
but the haplotype containing the *4 allele was associated with lower paclitaxel metabolism.665 
Although the mechanisms leading to the in vitro loss-of-function observed with the variant *4 
allele is not fully elucidated, Singh et. al. reported that the constructs expressing the variant *4 
allele affected CO binding to the heme moiety and were more sensitive to proteinase K digestion 
indicating improper heme insertion and protein folding.667 
Other CYP2C8 gene variants have also been reported to affect CYP2C8 levels, structure, 
or function.  In vitro expression studies reported reduced CYP2C8 protein levels associated with 
the *8668, *14668, and 404Ala659 polymorphisms, but no change in mRNA expression was observed 
with the *13 polymorphism668.  The reduced protein levels associated with the *8 polymorphism 
were restored to WT levels using a proteasome inhibitor MG-132 indicating the decreased levels 
may be due to enhanced proteasomal degradation.668  In addition, reduced CO difference spectra 
observed with the *14 polymorphism suggested a lack of a functional heme group.669  Likewise, 
constructs expressing the 404Ala polymorphism showed altered heme and/or substrate binding.666  
Furthermore, there are a few polymorphisms in CYP2C8 that lead to significant loss of the protein 
structure.  The 159Pro (*5) polymorphism results in a frameshift transition at residue 177 and is 
most likely to be inactive since it lacks 64% of the protein structure including the heme-binding 
site and 5 of 6 substrate recognition sites.670  Likewise, the 186Ter (*7) polymorphism leads to an 
early stop codon that results in a truncated protein that lacks 60% of the C-terminal region 
including the heme binding site, which was undetectable when expressed in vitro.667  The 274Ter 
(*11) polymorphism also leads to an early stop codon but has not been evaluated in vitro.  In regard 
to samples from humans, liver microsomes from patients with the variant *1B allele showed 
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increased binding of nuclear proteins and 1.8-fold higher transcription rate than WT.665  However, 
another study protein levels in human liver samples from patients with the variant *1B and *1C 
alleles were not different than WT.662  Collectively, these studies suggest that CYP2C8 
transcription is increased with *1B and unchanged with *8 polymorphisms, CYP2C8 protein 
expression is reduced with the *2, *8, *14, and 404Ala polymorphisms, and CYP2C8 protein 
structure and function is significantly altered with the *5, *7, and *11 polymorphisms.  
Other studies investigated the effects of CYP2C8 polymorphism on metabolism of some 
drugs in vitro.  For example, it has been reported that in vitro metabolism of paclitaxel is reduced 
cell expressing the 269Phe (*2)657, 664, 186Gly (*8)668, 238Pro (*14)669, and 404Ala659, 666 
polymorphism and a haplotype containing the *1B665 polymorphism whereas complete loss of 
enzymatic activity is observed with the 186Ter (*7)668 polymorphism. Similarly, in vitro 
metabolism of amiodarone is reduced with the *2657 and 404Ala659 polymorphism.  Although the 
effects of these variants on AA metabolism have not been reported, evaluation of these 
polymorphism represent an important area of future study due to the significant effects observed 
on CYP2C8 functional activity.  Collectively, these studies suggest that the *2, *8, *14, 404Ala, 
and possibly *1B polymorphisms lead to moderate loss-of-function while *7 leads to complete 
loss-of-function of CYP2C8. 
1.8.1.5 CYP2C9 in vitro metabolism:  Zhou et al. also provided an extensive and excellent 
discussion on CYP2C9 functional polymorphisms and their relevance to drug disposition and 
disease.671  This review discusses the in vitro studies that demonstrate loss of function with the *2, 
*3, *4, *5, *13, *25, *26, *28, and *30 polymorphisms.  Additional studies by Delozier et al. 
report that in vitro expression of *15 and *18 polymorphisms resulted in proteins that could not 
be detected, *17 and *19 polymorphisms exhibited a 30-40% decrease in catalytic activity, and 
*14 and *16 polymorphisms exhibited 80-90% lower catalytic activity toward tolbutamide, 
respectively, when compared to WT protein.672 Likewise, the in vitro intrinsic clearance of 
diclofenac by constructs with the *33 polymorphism was reduced 5-fold when compared to WT 
enzyme.673  In addition, Blaisdell et al. reported that the in vitro metabolism of tolbutamide was 
altered by genetic polymorphisms.674   To illustrate, increased metabolism was associated with the 
*8 polymorphism, decreased metabolism was associated with the *11, and *12 polymorphisms 
and no change in metabolism was observed in constructs with the *7, *9, and *10 polymorphisms 
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when compared to WT enzyme.674  However, another in vitro study reported that constructs with 
the *8 polymorphism led to a 30% reduction in intrinsic clearance of S-warfarin compared to WT 
enzyme.675  These data suggest that there are multiple gene variants in CYP2C9 that primarily lead 
to loss of enzymatic function. 
1.8.1.6 EPHX2 in vitro metabolism:  Currently, there are no published studies investigating the 
role of gene variants in the EXPH2 regulatory region on mRNA expression or protein levels.  
However, numerous studies have reported that EPHX2 gene variants can alter SEH activity in 
vitro.  For instance, the activity of the 55Arg, 103Cys, 154Tyr, and 287Gln polymorphisms were 
increased, not changed, increased, and decreased using trans-stilbene oxide (t-SO) and trans-
diphenylpropene oxide (t-DPPO) as substrates.676  Similar results were shown when using 14,15-
EET as an SEH substrate.676  Also, Koerner et al. reported that primary cortical neuronal cultures 
transduced with cDNA containing the 55Arg, 103Cys, 154Tyr, and 287Gln polymorphisms 
showed increased, no change, no change, and decreased 14,15-DHET formation, respectively, 
after exogenous administration of 14,15-EET when compared to WT transfected cells.641  
Similarly, Merkel et al. reported that cardiomyocytes from SEH knockout and WT mice 
transduced with the 55Arg and 287Gln polymorphic constructs showed no difference and 
decreased 14,15-DHET formation.677  Conversely, Sandberg et al. reported that Chinese Hamster 
Ovary (CHO) and African Green Monkey Kidney (COS-7) cells transfected with the 287Gln 
polymorphic construct showed no change in SEH activity towards t-SO when compared to WT.678  
Other in vitro studies showed that the 287Gln, but not the 55Arg, 103Cys, and 154Tyr 
polymorphisms, reduce enzyme stability.678, 679  Although there are some conflicting results, the 
majority of the studies suggest that SEH activity is increased with the EPHX2 55Arg and 154Tyr 
polymorphisms, decreased with the 287Gln polymorphism, and not impacted by the 103Cys 
polymorphism.   
A few studies also investigated the effect of the Arg402-403 insertion, 422Ala, and 470Gly 
polymorphism on the activity of EPHX2.  Sandberg et al. reported that CHO and COS-7 cells 
transfected with constructs containing the Arg402-403 insertion polymorphism showed lower SEH 
activity (~40% of WT) towards t-SO when compared to WT.678  Another study reported that 
constructs with the 470Gly polymorphism expressed in vitro showed increased SEH activity 
towards t-SO and t-DPPO, but no difference in activity towards 14,15-EET as compared to WT.676  
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Also, the stability of the Arg402-403 insertion enzyme declined more rapidly than the WT enzyme.  
However, other studies showed that constructs expressing the 470Gly and 422Ala polymorphism 
did not affect enzyme stability.679  These studies suggest that Arg402-403 insertion leads to decreased 
SEH activity whereas the 422Ala polymorphism is not likely to affect function of the enzyme.  
However, the functional effects of the 470Gly polymorphism are unclear and warrant further 
studies. 
1.8.2 In vivo studies of substrate metabolism:   
This section will identify candidate gene polymorphisms reported to alter endogenous substrate or 
drug metabolism in vivo.  Tables at the end of Section 1.8 summarize key findings from this 
section.   
 
1.8.2.1 CYP4A11 in vivo metabolism:  As previously discussed, 20-HETE elicits multiple 
biological effects in vivo including a complex role in the regulation of blood pressure.680 As a 
result, some studies have investigated the association of CYP4A11 polymorphisms with the 
urinary excretion of 20-HETE in hypertensive patients.  Laffer et al. reported that hypertensive 
patients with the variant 434Ser allele showed reduced 20-HETE in urine in response to salt 
loading compared to patients with the 433Phe/Phe (WT) genotype after adjusting for the effect of 
serum insulin on 20-HETE excretion.681   Another study reported that urinary 20-HETE excretion 
was 27% higher in hypertensive patients compared to normotensive patients, while no difference 
in urinary sodium excretion was observed in these groups.682  In this study, individuals with the 
variant 434Ser allele showed ~30% reduction in 20-HETE excretion in urine.682 Also, the variant 
434Ser allele showed a trend to predict reduced urinary 20-HETE excretion, but not blood 
pressure, both before and after adjustment for covariates.  These studies demonstrate that the 
variant 434Ser allele in CYP4A11 is associated with reduced urinary 20-HETE levels in 
hypertensive and normotensive patients.   
1.8.2.2 CYP4F2 in vivo metabolism:  There are a numerous studies that investigated the 
association of CYP4F2 polymorphisms with the metabolism of drugs, vitamins, and endogenous 
compounds in humans.  Hu et al. reported that urinary concentrations of the AA metabolite 20-
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HETE were significantly different across the Val433Met (*3) genotypes in Chinese men, women, 
and both sexes combined, before and after adjustment for clinical covariates.683  In men and women 
combined, the unadjusted geometric mean urinary 20-HETE concentration was 115% and 210% 
higher in individuals with *1/*3 and *3/*3 genotypes, respectively, compared to the *1/*1 (WT) 
group.  There was no overall association between genotypes describing the -458T>C and -91T>C 
transitions and urinary 20-HETE concentration.  A similar study in an Australian population 
reported that individuals with variant *3 allele showed increased urinary 20-HETE excretion 
compared to those with the *1/*1 genotype.682 The variant *3 allele predicted increased urinary 
20-HETE excretion before and after adjustment for age and BMI, but only showed a trend for 
significance when sex was added to the model.  Major et al. reported an association between 
patients with the variant *3 allele and decreased vitamin E metabolism in the -Tocopherol, -
Carotene Cancer Prevention (ATBC) Study cohort and in a meta-analysis.684  In a meta-analysis 
by Denese et al., individuals with the variant *3 allele required an 8.3% higher mean daily warfarin 
dose to reach a stable international normalized ratio (INR) than those with the *1/*1 (WT) 
genotype possibly due to reduced vitamin K1 metabolism549, 685  Collectively, these data suggest 
that individuals with the variant CYP4F2*3 allele are likely to have reduced 20-HETE in urine, 
decreased metabolism of vitamin E, and higher dose of warfarin.  
1.8.2.3 CYP2J2 in vivo metabolism:  The effect of the CYP2J2*7 variant allele on the 
metabolism of endogenous substrates of CYP2J2 in humans was evaluated in multiple studies.  In 
these studies, plasma concentrations of 14,15-DHET were measured as a surrogate marker of AA 
metabolism by CYP2J2.  One study reported that the *7 allele in myocardial infarction patients 
and controls was associated with a 44% and 54% reduction in plasma 14,15-DHET concentrations, 
respectively.652  In a study of German patients with coronary artery disease and controls, 
individuals with the *7 allele had 29% lower plasma 14,15-DHET concentrations compared to 
those with the *1/*1 (WT) genotype.505  Similarly, Chinese patients with type 2 diabetes with the 
*7 allele showed 67% lower plasma 14,15-DHET levels.686  On the other hand, Gervasini et al. 
reported that ebastine metabolite levels in urine from Caucasians with the *7 allele were not 
different than those from individuals with WT genotype.687  Taken together, these data suggest 
that the CYP2J2*7 variant is associated with reduced metabolism of AA, but additional studies 
are needed to determine the effects of CYP2J2*7 and other functional polymorphisms on the 
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clearance of ebastine and other CYP2J2 substrates in humans.  
1.8.2.4 CYP2C8 in vivo metabolism:  Daily et al. provides an excellent review of clinical studies 
investigating the pharmacogenetics of CYP2C8.688  One of the most extensively studied CYP2C8 
polymorphisms is the loss-of-function *3 variant that has been reported to alter the 
pharmacokinetics of some drugs and endogenous substrates.  For example, most healthy volunteer 
studies have found variant *3 allele is associated with increased clearance or decreased trough 
concentrations of pioglitazone and rosiglitazone.689-694  On the other hand, some studies report that 
the pharmacokinetics of rosiglitazone and N-desmethylrosiglitizone were not statistically different 
between *3 allele carriers and *1/*1 groups.695  Similarly, the *3 polymorphism has been 
associated with increased clearance and decreased maximum concentration (Cmax) of repaglinide 
in most studies665, 696-698, but some studies report no association between the *3 polymorphism and 
repaglinide pharmacokinetics or pharmacodynamics at clinically relevant doses699, 700.  In contrast, 
multiple studies reported that the variant *3 allele reduces the metabolism of nonsteroidal anti-
inflammatory drugs (NSAIDs) such as ibuprofen701-704 and diclofenac705.  Although some studies 
have reported an association between *3 polymorphism and an increased risk of neurotoxicity 
during paclitaxel treatment706-709, most clinical reports suggest that CYP2C8*3 is not a major 
determinant of paclitaxel pharmacokinetics375, 706, 710-712.  The discrepancy between in vitro and in 
vivo findings regarding the association between the metabolism of paclitaxel and the *3 
polymorphism has been proposed to be the result of the contribution of drug transporters to 
paclitaxel disposition in humans.713  There is a lack of studies evaluating the role of CYP2C8 gene 
variants on the metabolism of endogenous substrates such as AA.  However, one study evaluated 
the relationship between the *3 polymorphism and urinary excretion of DHETs and reported that 
carriers of the variant *3 allele had paradoxically increased levels of DHETs in urine before and 
after rosiglitazone treatment.714  The discrepancy between the in vitro studies and in vivo studies 
has not yet been fully elucidated.  Taken together, these studies suggest that CYP2C8*3 
polymorphism is associated with increased urinary DHET excretion and clearance of structurally 
diverse drugs with the exception of NSAIDs. 
The effect of other CYP2C8 gene variants on drug disposition in humans has not been 
studied extensively.  Studies by Niemi et al. report that the variant *4 allele is not associated with 
altered clearance of repaglinide in healthy volunteers697, 698  In addition, there are only a few studies 
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that have investigated the effect of rare CYP2C8 gene variants and haplotypes on drug disposition 
in humans.  In healthy Asian individuals, the rare *1/*11 genotype was associated with lowered 
activity towards rosiglitazone compared to the *1/*1 genotype.376  In healthy Finish Caucasians, 
individuals with haplotype B containing the *1B polymorphism and haplotype D containing the 
*3 polymorphism showed increased clearance of repaglinide whereas haplotype C was associated 
with decreased clearance of repaglinide.665  Further in vitro studies showed *1B polymorphism 
was the causal variant that led to the increased activity of haplotype B.665  In another study, 
individuals with the CYP2C8 haplotype C had lower urinary DHET excretion before and during 
rosiglitazone, which was shown to decrease urinary DHET excretion by 10%.714  Collectively, 
these studies suggest that individual gene variants may not predict drug disposition as well as 
multiple gene variants or haplotypes.  
1.8.2.5 CYP2C9 in vivo metabolism:  As previously discussed by Zhou et al., CYP2C9*2 and *3 
alleles are important determining factors for drug clearance and drug response to multiple 
NSAIDs, sulfonylurea antidiabetic drugs, and oral anticoagulants 671  Other studies have reported 
associations of the less frequent CYP2C9 variants and drug disposition. For example, Guo et al 
reported that three patients with the *1/*13 genotype showed a 1.9-fold increase in AUC and 44% 
decrease in the oral clearance of lornoxicam when compared to patients with *1/*1 genotype.715  
Other studies by Allabi et al. showed that the *5, *6, *8 and *11 allele, but not the *9 allele, are 
associated with a decreased phenytoin metabolism in humans.716.  On the other hand, patients with 
the *11 allele did not require different dosing regimens of warfarin.717  There is a lack of studies 
investigating the effect of CYP2C9 polymorphic variants on the metabolism of endogenous 
substrates.  However, one study by Lundbad et al. reported that the expression of *2 and *3 in 
yeast shows reduced activity towards AA metabolism with a lower Clint and Vmax, and higher 
Km.
404  Furthermore, incubations of human liver microsomes from patients with the double 
homozygous variant *3/*3 and *2/*2 genotype led to a 34% decrease in EET formation.404  
Collectively, these studies suggest that the CYP2C9*2, *3, and *4 variants are the most clinically 
relevant polymorphisms associated with drug disposition and metabolism of endogenous 
substrates.   
1.8.2.6 EPHX2 in vivo metabolism:  There are a numerous studies that investigated the 
association of EPHX2 polymorphisms with the metabolism of drugs and endogenous compounds 
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in humans.  In Korean patients with IgA nephropathy, the 287Gln allele had higher plasma 
epoxyoctadecenoic acid (EpOME)/dihydroxyoctadecenoic acid (DiHOME) ratios.  Specifically,  
9,10-EpOME/9,10-DiHOME and 12,13-EpOME/12,13-DiHOME ratios were increased in these 
patients whereas no association was observed in control patients.718  Two other EPHX2 gene 
variants, c.1784A>G (rs1042032) in the promoter region and 55Arg, were not associated with 
plasma 9,10-EpOME/9,10-DiHOME ratios and 12,13-EpOME/12,13-DiHOME ratios in patients 
with IgA nephropathy and control patients.718  Lee et al. also investigated the relationship between 
EPHX2 polymorphisms and plasma 9,10-EpOME/9,10-DiHOME and 12,13-EpOME/12,13-
DiHOME ratios in Americans with CVD and control patients in the Atherosclerosis Risk in 
Communities study (ARIC) and reported that individuals with the variant 55Arg allele had 22% 
and 30% lower 12,13-EpOME/12,13-DiHOME ratios, respectively, compared to those with the 
WT genotype.719   No association of the 55Arg genotype and plasma 9,10-EpOME/9,10-DiHOME 
ratios was observed.  In the race stratified analysis, individuals with the 55Lys/Arg and 55Arg/Arg 
genotype were associated with 33% and 43% lower plasma 9,10-EpOME/DiHOME ratios and 
36% and 40% lower plasma 12,13-EpOME/DiHOME ratios, respectively, in Caucasians but not 
in African Americans.  In addition, Edvardsen et al. investigated the relationship between 
polymorphisms in EPHX2, and other genes involved in reactive oxygen species (ROS) formation, 
and docetaxel clearance in Norwegian patients with non-small cell lung carcinoma (NSCLC) and 
reported that the 287Gln polymorphism predicted docetaxel clearance.720  Sato et al. investigated 
the relationship between the 287Gln polymorphism and plasma cholesterol and triglyceride 
concentration in individuals with familial hypercholesterolemia.721  In individuals harboring the 
IVS14+1G>A polymorphism in the low-density lipoprotein receptor (LDLR), plasma cholesterol 
and triglyceride levels were 18% and 54% higher, respectively, among those with the variant 
287Gln allele compared to those with the WT genotype.  No association was observed between 
genotype and plasma cholesterol and triglyceride levels in non-carriers of the LDLR 
polymorphism.  Chen et al. investigated the relationship between the 287Gln polymorphism and 
concentrations of polycystic aromatic hydrocarbon metabolites in urine from Chinese coke oven 
workers and controls and reported no association between genotype and urinary 1-hydroxypyrene 
concentration.722  Together, these data suggest that individuals with the EPHX2 287Gln 
polymorphism, and possibly the 55Arg polymorphism, are likely to have reduced metabolism of 
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various endogenous and xenobiotic substrates.   
1.8.3 In vitro studies of cerebral ischemic injury   
This section will identify candidate gene polymorphisms reported to alter ischemic cell death in 
vitro.  Tables at the end of Section 1.8 summarize key findings from this section.   
 
1.8.3.1 EPHX2 in vitro ischemia:  A few studies investigated the impact of EPHX2 gene variants 
on cell death using in vitro ischemia models.  Merkel et al. transduced cardiomyocytes from SEH 
knockout and WT mice with TAT-SEH fusion proteins containing various polymorphic and WT 
constructs and assessed their tolerance to oxygen and glucose deprivation and reoxygenation and 
glucose repletion (OGD/RGR).677  In this study, there was no significant difference in cell death 
between cardiomyocytes expressing naive, WT, and polymorphic 55Arg, 103Cys, and 154Tyr 
proteins, but expression of the 287Gln variant showed decreased cell death compared to the WT 
transfected cells.  In a similar study, Koerner et al. transduced primary cortical neuronal culture 
with TAT-hSEH fusion proteins containing various polymorphisms and WT constructs and 
assessed their tolerance to OGD/RGR.641  The 55Arg and 154Tyr polymorphisms had no impact 
on neuronal cell death, but the cells transfected with the 103Cys and 287Gln polymorphisms 
showed increased and decreased cell death, respectively, compared to WT transfected cells.  These 
data suggest that the 287Gln polymorphism is associated with improved cell survival after 
ischemia, but the effects of the 103Cys polymorphism on cell survival after ischemia need to be 
further investigated.   
Furthermore, these studies also investigated the effect of SEH inhibitors and 14,15-EET on 
survival of cells transfected with SEH gene variants after OGD/RGR.  Merkel et al. reported that 
inhibition of SEH and addition of excess 14,15-EET improved cardiomyocyte cell survival in WT, 
55Arg, 103Cys, and 154Tyr variants, but did not affect cell survival in the 287Gln variant.677  Also, 
the 287Gln variant had no effect on cell survival of cardiomyocytes from SEH knockout mice 
transduced with SEH.  Likewise, Koerner et al. reported that inhibition of SEH and addition of 
14,15-EET improved neuronal cell survival in the 103Cys and 154Tyr variants, but did not affect 
cell survival in the 55Arg, and 287Gln variants.641  These data suggest that the 103Cys and 154Tyr 
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polymorphisms may alter cell survival after ischemia through mechanisms involving SEH.    
 
1.8.4 Candidate gene variants in stroke patients   
This section will identify candidate gene polymorphisms associated with various stroke subtypes 
in clinical studies.  Tables at the end of Section 1.8 summarize key findings from this section.   
 
1.8.4.1 CYP4A11 variants in stroke:  A few studies have investigated the association between 
genetic variation in CYP4A11 and the occurrence of stroke.  One study by Fava et al. showed that 
the variant 434Ser allele was not associated with the occurrence of ischemic stroke (IS) in a 
Swedish population.723  Another study showed that multiple tagging polymorphisms and 
haplotypes were not associated with IS in a mixed race panel.724  Similarly, a study by Ding et al. 
investigated the relationship between gene variants of CYP4A11, including tagging 
polymorphisms and potential functional polymorphisms, and the occurrence of IS and 
hemorrhagic stroke in a Chinese population and reported that patients with the variant -296T allele 
had not difference in the occurrence of hemorrhagic stroke (HS), but had higher occurrence of IS 
when compared to controls.647 When IS was grouped into large vessel disease and lacunar stroke, 
the variant -296T allele was associated with an increased occurrence of large vessel disease but 
not lacunar stroke when compared to controls.  Also, patients with the variant 434Ser allele showed 
a trend for decreased occurrence of IS and HS when compared to controls.  Individual haplotypes 
did not show an association with HS and IS even when IS was broken into lacunar stroke and large 
vessel disease group.  These studies suggest that the variant -296T allele may be associated with a 
higher risk for IS and worse outcomes in HS.   
A study by Fu et al. investigated the relationship between tagging polymorphisms of 
CYP4A11 and the occurrence of cerebral infarction (CI) in Japanese population.725  When 
considering individual tagging polymorphisms only in the analysis, it was reported that genotype 
distribution and frequency of carriers for the variant 434Ser allele and g.10733A allele (rs2269231) 
was not statistically different between patients with CI and controls in total, men, and women 
groups in a Japanese population.  Another study showed that the presence of the variant g.15254A 
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allele (rs9333025) was associated with a decreased occurrence of CI when compared to the WT 
genotype in the total population and in the male group, but not in the female group.   Furthermore, 
a regression model showed that the G/G (WT) genotype was more frequent in patients with 
cerebral infarction than controls after adjusting for history of hypertension and diabetes mellitus.  
In the haplotype analysis, seven haplotypes were specified and the overall distribution of 
haplotypes showed a significant difference between cerebral infarction patients and controls in 
total group, but not when patients were grouped by sex.  Specifically, Haplotype 6 was more 
frequent in controls compared CI patients in the total, but not in men and women group.  These 
data suggest that the variant g.15254A allele (rs9333025) and Haplotype 6 was associated with a 
lower occurrence of CI, which may be more prominent in men, thereby implying that future genetic 
association studies should include sufficient numbers of subjects to evaluate gene polymorphism 
effects dichotomized by sex.   
1.8.4.2 CYP4F2 variants in stroke:  A few studies have investigated the association of the loss-
of-function CYP4F2*3 (433Met) and the occurrence of stroke.  One study showed that that the 
hazard ratio for IS in Swedish males with the variant *3 allele was significantly higher than those 
with *1/*1 (WT) genotype after adjustment for major cardiovascular risk factors.723  Similarly, in 
a Chinese cohort of stroke patients, the frequency of the genotypes containing the variant *3 allele 
were higher than the *1/*1 genotype in IS but not in hemorrhagic stroke.647  When the IS group 
was further grouped in to large vessel disease and lacunar infarcts, the frequency of the variant *3 
allele carriers were higher in the large vessel disease group and showed a trend for significance for 
lacunar infarcts group in the adjusted model.  Also, the individual and combined haplotypes did 
not show different frequencies in HS, IS, LVD, and lacunar stroke groups when compared to 
controls.  Furthermore, Munshi et al. showed that hypertensive and non-hypertensive individuals 
with the variant *3/*3 genotype and *3 allele have a higher occurrence of IS compared to those 
with the WT *1/*1 genotype and *1 allele, respectively.726 On the other hand, Deng at al. reported 
that the *1/*1 (WT) genotype in men had a higher occurrence of IS compared to those with the *3 
allele, but no difference was found in all participants and females.727  In the multiple logistic 
regression analysis, the *1/*1 genotype was associated with an increased risk of IS in men 
compared to the *3/*3 genotype after adjustment for clinical covariates.  Although there are some 
conflicting results, these data suggest that individuals with the CYP4F2*3 variant are at higher 
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risk for IS.  Future meta-analyses of conducted studies or genetic studies in larger populations 
would likely allow for a more definitive determination of the effects of this variant on stroke risk. 
One study investigated the relationship between polymorphisms in CYP4F2 and 
occurrence of CI.  Fu et al. reported that the frequency of the WT *1/*1 genotype in males was 
significantly higher in cerebral infarction patients as compared to *3 allele carriers.728  In this 
study, the TCG haplotype was defined by the c.199-105T (WT), c.989C (*3 variant), and c.-698T 
(WT) alleles.  The TCG haplotype containing the variant *3 allele was more frequent in control 
subjects compared to cerebral infarction patients before and after adjustment for confounding 
factors.  On the other hand, the variant alleles 519Met, *2, c.449A (rs3093135), and c.7256T 
(rs3093139) were not associated with cerebral infarction.  These results suggest that CYP4F2*3 
allele is associated with a decreased risk for cerebral infarction.  
1.8.4.3 CYP2J2 variants in stroke:  The impact of genetic polymorphisms in CYP2J2 on the 
occurrence and outcomes in stroke has not been studied extensively.  One study reported that the 
frequency of the variant *7 allele and WT genotype in IS patients was not different than in 
controls.729  A similar study reported no association with the variant *7/*7 genotype and the 
cumulative occurrence of IS before and after adjusting for major cardiovascular risk factors.730  In 
addition, Marciante et al. found no association between ten tagging polymorphisms of CYP2J2 
and multiple haplotypes and the occurrence of IS.724  Currently, there is little data supporting an 
association between CYP2J2 polymorphisms and the risk for IS.   
1.8.4.4 CYP2C8/9 variants in stroke:  Few studies have investigated the relationship between 
CYP2C8/9 polymorphisms on the occurrence of stroke.  In a large study involving over 52,000 
patients with CVD in Denmark the CYP2C9*2 and CYP2C9*3 polymorphisms were not 
associated with the risk for IS and ischemic cerebrovascular disease.731  Similarly, the CYP2C9*2 
and CYP2C9*3 genotypes were not associated with IS both before and after adjusting for multiple 
cardiovascular risk factors when compared to controls in a cohort of 389 patients from the Vienna 
Stroke Registry.732  Also, there was no association with the CYP2C9*2 and CYP2C9*3 genotypes 
and stoke etiology and neurological outcome at one week after the stroke.  In a US cohort of 368 
patients with IS, multiple tagging polymorphisms and haplotypes of CYP2C8/9 in men, women, 
and combined sexes were not associated with IS both before and after adjustment for demographic 
and cardiovascular risk factors when compared to controls.724  Furthermore, similar results were 
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observed in subgroups of defined by sex, hypertension, smoking, CVD, and race.  These studies 
suggest that polymorphisms in CYP2C8 and CYP2C9 do not play a major role in the risk for IS.   
1.8.4.5 EPHX2 variants in stroke:  Multiple studies have investigated the impact of genetic 
variation in EPHX2 on the occurrence of IS.  Fava et al. demonstrated that males with the 
55Arg/Arg genotype had higher occurrence of ischemic strokes when compared to those with the 
WT genotype before and after adjustment of cardiovascular risk factors.733  In contrast, two other 
studies reported no association with the 55Arg polymorphism and occurrence of IS.734, 735  Multiple 
studies reported no association between the 103Cys polymorphism and the occurrence of IS.733, 
735, 736  Gschwendtner et al. reported that individuals with 287Gln allele were associated with a 
higher occurrence of IS compared to those with the WT allele.734  On the other hand, Zhang et al. 
reported that the 287Gln polymorphism was associated with a lower occurrence of IS after 
adjustment for sex, age, and multiple cardiovascular risk factors.729  A few other studies reported 
no association with the 287Gln polymorphism and occurrence of IS.733, 735, 736  Also, the variant 
c.1170+4855C (rs7357432) and c.1291-124A (rs2291635) alleles located in the intronic regions 
of EPHX2 were associated with increased occurrence of IS.734  There was no relationship between 
IS and the Arg402-403ins735, 736, 470Gly734, 735, c.-1452C (promoter)733,  c.1784G (near 3’-UTR)733 
polymorphisms734.  In a haplotype analysis of EPHX2, Fornage et al. reported a decreased risk of 
IS predicted by the ATACGGT Haplotype and increased risk of IS predicted by the ACACAGT 
Haplotype.735  Together, these studies that there are no strong relationships with EPHX2 gene 
variants and IS.   
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CYP4A11 Gene Variants  
IS, ischemic stroke; LVD, stroke from large vessel disease; HS, hemorrhagic stroke; CI, cerebral infarction 
AA, arachidonic acid; 20-HETE, 20-hydroxyeicosatetraenoic acid;  




↔ transcription647  unknown  
↑ IS647 





↓ transcription646  unknown    unknown  
434Phe>Ser [c.8590T>C] 
(rs1126742) 
↓ activity (AA)540   
↓ 20-HETE (urine)681, 
682 
↔ CI725   
Haplotype 6 unknown  unknown  ↓ CI725 
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CYP4F2 Gene Variants 
SNP (rs#) In vitro Metabolism In vivo metabolism Stroke 
12Trp>Gly [*2] 
(rs3093105) 
↑ activity (AA, vit E)650   
↔ activity (AA)651 
unknown ↔ CI728   
433Val>Met [*3] 
(rs2108622) 
↓ activity (AA, vit E, vit K1)549, 650, 651   
↓ protein levels549 
↔ translation549 
↓ metabolism (vit. E)684 
↑ warfarin dosing549, 685 
↑ 20-HETE (urine)682, 683   
↓ CI728 
↓ IS727 
↑ IS647, 723, 
726    
↑ LVD647   
↔ HS 647  
12Trp>Gly / 433Val>Met [*2/*3] 
(rs3093105/rs2108622) 








unknown ↔ 20-HETE (urine)683   unknown  
c.-91T>C 
(rs3093098) 
↓ translation649 ↔ 20-HETE (urine)683   unknown 
g.7222002G>A 
(rs2189784) 
unknown  ↓ time-to-therapeutic INR737   unknown 
Haplotype TCG unknown unknown ↓ CI728 
Haplotype II ↓ translation649 unknown unknown 
IS, ischemic stroke; LVD, stroke from large vessel disease; HS, hemorrhagic stroke; CI, cerebral infarction 




CYP2J2 Gene Variants 
SNP (rs#) In vitro Metabolism In vivo metabolism Stroke 
143Thr>Ala [*2] 
(rs55753213) 
↓ activity (AA, LA)439   unknown unknown  
158Arg>Cys [*3] 
(rs56307989) 
↓ activity (AA, LA)439   unknown unknown 
192 Ile>Asn [*4] 
(rs66515830) 
↓ activity (AA)439   unknown unknown 
404Tyr>Asn [*6] 
(rs72547598) 
↓ metabolism (AA, LA)439   unknown unknown 
c.-50G>T [*7] 
(rs890293) 
↓ transcription505, 652, 653 
↓ protein levels654 
↓ DHETs (plasma)505, 652,686 
↔ metabolism (urinary ebastine)687 
↔ IS729, 730 
312Gly>Arg [*8] 
(rs150461093) 
↓ activity (ebastine)655 unknown unknown 
115Pro>Leu [*10] 
(NA) 
↓ activity (terfenidine)656   unknown unknown 




CYP2C8 Gene Variants 








↔ protein level662   unknown unknown 
269Ile>Phe [*2] 
(rs11572103) 





↓ protein level659 








↔ translation515, 662 
↔ protein level515, 657-659, 662 
↓ activity (paclitaxel, 
amiodarone, AA)657-659, 662-664 
↔ activity (paclitaxel, 
amiodarone)658, 665 
↑ CL (pioglitazone, rosaglitazone, 
repaglinide)665, 689-694, 696-698 
↔ CL (rosiglitazone, repaglinide, 
paclitaxel)375, 695, 699, 700, 706, 710-712 
↓ CL (ibuprofen, diclofenac)701-705 




↔ translation515, 662 
↔ protein levels515, 662 
↓ activity (paclitaxel, 
amiodarone, nifedipine, AA)657, 
662, 663, 666, 667 
↔ activity (paclitaxel)665 
↑ CL (repaglinide)698 






Truncated protein670   unknown unknown 
186Arg>Ter [*7] 
(rs72558195) 
Truncated protein667   





↓ protein levels668 




unknown ↓ CL of rosiglitazone376 unknown 
238Ala>Pro [*14] 
(rs188934928) 
↓ protein levels668 




↓ protein levels659 
↓ activity (paclitaxel and 
amiodarone)659 
unknown unknown 
Haplotype B  
(containing *1B) 
↓ activity (paclitaxel)665 ↑ CL of repaglinide665  unknown 





CYP2C9 gene variants 




↓ CL (NSAIDs, anti-
coagulants, anti-diabetic 
drugs)671   
↔ IS731, 732 




↓ CL (NSAIDs, anti-
coagulants, anti-diabetic 
drugs)671   





↓ CL (NSAIDs, anti-
coagulants, anti-diabetic 




↓ activity671 ↓ CL (phenytoin)716 unknown 
273 Frameshift [*6] 
(rs9332131) 
shortened protein671 ↓ CL (phenytoin)716 unknown 
19Ile>Leu 
(rs67807361) 
↔ activity (tolbutamide)674 unknown  unknown 
150Arg>His [*8] 
(rs7900194) 
↑ activity (tolbutamide)674 
↓ activity (warfarin)675 
↓ CL (phenytoin)716 unknown 
251His>Arg [*9] 
(rs2256871) 
↔ activity (tolbutamide)674 unknown unknown 
272Glu>Gly [*10] 
(rs9332130) 
↔ activity (tolbutamide)674 unknown unknown 
335Arg>Trp [*11A] 
(rs28371685) 
↓ activity (tolbutamide)674 
↔ warfarin dosing717 




↓ activity (tolbutamide)674 unknown unknown 
90Leu>Pro [*13)] 
(rs72558187) 
↓ activity671 ↓ CL (lornoxicam)715   unknown 
125Arg>His [*14] 
(rs72558189) 
↓ activity (tolbutamide)672 unknown unknown 
Ser162Ter [*15] 
(rs72558190) 
no protein672 unknown unknown 
299Thr>Ala [*16] 
(rs72558192) 
↓ activity (tolbutamide)672 unknown unknown 
382Pro>Ser [*17] 
(C09G1362C) 
↓ activity (tolbutamide)672 unknown unknown 
359Ile>Leu / 397Asp>Ala 
[*18] (rs1057910/rs72558193) 
no protein672 unknown unknown 
454Gln>His [*19] 
(C09G208C) 
↓ activity (tolbutamide)672 unknown unknown 
118Lys>Arg (Frameshift) [*25] 
(rs72558188) 
no protein671 unknown unknown 
130Thr>Arg [*26] 
(rs5031019) 
↓ activity671 unknown unknown 
214Gln>Leu [*28] 
(C09A641T) 
↓ activity671 unknown unknown 
 477Ala>Thr [*30] 
(C09G1429A) 
↓ activity671 unknown unknown 
132Arg>Gln [*33] 
(rs72558184) 
↓ activity (diclofenac)673   unknown unknown 
CL, clearance; NSAID, non-steroidal anti-inflammatory; IS, ischemic stroke; ICVD, ischemic cerebrovascular disease   
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EPHX2 gene variants 
SNP (rs#) In vitro Metabolism In vivo metabolism Stroke SNP (rs#) 
55Lys>Arg 
(rs41507953) 
↑ activity (t-SO, t-
DPPO)676 
↑ activity (EET)641 
↔ activity (EET)677 
↔ metabolism (EpOME)718 
↓ metabolism (EpOME)719 
 
↔ death (CM)677 
↓ death (CM) [+SEHi, +EET]677 
↔ death (NC) [±SEHi, ±EET]641 
↑ IS733 
↔ IS734, 735 
103Arg>Cys 
(rs17057255) 
↔ activity (t-SO , t-
DPPO, EET)641, 676 
 
unknown 
↔ death (CM)677 
↓ death (CM) [+SEHi, +EET]677 
↓ death (NC) [±SEHi, ±EET]641 




↑ activity (t-SO , t-
DPPO) 676 
↔ activity (EET)641 
 
unknown 
↔ death (CM) 677 
↔ death (NC)641 
↓ death (CM) [+SEHi, +EET]677 




↔ activity (t-SO)678 
↓ activity (t-SO, t-
DPPO, EET)641, 676 
738 
 
↔ metabolism (PAH)722 
↓ metabolism (EpOME)718 
↑ cholesterol, triglycerides721 
docetaxel CL720 
↓ death (CM)677 
↔ death (NC)641 
↔ death (CM) [+SEHi, +EET]677 
↓ death (NC) [±SEHi, ±EET] 641 
↑ IS734 
↓ IS729 





↓ activity (t-SO)678 unknown unknown 




↑ activity (t-SO, t-
DPPO)676 
↔ activity (EET)676 
unknown unknown ↔ IS734, 735 
g.44201A>C 
(rs7357432) 
unknown unknown unknown ↑ IS734 
g.57498G>A 
(rs2291635) 
unknown unknown unknown ↑ IS734 
EET, epoxyeicosatrienoic acid; t-SO, trans-stilbene oxide, t-DPPO, trans-diphenylpropene oxide; EpOME, epoxyoctadecenoic 
acid; PAH, polycystic aromatic hydrocarbon; CM, cardiomyocyte; NC, neuronal cell; SEHi, soluble epoxide hydrolase inhibitor; 






Subarachnoid hemorrhage (SAH) due to a ruptured aneurysm is a type of stroke associated with 
high rates of mortality and significant cost.  Survivors of SAH are often left with physical disability 
and cognitive impairments that can affect their quality of life and ability to return to work.  Despite 
identification of risk factors for SAH and advances in preventative measures, the worldwide 
incidence of SAH has been relatively constant over the last few decades.  Individuals with SAH 
commonly suffer multiple medical complications that develop over different time periods after the 
hemorrhage.  The most important acute complications after SAH are increased ICP, aneurysm 
rebleeding, and hydrocephalus whereas development of CND and DCI are important 
complications that typically occur 3-14 days after the hemorrhage.  Mechanisms of acute and 
delayed injury including oxidative stress, inflammation, cerebrovascular dysregulation, 
microthrombosis, and cerebral ischemia.  Since CND and DCI are potentially reversible and 
typically develop days after hemorrhage, these conditions serve as a target for monitoring and 
aggressive preventive and treatment strategies.  Key methods used for the diagnosis and prediction 
of these delayed ischemic complications include clinical grading scales, radiographic monitoring 
modalities, physiological indicators, biochemical markers, and genetic markers.  Yet, despite the 
time window for therapeutic intervention, strategies to prevent these delayed ischemic 
complications have had limited success in part due to the lack of understanding of the underlying 
mechanisms involved. 
Growing evidence suggests that AA metabolites of CYP enzymes, also known as CYP 
eicosanoids, play an important role the pathophysiology of a wide array of diseases including SAH.  
In humans, AA is metabolized by CYP4A11 and CYP4F2 enzymes to form 20-HETE and by 
CYP2C8/9 and CYP2J2 enzymes to form four EET regioisomers.  In the brain, 20-HETE promotes 
vasoconstriction, angiogenesis, inflammation, apoptosis, and platelet aggregation while EETs 
promote vasodilation and angiogenesis and inhibit inflammation, apoptosis, and platelet 
aggregation.  The cellular action of EETs is limited through its metabolism by SEH to form 
inactive DHETs.  Recent evidence suggest that CYP eicosanoids play an important role in 
hypertension and vascular homeostasis and may contribute to the pathogenesis of IA and risk of 
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rupture.  In addition, CYP eicosanoids have been shown to be key regulators of cerebrovascular 
tone and CBF and are implicated in the pathophysiology of cerebral injury due to ischemic and 
hemorrhagic stroke in preclinical studies.  Human polymorphisms in genes responsible for CYP 
eicosanoid biosynthesis and metabolism have been associated with altered function in vitro and in 
vivo and have been associated with the risk for SAH and other types of stroke.  However, there are 
few clinical studies that investigate the role of CYP eicosanoids in the pathophysiology of SAH 
due to the difficulty to measure these compounds in human CSF.  Based on these studies, we 
hypothesized that polymorphisms in genes involved in CYP eicosanoid biosynthesis and 
metabolism will lead to increased 20-HETE or decreased EET concentrations in CSF resulting in 
the development of ischemic complications and unfavorable long-term functional outcomes in 
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Based on the preclinical and clinical evidence establishing the importance of CYP eicosanoids in 
the regulation of CBF and the pathophysiology of SAH, there is a need for sensitive, selective, and 
reproducible methods for measuring 20-HETE, EET, and DHET metabolites in human biological 
fluids.  Multiple methods have been previously developed for the detection and quantification of 
CYP Eicosanoids.  Gas chromatography-mass spectrometry739, 740, liquid chromatography (LC) -
mass spectrometry (MS)741, 742, LC-fluorescence detection743, radioimmunoassay744, 
electrophoresis745, and enzyme immunoassays746, have all aided in the quantitative analysis of 
these compounds from many different matrices.  Although these assays are useful, limitations of 
these methods include high cost, limited sensitivity, cross-reactivity, and time-consuming 
analysis.747  However, the most significant issue is the specificity for quantification of these highly 
similar isomeric metabolites in complex biological matrices.   
While high performance liquid chromatography (HPLC) with tandem mass spectrometry 
(MS/MS) continues to be in the forefront in the investigation of these compounds from matrices 
including cell culture748, 749, tissue750-752, and biological fluids620, 753, the limitation of flow rate 
applied to routine HPLC systems has resulted in extended run times for most reported AA 
metabolite methods.  A more efficient approach has been developed with the use of ultra-
performance liquid chromatography (UPLC), which uses high flow rates without the limitations 
of increased pressure or loss of performance.  This new technique, developed in 2004, offers 
significant advantages over traditional HPLC methods, providing greater separation efficiency, 
improved sensitivity, and shortened run times.754, 755  UPLC systems, in conjunction with 
appropriate mobile phases and analytical columns, also offer benefits such as lower sample 
injection volumes and improved peak resolution.754, 755  As a result, our lab investigated the utility 
of ultra-performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS) to 
quantify these highly similar isomeric metabolites.   
In 2009, our lab developed and validated a rapid, sensitive, and selective UPLC-MS/MS 
quantitation method to simultaneously measure CYP eicosanoids in CSF from SAH patients, rat 
cortical tissue, and rat cortical microsomal incubates.  Work performed by others in our lab 
reported the validation of linear calibration curves ranging from 0.208 to 33.3 ng/ml. The inter-
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day and intra-day variance was less than 15% at most concentrations with extraction efficiency 
greater than 73%. My contribution to the method development and validation was to investigate 
the effects of the matrix on the reproducibility and reliability of the data as recommended by the 
Food and Drug Administration (FDA) Quantitative Bioanalytical Methods Validation Report and 
other validation guidance documents.756, 757  Development of this method is necessary for future 
evaluation of these metabolites as potential quantitative biomarkers in larger clinical trials.   
Using our validated UPLC-MS/MS quantitation method, our lab found a low percentage 
of samples with detectable CYP eicosanoids in 1ml of fresh CSF samples collected directly from 
external ventricular drains on patients with SAH.  This limited our ability to determine temporal 
concentration profiles of these compounds in CSF from SAH patients.  Based on these quantitative 
limitations, we set out to improve the ability to measure multiple CYP eicosanoids in human CSF 
using UPLC-MS/MS and determine temporal concentration profiles of these compounds in the 
CSF of patients with SAH.  Specifically, we investigated methods to further concentrate the CSF 
during sample processing in an effort to improve UPLC-MS/MS peak response and decrease our 
lower limit of quantitation (LLOQ).  In an effort to utilize the larger volumes of CSF (>200ml) 
available in the drainage bags attached to the ventricular drains, we determined the recovery of 
these metabolites from the drainage bags and the room temperature stability of these CYP 
eicosanoids over the 12 hour collection period.  In addition, we performed modifications to our 
solid phase extraction (SPE) method to further concentrate the CSF samples.   
2.2 MATERIALS AND METHODS 
2.2.1 Materials 
 
Stock standards of 20-hydroxy-5Z, 8Z, 11Z, 14Z-eicosatetraenoic acid (20-HETE), (±)14,15-
epoxy-5Z, 8Z, 11Z-eicosatrienoic acid (14,15-EET), (±)11,12-epoxy-5Z, 8Z, 14Z-eicosatrienoic 
acid (11,12-EET), (±)8,9-epoxy-5Z, 11Z, 14Z-eicosatrienoic acid (8,9-EET), (±)14,15-dihydroxy-
5Z, 8Z, 11Z, 17Z-eicosatrienoic acid (14,15-DHET), (±)11,12-dihydroxy-5Z, 8Z, 14Z-
94 
 
eicosatrienoic acid (11,12-DHET), (±)8,9-dihydroxy-5Z, 8Z, 14Z-eicosatrienoic acid (8,9-DHET), 
(±)5,6-dihydroxy-8Z, 11Z, and 14Z-eicosatrienoic acid (5,6-DHET), 20-hydroxy-5Z, 8Z, 11Z, and 
14Z-eicosatetraenoic acid-d6 (20-HETE-d6) were purchased from Cayman Chemical Company 
(Ann Arbor, MI).  In some studies, EETs are also referred to as EpETrE and DHETs are referred 
to as DiHETrE or DiHETEs.  High purity organic solvents were purchased from VWR (West 
Chester, PA) and all other chemicals were purchased from Sigma–Aldrich (St. Louis, MO). 
Artificial cerebrospinal fluid (aCSF) was purchased from Tocris Bioscience (Ellisville, MO). 
 
2.2.2 Patient population and CSF sample collection  
 
All protocols have been approved by the Institutional Review Board at the University of Pittsburgh 
and informed consent was obtained from the human subjects or their representatives.   
This study included patients with SAH verified by cerebral angiography within 5 days of injury.  
Also, Fisher grade ≥ 2 were chosen as inclusion criteria to increase the likelihood that subjects will 
have degree of hemorrhage sufficient for elevated biomarker concentrations.  CSF samples used 
in this study were collected from 38 patients at approximately 12 hour intervals throughout a 14 
day period following SAH.  In this study, samples were categorized as either fresh CSF or bag 
CSF based on the method and location of CSF sampling.  Fresh CSF samples were collected, 
stored, and prepared as previously described.643  Briefly, fresh CSF samples of 0.11 – 1.0 ml were 
withdrawn directly from the CSF drainage line using a sterile needle and syringe, aliquoted into 
preservative-free cryostat vials, and immediately stored at -80ºC until analysis.  Prior to extraction, 
fresh CSF samples were diluted using 0.12 M potassium phosphate buffer (pH = 7.4) containing 5 
mM magnesium chloride and 0.113 mM butylated hydroxytoluene as an antioxidant to a final 
sample volume of 2 ml.  Bag CSF samples were withdrawn from CSF drainage bags using a needle 
and syringe.  Sample volumes of 2.0-5.0 ml of bag CSF were collected, aliquoted into preservative-




2.2.3 Preparation of calibration standards and quality control samples   
 
For the validation studies, a stock solution of metabolites was prepared by combining 10µg/ml of 
each metabolite in methyl acetate.  This solution was further diluted with 80:20 methanol: 
deionized water (MeOH:dH20) to achieve a series of working solutions at 1µg/ml, 100ng/ml, and 
25ng/ml concentrations.  A solution of 20-HETE-d6, used as the internal standard (IS), was 
prepared in 80:20 MeOH:dH20 at a concentration of 1µg/ml.  Calibration standards and quality 
control (QC) samples were prepared from separate stock dilutions by spiking appropriate amounts 
of the working solutions into buffer.  Calibrants were prepared at 0.208, 0.417, 0.833, 1.25, 1.67, 
4.17, 8.33, 12.5, 16.67, and 33.33 ng/ml (12.5, 25, 50, 75, 100, 250, 500, 750, 1000, 2000 pg on 
column, respectively).  QC’s were prepared at 1.50, 7.50, and 20.83 ng/ml (90, 450, 1250 pg on 
column, respectively). 
For the modified method, stock solutions of CYP eicosanoids were combined and diluted 
with 80:20 MeOH:dH20 to achieve a series of working solutions at 0.30, 0.04, and 0.005 ng/ml 
concentrations.  20-HETE-d6 was used as IS and was prepared in 80:20 MeOH:dH20 at a 
concentration of 0.25 ng/ml.   Calibration standards and QCs were prepared from separate stock 
dilutions by spiking appropriate amounts of the working solutions and IS into buffer.  These 
calibrants and QCs were spiked with IS to a final concentration of 12.5 ng/ml.   For quantitation 
of metabolites using our modified method, calibrants were prepared at 0.014, 0.028, 0.056, 0.11, 
0.17, 0.22, 0.56, 1.11, 1.67, 2.22, 4.44 ng/ml (12.5, 25, 50, 75, 100, 250, 500, 750, 1000, 2000 pg 
on column, respectively) and QCs at 0.20, 1.00, 2.78 ng/ml (90, 450, 1250 pg on column, 
respectively).  These calibrants and QCs were spiked with IS to a final concentration of 1.67 ng/ml.  
The standard curves for UPLC-MS/MS analysis were constructed the same day as the sample 
analysis. 
 




The CYP eicosanoid concentrations in the CSF samples, as well as in the calibrants and quality 
controls, were determined using a solid phase extraction (SPE) procedure. Fresh CSF samples 
were processed as previously described.643  Briefly, fresh CSF samples were spiked with 20-
HETE-d6 as the IS to a final concentration of 6.25 ng/ml (750 pg on column).  Fresh CSF samples 
of up to 1ml were loaded onto 1cc Oasis HLB SPE cartridges (30mg sorbent, 30m particle size) 
(Waters, Milford, MA) that were conditioned and equilibrated with 1ml of MeOH and 1ml of 
dH20, respectively. Columns were washed with three 1 ml volumes of 5% MeOH and were eluted 
with 100% MeOH. Extracts were dried under nitrogen gas at 37ºC and reconstituted in 125 l of 
80:20 MeOH:dH20.  Bag CSF samples were processed using the method described above with 
minor modifications.  Modifications included spiking the samples with IS to a final concentration 
of 1.67 ng/ml (750 pg on column), loading 2.0-3.0 ml sample volumes onto 3 cc Oasis HLB SPE 
cartridges (60mg sorbent, 30m particle size) (Waters, Milford, MA) that were conditioned and 
equilibrated with 2 ml of MeOH and 2 ml of dH20, respectively, washing the column with 3 ml of 
5% MeOH, eluting the column with 3 ml of 100% MeOH, and reconstituting the samples in 50 l 
of 80:20 MeOH:dH20.  
 
2.2.5 Chromatographic and mass spectrometric conditions 
Liquid chromatography was performed using an Acquity ultra performance LC autosampler 
(Waters, Milford, MA).  Separation of analytes was conducted on a UPLC BEH C18, 1.7µm (2.1 
x 100mm) reversed-phase column (Waters, Milford, MA) protected by a guard column (2.1 x 
5mm; Waters, Milford, MA,) of the same packing material.  Column temperature was maintained 
at 55º C.  Mobile phases, delivered at a flow rate of 0.5ml/min, consisted of 0.005% acetic acid, 
5% acetonitrile in deionized water (A) and 0.005% acetic acid in acetonitrile (B) at an initial 
mixture of 65:35 A and B, respectively.  Mobile phase B increased from 35% to 70% in a linear 
gradient over 4 minutes, and again increased to 95% over 0.5 minutes where it remained for 0.3 
minutes.  This was followed by a linear return to initial conditions over 0.1 minutes with a 1.5 
minute pre-equilibration period prior to the next sample run.  Total run time per sample was 6.4 
minutes and all injection volumes were 7.5µl.   
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Mass spectrometric analysis of analyte formation was performed using a TSQ Quantum 
Ultra (Thermo Fisher Scientific, San Jose, CA) triple quadrupole mass spectrometer coupled with 
heated electrospray ionization (HESI) operated in negative selective reaction monitoring (SRM) 
mode with unit resolutions at both Q1 and Q3 set at 0.70 full width at half maximum. Quantitation 
by SRM analysis on CYP eicosanoids was performed by monitoring their m/z transitions.  The 
SRM conditions for these molecules and their retention times are shown in Table 2-1: SRM 
conditions for quantitation of CYP eicosanoids by UPLC-MS/MS.  Parameters were optimized to 
obtain the highest [M-H]¯ ion abundance and were as follows: capillary temperature, 400º C, spray 
voltage, 3000 kV, and a source collision-induced dissociation set at 0V.  Sheath gas, auxiliary gas, 
and ion sweep gas pressures were set at 65, 55, and 3, respectively.  Scan time was set at 0.01s and 
collision gas pressure was set at 1.3 mTorr.  Analytical data was acquired and analyzed using 
Xcaliber software version 2.0.6 (ThermoFinnigan, San Jose, CA). 
Table 2-1: SRM conditions for quantitation of CYP eicosanoids by UPLC-MS/MS 
Selective reaction monitoring (SRM) conditions for UPLC-MS/MS operated in negative heated electrospray 
ionization (HESI) mode. 
 
2.2.6 Metabolite stability and recovery determination 
Stability of CYP eicosanoids at room temperature and recovery from Medtronic Exacta drainage 
bags (Medtronic Neurosurgery, Goleta, CA) was measured over 12 hours in order to determine the 
appropriateness of evaluating CSF collection bag samples for these metabolites.   The duration of 
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the experiment was chosen based on the time period between collection of CSF samples.  For the 
evaluation of temperature stability, pooled bag CSF was aliquotted into silanized test tubes.  One 
set of samples was spiked with metabolites at a concentration of 33.33 ng/ml while the other set 
of vials included control CSF with no metabolites for subtraction of basal CSF concentrations.  All 
samples were kept at room temperature for up to 12 hours.  500l aliquots were collected at 
baseline (time 0) and at 1, 6 and 12 hours after start of incubation (n = 3 per time point).  Sample 
aliquots were immediately frozen at -80°C after room temperature incubation.   
For evaluation of recovery from collection bags, CSF was pooled from SAH patients and 
aliquots of 18ml were added into 1L Medtronic Exacta drainage bags constructed of 
polyvinylchloride (PVC).  One bag was spiked with 33.33 ng/ml of metabolites while the other 
bag included control CSF with no metabolite addition.  500l aliquots were collected at baseline 
(time 0) and at 1, 6 and 12 hours after start of incubation (n = 4 per time point).  Sample aliquots 
were immediately frozen at -80°C after room temperature incubation.   
At the time of sample processing, frozen samples from the above two experiments were 
thawed and processed using SPE and concentrations of metabolites were determined by UPLC-
MS/MS as described previously.  Concentration of metabolites measured in the control CSF was 
subtracted from the concentration of metabolites measured in the spiked CSF.  Results were 
expressed as a percentage of initial concentration. 
It is noteworthy that a direct measurement of 5,6-EET has not been attempted in most 
studies because, unlike the other EET regioisomers, 5,6-EET has been reported to be chemically 
unstable in physiological buffer solution and alkaline aqueous solution.745, 758, 759  Also, 5,6-EET 
is hydrolyzed to 5,6-DHET and its lactone under neutral and acidic conditions.745, 758  Therefore, a 
measurement of 5,6-EET in human CSF was excluded from our analysis.   
 
2.2.7 Evaluation of matrix effects 
Matrix effects were evaluated using 2ml volume of the same phosphate buffer used for processing 
human CSF samples, rat cortical tissue extracts, and rat brain microsomal incubations and also 
artificial cerebrospinal fluid (aCSF) spiked with 0.113mM BHT.  Both matrices were extracted via 
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SPE using the method described above and the eluate was spiked with low and high concentrations 
of CYP eicosanoids at 1.5 ng/ml and 20.83 ng/ml, respectively, and 20-HETE-d6 internal standard 
at 12.5 ng/ml.  Neat samples containing the same concentrations of CYP eicosanoids and 20-
HETE-d6 internal standard were prepared in 80:20 MeOH:dH20.  Samples were analyzed using 
UPLC-MS/MS as described above.  The internal standard normalized matrix factor (IS-normalized 
MF) for each sample was calculated based on the area ratio (analyte/internal standard) of the post-
extraction spiked samples to the neat samples as described by Viswanathan et al.757   IS-normalized 
MF results are expressed as average ± standard deviation (SD) with coefficient of variation (CV) 
(n=6). Values less than 1.00 indicate ion suppression and values greater than 1.00 indicate ion 
enhancement.756   
 
2.2.8 Comparison of published and modified quantitation methods 
 
We investigated the effect of using larger load volumes and SPE cartridges on the recovery of 
CYP eicosanoids spiked in buffer.  The effect of SPE column size on the recovery of CYP 
eicosanoids was compared by spiking the same amount of analyte and IS (0.83 ng) in 1ml and 3 
ml phosphate buffer (pH=7.4), processing the samples using 1cc and 3cc SPE cartridges, 
respectively, and reconstituting the samples in 125 l of 80:20 MeOH:dH20.  Next, we investigated 
the effect of using various reconstitution volumes on the recovery of CYP eicosanoids spiked in 
buffer.  The effect of the reconstitution volume on the recovery of CYP eicosanoids was 
determined by spiking analyte and IS to 0.276 ng/ml in 3 ml of phosphate buffer, processing 
samples using 3 cc SPE columns, and reconstituting the samples in 25, 75, 125 and 200 l of 80:20 
MeOH:dH20.  CYP eicosanoids were quantitated using UPLC-MS/MS and recovery was 
determined using the mean area ratio of analyte to IS.   
The combined effect of load volume and reconstitution volume on the peak response of the 
assay to measure CYP eicosanoids was determined by spiking the analyte and IS to 0.276 ng/ml 
in phosphate buffer, processing sample load volumes of 1 ml using 1 cc SPE columns and sample 
load volumes of 3 ml using 3 cc SPE columns, and reconstituting the samples in 50 l and 125 l 
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of 80:20 MeOH:dH20.  CYP eicosanoids were quantitated using UPLC-MS/MS and peak response 
was compared using the mean area of analytes and IS.   
The peak response to measure CYP eicosanoids in bag CSF using our published method643 
was compared to our modified method.  Using our published method, the bag CSF samples were 
processed using a 1 ml sample load volume with 1 cc SPE cartridge and reconstitution volume of 
125 l.  Using our modified method, the bag CSF samples were processed using 3ml sample load 
volume with 3 cc SPE cartridge and reconstitution volume of 50 l.  CYP eicosanoid peak 
responses were measured using UPLC-MS/MS.  The UPLC-MS/MS detector responses were 
normalized to the maximum value and chromatograms were displayed.  In addition, 20-HETE 
concentrations were measured in fresh and bag CSF from patients with SAH using our published 
and modified quantitation methods while EET and DHET concentrations in bag CSF were 
quantified using our modified quantitation method.    
 
2.2.9 Statistical analysis 
 
Statistical analysis was completed using GraphPad Prism software, version 4.03 (GraphPad 
Software, La Jolla, CA). In the metabolite stability and recovery studies, the percentage of initial 
concentration at each time point was compared using repeated measures one-way analysis of 
variance (ANOVA) with Dunnett’s post hoc test for each metabolite.  In the matrix effects studies, 
IS-normalized MF values were compared using unpaired t-test (2 tailed).  In the study investigating 
the effect of SPE column size on recovery on CYP eicosanoids, data were normalized to the 
recovery observed using 1cc SPE columns and compared using unpaired t-test (2-tailed).  In the 
study investigating the effect of reconstitution volume on recovery of CYP eicosanoids, data were 
normalized to the recovery observed using 125l reconstitution volume and compared using one-
way ANOVA with Dunnett post-hoc test.  For all statistical tests, statistical significance was 






2.3.1 Development of UPLC-MS/MS method 
 
The chemical structures of CYP eicosanoids and selective reaction monitoring (SRM) conditions 
for quantitation using UPLC-MS/MS is shown in Figure 2-1: Chemical structures of CYP 
eicosanoids and internal standard and Table 2-1: SRM conditions for quantitation of CYP 
eicosanoids by UPLC-MS/MS, respectively.  12-HETE and 15-HETE are AA metabolites that are 
formed from COX and CYP enzymes.  These metabolites are referenced in Figure 2-1: Chemical 
structures of CYP eicosanoids and internal standard and Figure 2-3: CYP eicosanoid levels in fresh 
CSF, but will not be discussed in this dissertation.   
 
 











The representative chromatograms of a standard calibrant at 0.208 ng/ml (25pg on column) 
of CYP eicosanoids are depicted in Figure 2-2: Chromatographic profiles for CYP eicosanoids.  
The elution sequence was identified as 14,15-DHET, 11,12-DHET, 8,9-DHET, 20-HETE, 5,6-
DHET, 14,15-EET, 11,12-EET, and 8,9-EET as determined by comparison to injections of 






Figure 2-2: Chromatographic profiles for CYP eicosanoids     
Chromatographic profiles, corresponding to 25 pg on column, depicting the separation of CYP eicosanoids using a 
UPLC tandem MS/MS triple quadrupole mass spectrometer. Resolution of the extracted standard mixture was 
performed on a reversed-phase Acquity BEH (Waters, Milford, MA) C-18 column (2.1mm×100mm; 1.7mm particle 
size). Metabolites were eluted at a flow rate of 0.5 ml/min over 6.4 min with a gradient from 35% acetonitrile 
containing 0.005% acetic acid to 95% acetonitrile containing 0.005% acetic acid. 
 




Calibration standards over a range of 0.208-33.3 ng/ml were used to construct the curves for all 
metabolites.  The weighting factor 1/Y typically provided the best fit of the plot as determined by 
visual inspection, correlation coefficient, and analysis of the residuals.  Over 93% of the calibration 
standards fell within 15% deviation of back-calculated amounts from nominal spiked amounts for 
all levels.  The remaining standards fell within 20% RSD and the correlation coefficients (R²) were 
>0.99 for each metabolite.   
The intra- and inter-day accuracy and precision for the assay were evaluated at three levels: 
1.50, 7.50, and 20.83 ng/ml (90, 450, 1250 pg on column, respectively), using the QC samples 
within the three validation runs.  Ten replicates at each concentration within a single day of 
validation were used to determine the intraday reproducibility.  Inter-day reproducibility was 
determined over three separate days using an n = 5 at these concentrations. Calculated values of 
the QCs were generated using the equation of linear regression obtained from the calibration curves 
run within the same sequence.  Results are shown in Table 2-2: Quantitation method accuracy and 
precision.  The %RSD for all analytes fell within 15%, indicating favorable reproducibility of the 





Table 2-2: Quantitation method accuracy and precision 
 
Accuracy and precision of the assay, represented by quality controls, for CYP eicosanoids extracted in buffer.  Intra- 
and inter-assay relative standard deviation (RSD) ranged from 2.70 to 14.38% and 2.78 to 10.32%, respectively.  Intra- 
and inter-assay relative error (RE) ranged from -3.40 to 7.46% and -7.99% to 5.06% and 14.38%, respectively.  
 
 
2.3.3 Recovery of CYP eicosanoids after extraction 
The recovery efficiencies for all metabolites were determined at two different levels, at 1.50 ng/ml 
and 20.83 ng/ml (90 and 1250 pg on column) as shown in Table 2-3: Recovery efficiencies of CYP 
eicosanoids after extraction from buffer.  The recovery ranged from 73% - 94%, with the EETs 
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having the lowest recovery, however, all demonstrated favorable reproducibility with a %RSD 
below 15%.  
 
 
Table 2-3: Recovery efficiencies of CYP eicosanoids after extraction from buffer 
 
Recovery efficiencies and relative standard deviation (RSD) of CYP eicosanoids in buffer after solid phase extraction.  
Recovery efficiencies were calculated from the peak area ratio of the extracted to the unextracted samples. 
2.3.4 Analysis of CSF samples from SAH patients 
The method was applied to establish CYP eicosanoid concentrations in fresh human CSF samples 
from eight subarachnoid hemorrhage patients. Samples taken at different time points from each 
patient were analyzed and concentrations were determined by using the equation of linear 
regression obtained from the calibration curves.  Because these compounds are found 
endogenously in human CSF, it was not possible to conduct this validation using blank samples of 
this biological matrix.   
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Peaks of 8,9-DHET and 20-HETE were found in quantitative amounts in all but one 
patient.  Peaks of 14,15-DHET, 11,12-DHET, and 5,6-DHET were found in amounts above the 
limit of detection (LOD) but below LOQ.  No detectible amounts of 14,15-EET, 11,12-EET, or 
8,9-EET were seen in these samples.  All peaks were verified by comparing their m/z fragment 
and retention time with that of an authentic standard.  The peak concentrations over the 14 day 
collection period are reported in Figure 2-3: CYP eicosanoid levels in fresh CSF.  These results 
indicate that multiple CYP eicosanoids in CSF from SAH patients can be quantified using this 
method and the metabolite with the highest concentration measured was 20-HETE. 
 
 
Figure 2-3: CYP eicosanoid levels in fresh CSF  
Concentrations of arachidonic acid metabolites detected in fresh human CSF. Concentrations given are the highest 
concentrations seen in that patient over 14 days.  Concentrations from seven patients ranged from 0.293 to 24.9 ng/ml 
for detected metabolites. 
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2.3.5 Analysis of matrix effects 
The effects of the phosphate buffer and aCSF matrix on the reproducibility of the assay to measure 
low and high concentrations of metabolites were determined. Table 2-4: Evaluation of matrix 
effects shows the coefficient of variation (CV) of the peak area of each metabolite and IS and area 
ratio (analyte/IS) of the post-extraction spike in buffer and aCSF along with the CV of neat samples 
prepared in 80:20 MeOH:dH20 (n=6).  All of the CV values in Table 2-4: Evaluation of matrix 
effects were below 15%, which demonstrated favorable precision and reliability of the assay.  Most 
of the CV values (80%) for the area and area ratio of high metabolite concentrations were lower 
than the CV values for the low metabolite concentration in both aCSF and buffer.  This indicates 
less variability in the assay at high concentrations of metabolites.  Also, the CV of the area ratio 
was larger than the CV of the area of the metabolites and internal standard for most samples (86%) 
spiked post-extraction.  This indicates that there was not a compensating effect of the internal 
standard on the matrix effects as described by Matusweski et al.756   
 
 
Table 2-4: Evaluation of matrix effects 
 
Assessment of matrix effects of the phosphate buffer and artificial cerebrospinal fluid (aCSF) on the reproducibility 
of the assay to measure low and high concentrations of metabolites. Data is represented as coefficient of variation (CV 
%) of the peak area of each metabolite and IS and area ratio (analyte/IS) of the post-extraction spike in phosphate 
buffer and aCSF along with the CV of neat samples prepared in 80:20 MeOH:dH20 water  (n=6).  The samples were 
spiked with low and high concentrations of CYP eicosanoids at 1.5 ng/ml and 20.83 ng/ml, respectively.  Results 
indicate favorable reproducibility and reliability of the assay to measure low and high concentrations of metabolites 
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in both phosphate buffer and aCSF.  
 
Table 2-5:  Evaluation of internal-standard normalized matrix factor shows the average IS-
normalized MF values of the samples ± standard deviation (SD) and the CV (n=6). The average 
IS-normalized MF values ranged from 0.92-1.13 with most of the values (68%) within 5% of 1.00.  
An IS-normalized MF (or absolute MF) of 1 signifies no matrix effects. A MF value less than 1 
signifies ion suppression while a value greater than 1 signifies ion enhancement or analyte loss in 
the absence of matrix.  An IS-normalized MF (or absolute MF) of 1 is not necessary for a reliable 
bioanalytical assay.  However, a highly variable MF would indicate lack of reproducibility in the 
assay.  All of the CV of the IS-normalized MF values were below 15%, which demonstrates 
minimal effects of the phosphate buffer and aCSF matrix on the precision and reliability of the 
assay at low and high metabolite concentrations.  Also, the matrix effects, measured by IS-
normalized MF values, were not significantly different in aCSF as compared to buffer for all 
metabolites.  
    
Table 2-5:  Evaluation of internal-standard normalized matrix factor 
 
Comparison of the internal standard-normalized matrix factor (IS-normalized MF) of the phosphate buffer and 
artificial cerebrospinal fluid (aCSF) at low and high concentrations of metabolites. Data is shown as the average IS-
normalized MF values ± standard deviation (SD) and the CV for phosphate buffer and aCSF spiked with low and high 
concentrations of CYP eicosanoids at 1.5 ng/ml and 20.83 ng/ml, respectively (n=6).  IS-normalized matrix factor 
values in phosphate buffer were compared to aCSF.  Significant differences are denoted by *p<0.05.  Results indicate 
minimal effects of the phosphate buffer and aCSF matrix on the reproducibility and reliability of the assay and no 




2.3.6 Stability and recovery of CYP eicosanoids from CSF drainage bags 
Table 2-6: Room temperature stability of CYP eicosanoids demonstrates that CYP eicosanoids 
were not significantly altered from baseline for up to 12 hours of room temperature incubation in 
silanized borosilicate glass. Whereas, Table 2-7: Recovery from CSF drainage bags shows some 
of these metabolites were significantly reduced upon room temperature incubation in PVC bags.  
Specifically, the recovery of 8,9-EET, 11,12-EET and 14,15-EET was significantly altered by 
contact with the PVC collection bags over 12 hours (p<0.05).  Only 8,9-EET, 11,12-EET and 
14,15-EET showed a  significantly lower recovery as early as 1 hour after addition to the PVC bag 
and a highly significant recovery loss at 6 and 12 hours after addition to the PVC bag (p<0.01).  
20-HETE and DHET metabolites were not significantly altered at any of the time points evaluated. 
These results suggest that the use of CSF collection bag samples for assessment of EET metabolites 
will be substantially confounded by recovery loss to the PVC material in the tubing and collection 
bags.  
 
Table 2-6: Room temperature stability of CYP eicosanoids 
Comparison of CYP eicosanoid levels during 12-hour incubation in silanized tubes.  Data at each time point is 
presented as mean percentage of initial concentration ± s.d. (n=3).  The percentage of initial concentration at each 
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time point was compared using repeated measures one-way analysis of variance (ANOVA) with Dunnett’s post hoc 
test. Significant difference was established at *p<0.05.  Results indicate that incubation of CSF in silanized test tubes 
over 12 hours does not significantly affect the measurable amount of the CYP eicosanoids. 
 
Table 2-7: Recovery from CSF drainage bags 
 
Comparison of CYP eicosanoid levels during 12-hour incubation in Medtronic Exacta Drainage Bags.  Data at each 
time point is presented as mean percentage of initial concentration ± SD (n=4).  The percentage of initial concentration 
at each time point was compared using repeated measures one-way analysis of variance (ANOVA) with Dunnett’s 
post hoc test.  Significant differences are denoted by *p<0.05 or **p<0.01.  Results indicate that incubation of CSF 
collected in drainage bags over 12 hours significantly reduces the measurable amount of 14,15-EET, 11,12-EET, and 
8,9-EET, while the measurable amount of 20-HETE, 14,15-DHET, 11,12-DHET, 8,9-DHET, and 5,6-DHET did not 
significantly change.  
 
 
2.3.7 Effect of method modifications on recovery and peak response  
 
The effect of the SPE column size on the recovery of the CYP eicosanoids in buffer is shown in 
Figure 2-4: Effect of SPE column size on recovery of CYP eicosanoids.  Recovery was represented 
as the mean area ratio of the analyte to IS ± SD (n=6).  Data were normalized to the recovery 
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observed using 1 cc SPE columns.  Results show that using 3 cc SPE columns instead of 1 cc SPE 


































































Figure 2-4: Effect of SPE column size on recovery of CYP eicosanoids 
CYP eicosanoid analytes and IS (0.83 ng) were spiked in 1 ml and 3 ml phosphate buffer (pH=7.4), processed using 
1cc and 3cc SPE cartridges, respectively, and reconstituted in 125 l.  Recovery was represented as mean area ratio 
of analyte to internal standard ± SD (n=6).  Data were normalized to the recovery observed using 1 cc SPE columns 
and compared using unpaired t-test (2-tailed).  Statistical difference was established at *p<0.05.   
 
The effect of reconstitution volume on the recovery of CYP eicosanoids in buffer is shown in 
Figure 2-5: Effect of reconstitution volume on the recovery of CYP eicosanoids.  Recovery was 
represented as the mean area ratio of the analyte to internal standard ± SD (n=6).  Recovery data 
were normalized to account for the different reconstitution volumes and expressed as a percentage 
recovery of the observed using 125l reconstitution volume.  Results show that using 









































































Figure 2-5: Effect of reconstitution volume on the recovery of CYP eicosanoids 
CYP eicosanoid analytes and IS was spiked to 0.276 ng/ml in 3ml of phosphate buffer (pH=7.4), processed using 3 
cc SPE columns, and reconstituted in 25, 75, 125 and 200 l.  Recovery was represented as mean area ratio of analyte 
to internal standard ± SD (n=6).  Recovery data were normalized to account for the different reconstitution volumes 
and expressed as a percentage recovery of the observed using 125 l reconstitution volume.  Data were compared 
using one-way ANOVA with Dunnett post-hoc test with a statistical difference established at *p<0.05. 
 
The effect of the load volume and reconstitution volume on the peak response of the UPLC-
MS/MS system to measure 20-HETE in buffer solution is shown in Figure 2-6: Improved detection 
of 20-HETE in buffer with processing modifications.  Peak response was expressed as mean peak 
area ± SD (n=6) and data were normalized to the values observed using the published method (1 
ml load volume and 125 µl reconstitution volume).  Results show 3.3 ± 0.3 (**p<0.0001), 3.6 ± 
0.4 (**p<0.0001), and 10.0 ± 0.6-fold (**p<0.0001) increases in peak response when using 50 µl 
reconstitution volume, 3 ml load volume, and combination of both modifications, respectively, as 
compared to the values observed using 1ml load volume and 125 µl reconstitution volume.  Data 
in Appendix A show similar increases in UPLC-MS/MS peak response when using our modified 
quantitation method to measure 20-HETE-d6, EETs, and DHETs.  Ultimately, these modifications 
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led to a decrease in the LLOQ to measure CYP eicosanoids in buffer solution from 0.208 to 0.028 
ng/ml when compared to published methods.643 
 
 
Figure 2-6: Improved detection of 20-HETE in buffer with processing modifications 
20-HETE was spiked in buffer to 0.83 ng/ml and measured by UPLC-MS/MS after processing 1 ml sample using 1cc 
SPE cartridge, 3 ml sample using 3cc SPE cartridge, and reconstituting samples in either 50 µl or 125 µl (n=6). Peak 
response was expressed as mean peak area ± SD and data were normalized to the values observed using the published 
method (1 ml load volume and 125 µl reconstitution volume) and compared using unpaired t-test (2-tailed).  Statistical 
difference was established at *p<0.05 and **p<0.0001. 
 
The effect of processing modifications on the UPLC-MS/MS peak response to measure 20-HETE 
in bag CSF is shown in Figure 2-7: Improved 20-HETE peak area with method modifications.  The 
UPLC-MS/MS detector responses were normalized to the maximum value and chromatograms 
were displayed.  Results show that the peak response after processing the CSF sample using our 
published method was approximately 8% of the peak response after processing the CSF sample 
using our modified. 
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Figure 2-7: Improved 20-HETE peak area with method modifications 
A bag CSF sample was simultaneously processed using our published method (1ml sample load volume with 1 cc 
SPE cartridge and reconstitution volume of 125 l) and our modified method (3 ml sample load volume with 3cc SPE 
cartridge and reconstitution volume of 50 l) and 20-HETE peak responses were measured using UPLC-MS/MS.  The 
UPLC-MS/MS detector responses were normalized to the maximum value and chromatograms were displayed. 
 
2.3.8 Analysis of CSF using method modifications 
Next, the metabolite concentrations in bag CSF of 38 patients with SAH were measured using the 
modified method.  Figure 2-8: Samples with detectable CYP eicosanoids in bag CSF shows > 50% 
of samples had detectable concentrations of each CYP eicosanoid except for 5,6-DHET (13%) and 
EETs (<6%). Less than 5% of samples were excluded due to sample processing issues such as 



































































Figure 2-8: Samples with detectable CYP eicosanoids in bag CSF 
CYP eicosanoids concentrations were measured in 412 bag CSF samples from 38 patients with SAH using the 
modified quantitation method (3 ml sample load and 50 l reconstitution volume) with a lower limit of quantitation 
(LLOQ) of 0.028 ng/ml. Results were shown as a percentage of samples with detectable metabolite concentrations 
(above LLOQ) and non-detectable metabolite concentrations (below LLOQ). 
 
In addition, the temporal concentration profiles of CYP eicosanoids from a single patient with 
SAH were shown.  Figure 2-9: Temporal concentration profile of CYP eicosanoids in bag CSF 
shows a decreasing concentration trend of 20-HETE and increasing concentration trend for DHETs 
in bag CSF after SAH.  The maximum concentration of 20-HETE, 14,15-DHET, 11,12-DHET, 
and 8,9-DHET in CSF of this patient with SAH was 0.23, 0.14, 0.14, and 0.25 ng/ml at 2.5, 13.5, 
13.5, and 6.5 days after SAH, respectively. 
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Figure 2-9: Temporal concentration profile of CYP eicosanoids in bag CSF 
CYP eicosanoid concentrations were measured in bag CSF of a single patient with SAH over 13 days using the 
modified quantitation method (3 ml sample load and 50 l reconstitution volume).  The CYP eicosanoid concentration 





In this study, we demonstrate that the matrix did not affect the reproducibility and reliability of 
our UPLC-MS/MS method.  Then, we improved our method for detection of CYP eicosanoids by 
utilizing bag CSF and modifying our sample processing method.  In order to utilize bag CSF, we 
first demonstrated room temperature stability of the CYP eicosanoids over the 12 hour collection 
period. However, recovery of EETs was significantly altered by contact with the drainage bag, 
which confounds the quantitation of EET metabolites.  Using our modified method, we report a 
high percentage of samples with detectable 20-HETEs and DHETs in 38 SAH patients and show 
the temporal concentration profiles of CYP eicosanoids for a single patient.  These data 
demonstrate that our modified quantitation method improves our ability to simultaneously measure 
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multiple CYP eicosanoids in CSF from SAH patients and demonstrates our ability to establish 
temporal concentration profiles.  
In this section, we describe the development and validation of a rapid, sensitive, and specific 
UPLC-MS/MS method to measure multiple CYP eicosanoids in CSF of SAH patients.  More 
specifically, we describe the validation of linear calibration curves ranging from 0.208-33.3 ng/ml. 
The inter-day and intra-day variance was less than 15% at most concentrations with an extraction 
efficiency of greater than 73%.  We demonstrated that the matrix effect of the phosphate buffer 
and aCSF did not significantly affect the reliability and reproducibility of the assay, the matrix 
effect of the phosphate buffer is not different than aCSF, and there was no change in UPLC-
MS/MS response due to the phosphate buffer and aCSF matrix for all metabolites measured.  
Therefore, the phosphate buffer can serve as a surrogate matrix for aCSF.   
As discussed in Section 1.7.1, there are only a few studies reporting concentrations of CYP 
eicosanoids in patients with SAH.  Previous studies by our group measured 20-HETE 
concentrations in fresh CSF from 108 patients with SAH using UPLC-MS/MS and found only 
32% of patients and 6% of CSF samples had detectable 20-HETE levels.644  In an effort to improve 
the quantitative assessment of CYP eicosanoids in human CSF, we modified our method to 
concentrate our CSF samples and possibly increase MS/MS peak response.  We concentrated our 
samples by using a smaller sample reconstitution volume during sample processing and utilizing 
the larger sample volumes available from bag CSF compared to fresh CSF.  The maximum volume 
of fresh CSF withdrawn from patients with SAH is limited to approximately 1 ml every 12 hours, 
while the bag CSF typically accumulates to volumes exceeding 30 ml over the same 12 hour 
sampling interval.  Thus, in order to utilize bag CSF, we first needed to investigate the room 
temperature stability of CYP eicosanoids and recovery from the collection bags. 
We demonstrated room temperature stability of the CYP eicosanoids over the 12 hour 
collection period.  However, significant recovery loss is observed for EETs when incubated in the 
drainage bags.  The largest degree of recovery loss was observed with the EET metabolites, which 
were reduced below 50% of baseline at 12 hrs.  The degree of recovery loss was directly related 
to the lipophilicity of the individual metabolites.  The most lipophilic class of metabolites are the 
EETs, which demonstrated significant loss of recovery as early as one hour of room temperature 
incubation in PVC bags.  Little to no significant losses were observed with 20-HETE or DHET 
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metabolites.  Collectively, these results suggest that CSF drainage samples from bags kept at room 
temperature for up to 12 hours are appropriate for quantification of 20-HETE and DHETs.  EET 
metabolites would be expected to undergo significant recovery loss and potentially confound 
variability if collected from tubing or collection bags made from PVC.  These data will be essential 
in the appropriate design of future clinical studies aimed at determining the utility of these 
metabolites as therapeutic targets and/or biomarkers for disease progression and complications. 
Using our modified method, we demonstrated that the recovery of these compounds during 
the sample processing step was not affected, but there was increased the peak response of the 
MS/MS signal without a corresponding increase in the baseline noise.  The improved sensitivity 
of the method can be attributed to increased signal-to-noise ratio.  These modifications decrease 
the LLOQ to measure CYP eicosanoids in CSF from 0.208 ng/ml to 0.028 ng/ml when compared 
to our published methods.643  Also, there was sufficient separation of the chromatograms for each 
metabolite as demonstrated in our published methods 643.  Furthermore, we demonstrated the 
ability to measure 20-HETE and DHETs, but not EETs, in the majority of bag CSF samples from 
patients with SAH.  We report temporal concentration profiles of CYP eicosanoids in the CSF 
from a single patient with SAH.  Collectively, these data demonstrate the ability to measure 
multiple CYP eicosanoids in CSF from SAH patients during the inpatient stay of 14 days using a 
highly sensitive and specific quantitation method. 
2.5 CONCLUSIONS 
These data are the first to demonstrate the utility of bag CSF for analysis of CYP eicosanoids in 
SAH patients.  The method described in this article showed lower detection limits and a higher 
percentage of samples with detectable amounts of CYP eicosanoids when compared to published 
methods thus allowing the analysis of development of temporal concentration profiles.  Additional 
studies are also needed to compare the temporal concentration profiles for CYP eicosanoids in bag 
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As discussed in Section 1.1, SAH is devastating condition associated with high rates of mortality 
and morbidity that can be attributed in large part to the development of ischemic complications 
such as CND and DCI that typically occur 3-14 days after SAH.  Despite this generous time 
window for therapeutic intervention, strategies to improve outcomes have had limited success in 
part due to the lack of reliable and accurate methods to identify high-risk patients and a unfavorable 
understanding of the underlying mechanisms.  Currently, there are no established predictors for 
the development of acute ischemic complications in the first two weeks after SAH and long-term 
functional outcomes.   
Previous studies report that eicosanoids derived from the CYP pathway of AA metabolism 
regulate cerebrovascular tone and structure.355  AA is released from phospholipid membranes can 
be metabolized by CYP enzymes to form EETs that consist of four regioselective isoforms (14,15-
, 11,12-, 8,9-, and 5,6-EET).  EETs are formed primarily by CYP2J2 and CYP2C8/9 enzymes and 
metabolized by SEH to their inactive DHETs.  In the brain, EETs dilate cerebral arteries, promote 
angiogenesis, and inhibit inflammation, apoptosis, and platelet aggregation.355  Collectively, these 
studies suggest that increasing EET levels in the brain may improve the regulation CBF and 
vascular homeostasis. 
Moreover, preclinical evidence shows that EETs regulate CBF in normal brain and after stroke 
and affects cerebral ischemic injury.  Studies have demonstrated that EET synthesis inhibition 
reduced baseline CBF in rats.633  Inhibition or gene deletion of SEH reduces infarct size and 
increases CBF in animal models of temporary focal ischemia.638, 639  In vitro studies demonstrate 
that EETs protect astrocytes against ischemic cell death.640 Also, variants in the EPHX2 gene, 
which codes for SEH, have been shown to affect SEH activity and neuronal survival after ischemic 
injury.641  These studies provide evidence that EETs alter CBF and cerebral ischemic injury in 
preclinical models and warrant further investigation in humans.   
Given the preclinical evidence that EETs are involved in the pathophysiology of stroke, we 
hypothesized that loss-of-function polymorphisms in EET synthesis genes (CYP2C8, CYP2C9, 
and CYP2J2) and gain-of-function polymorphisms in the EET metabolism gene EPHX2 will be 
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associated with decreased EET concentrations in CSF resulting in the development of ischemic 
complications and unfavorable long-term functional outcomes in patients with SAH.  Furthermore, 
we compared genotype frequencies in our SAH population with those reported in the general 
population using the Hapmap database to identify potential genetic markers for SAH.   
3.2 METHODS 
3.2.1 Design and participants 
Participants were prospectively recruited from patients admitted to the University of Pittsburgh 
Medical Center neurovascular intensive care unit (ICU).  The protocol was approved by the 
Institutional Review Board and informed consent was obtained from the patient or their proxy.  
The study included 363 adult patients (age 18-75) with SAH diagnosed via cerebral angiogram or 
head computed tomography (CT) and classified as Fisher grade >1.  Patients were not enrolled if 
they had a history of debilitating neurological disease or SAH from trauma, mycotic aneurysm, or 
arteriovenous malformation.  The number of patients was estimated based on the expected 
variances and differences between CYP eicosanoid levels in outcome groups.  CSF from 269 
patients was available for analysis of CYP eicosanoid levels.  We limited our genetic analyses to 
304 Caucasians in an attempt to address population stratification.760  All patients received standard 
nursing and medical care in the neurovascular ICU.760   
3.2.2 Analysis of EET and DHET CSF levels 
Chemical standards were purchased from Cayman Chemical Company (Ann Arbor, MI).  High 
purity organic solvents were purchased from VWR (West Chester, PA) and all other chemicals 
were purchased from Sigma–Aldrich (St. Louis, MO).  CSF samples were withdrawn from 
collection bags on external ventricular drains approximately every 12 hours during the inpatient 
stay (up to 14 days).  Samples were processed using solid phase extraction (SPE).  Sample volumes 
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of 2.0-3.0 ml were loaded onto 3cc Oasis HLB SPE cartridges (Waters, Milford, MA) that were 
conditioned and equilibrated with 2 ml of MeOH and dH20, respectively.  Columns were washed 
and eluted with 3 ml of 5% MeOH and 100% MeOH, respectively.  Samples were reconstituted in 
50 l of 80:20 MeOH:dH20.  Quantitation of EETs and DHETs was performed using a previously 
described UPLC-MS/MS method643 with minor modifications as described in Section 2.0 .  
Concentrations of EETs and DHETs were determined from the standard curve of the ratio of their 
peak areas to internal standard peak areas of 14,15-EET-d11 and 14,15-DHET-d11, respectively, 
over a linear range of 0.014 to 8.88 ng/ml.   
 
3.2.3 Analysis of gene variants in EET pathway 
Candidate genes in the EET metabolic pathway included CYP2C8, CYP2C9, CYP2J2, and 
EPHX2.  Tagging single nucleotide polymorphisms (tSNPs) were selected using the CEU 
population from Hapmap database (Release 27; www.hapmap.org) and criteria included r2 > 0.8 
and minor allele frequency ≥20% while functional SNPs (fSNPs) were defined as those previously 
reported to affect mRNA transcription, protein expression, or enzyme activity in vitro.  Our genetic 
analysis excluded SNPs with variant genotype frequencies <1% in our SAH population.  Also, 
rs11572080 and rs71220599 were excluded from the analysis because these SNPs were in 100% 
linkage disequilibrium with rs10509681 and rs71553864, respectively.  Our genetic analysis 
included 14 tSNPs (rs11572133, rs11572139, rs1934952, rs1934953, rs12772884, rs1934967, 
rs2253635, rs4086116, rs4918766, rs9332104, rs1155002, rs7515289, rs2071575, and 
rs7816586), eight fSNPs (rs10509681, rs1058930, rs1799853, rs1057910, rs890293, rs41507953, 
rs751141, and rs71553864) and one fSNP/tSNP (rs7909236) as shown in Table 3-1: Candidate 
gene variants in EET pathway included in the analysis.  Genotyping was performed for using 
Taqman allele discrimination assay with ABI Prism 7000 Sequence Detection System (Applied 
Bioscience, Carlsbad, CA, USA) for rs1057910, Affymetrix Human Genome-wide SNP Array 6.0 
(Affymetrix, Santa Clara, CA) for rs1934952, and iPLEX MassArray (Sequenom, San Diego, CA) 
for all other SNPs.  Consistency and integrity of genotyping data was checked by inclusion of 
duplicate CEPH controls on each plate for internal as well as plate-to-plate consistency, using 
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genotype call rate criteria of >85%, comparing the observed and Hapmap Caucasian (CEU) 
frequencies, and performing checks for Hardy-Weinberg Equilibrium (HWE) consistency.   
Analyses involving genetic data included both genotype groups (codominant model) and presence 
or absence of the variant allele (dominant model) groups.  SNPstats software was used to assign 
haplotypes for candidate genes and combinations of fSNPs on different candidate genes.761  
Haplotypes with frequencies < 5% were not evaluated.   
 
Table 3-1: Candidate gene variants in EET pathway included in the analysis 
 




3.2.4 Outcomes assessment 
Acute outcomes included the presence or absence of CND and/or DCI during the inpatient stay 
(up to 14 days).762  CND was determined by a decline in neurological exam for >1 hour evidenced 
by a documented global or focal deficit, decrease in NIH Stroke Scale or Glasgow Coma Scale 
score in the absence of medication administration, fever, seizure, rebleed, increased intracranial 
pressure, hydrocephalus.  DCI was defined as the presence of CND accompanied by evidence of 
impaired CBF (simultaneously or within 12 hours pre- or post-determination of CND).  Impaired 
CBF was determined using surrogate markers of blood flow including angiography (≥25% cerebral 
vessel narrowing) and/or elevated transcranial Doppler flow velocities (≥200cm/s or Lindegaard 
ratio ≥3) or CT/magnetic resonance (MR) perfusion scans (impaired perfusion or new cerebral 
infarction).  Long-term outcomes were determined by global functional recovery at 3 and 12 
months using the Modified Rankin Scale (MRS) obtained during face-to-face interview or phone 
call with the patient or their surrogate.   
 
3.2.5 Statistical analysis 
For the purpose of analysis, HH scores were dichotomized into high (3-5) and low (1-2) groups 
and MRS scores were dichotomized into favorable (MRS 0-2) and unfavorable (MRS 3-6) groups.  
CYP eicosanoid CSF concentrations below the lower limit of quantitation (LLQ) were reported as 
LLQ/2.  The mean and maximum CYP eicosanoid levels for each patient were calculated and were 
used to compare the mean ± standard error of the mean (SEM) in the genotype and outcome groups 
using t-test (with Welch’s correction as appropriate) or ANOVA with Bonferroni’s post-hoc test.  
To examine homogeneous latent trajectory classes of DHET CSF levels following SAH, group-
based trajectory analysis was performed with the PROC TRAJ macro in SAS version 9.4 as 
previously described.763  The time range of 2-11 days was selected to minimize missing data and 
the time from hemorrhage was rounded up to the nearest day.  Log transformation was applied to 
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reduce sample variation and skewness for better model fitting (See Appendix D and E).  The 
Bayesian Information Criterion (BIC) and the substantive utility of the classes (e.g., distinctiveness 
of the trajectories, proportion assigned to a given class) were used to determine the optimal solution 
for the number of trajectory groups.  Mean concentration values from the trajectory analysis were 
reported as the geometric mean ± 95% confidence interval (CI).  DHET trajectory groups and 
genotype/allele frequencies were compared to acute outcomes, long-term outcomes, and covariate 
groups using chi-square analysis or t-test.  Also, the relationship between genotype, CYP 
eicosanoid concentrations/trajectory groups, and outcomes was determined using logistic 
regression after controlling for covariates such as age, sex, race (for comparison of CYP eicosanoid 
levels and outcomes), and either Fisher grade (for analyses involving acute outcomes) or HH score 
(for analyses involving long-term outcomes).  Previous studies report that Fisher grade and HH 
score are strongly associated with acute and long-term outcomes, respectively.278   The cumulative 
incidence of acute outcomes during the inpatient stay in each genotype group was compared using 
Kaplan-Meier log-rank analysis and the model was adjusted for covariates using Cox regression.  
In addition, CYP eicosanoid levels and outcomes were compared in genetic haplotype groups 
before and after adjustment for covariates using SNPstats software.761  All other statistical analysis 
was performed using the Statistical Package for the Social Sciences (SPSS) version 21.0 for 
Windows (SPSS Inc., Chicago, IL, USA). Statistical significance was determined at p-
values<0.05.    
 
3.3 RESULTS 
3.3.1 Acute and long-term outcomes comparison 
A comparison of acute and long-term outcomes is shown in Table 3-2: Acute and long-term 
outcomes comparison.  The presence of CND was significantly associated with DCI and 
unfavorable MRS at 3 and 12 months (p<0.001).  In addition, the presence of DCI was significantly 
associated with unfavorable MRS at 3 and 12 months (p<0.001).  Also, unfavorable MRS scores 
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at 3 months were significantly associated with unfavorable MRS scores at 12 months (p<0.001).   
 
Table 3-2: Acute and long-term outcomes comparison 
 
DCI, delayed cerebral ischemia; CND, clinical neurological deterioration; MRS, Modified Rankin 
Scale score at 3 and 12 months: Unfavorable (3-6), Favorable (0-2); EET, epoxyeicosatrienoic 
acids; DHET, dihydroxyeicosatetraenoic acid (DHET); SEM, standard error of the mean. § 
Multivariate analysis included correction for age, sex, and either Fisher Grade (for acute outcomes) 
or Hunt & Hess Score (for long-term outcomes)  




3.3.2 Covariates and outcomes comparison 
 
Results comparing covariates with acute and long-term outcomes are shown in Table 3-3: 
Covariate and outcome comparison.  As expected, the severity of injury measured by Fisher grade 
and HH scores were associated with worse acute and long-term outcomes (p<0.001), respectively.  
Increased age was associated with the presence of CND (p=0.001) but not DCI and long-term 
outcomes.  Race was associated with better outcomes at 3 months, but not at 12 months, in 
Caucasians compared to Non-Caucasians (p=0.003).  Sex was not associated with acute and long-
term outcomes.   
 
Table 3-3: Covariate and outcome comparison 
 
DCI, delayed cerebral ischemia; CND, clinical neurological deterioration; MRS, Modified Rankin Scale score at 3 




3.3.3 CYP eicosanoid quantitation  
Results showing the percentage patients and samples with detectable CYP eicosanoid levels and 
the mean and maximum CYP eicosanoid levels in all patients are shown in Table 3-4:  Quantitation 
of EETs and DHETs in CSF samples.  Detectable EET and DHET levels were measured in 64.3% 
and 98.9% of patients (n=269) patients and 13.1% and 97.9% of samples (n=3151), respectively. 
Mean and maximum EET levels were 0.073 ± 0.007 ng/ml and 0.153 ± 0.018 ng/ml, respectively. 
Mean and maximum DHET levels were 1.271 ± 0.069 ng/ml and 2.462 ± 0.140 ng/ml, 
respectively.   
 
Table 3-4:  Quantitation of EETs and DHETs in CSF samples 
 
Detectable, Concentration > 0.014 ng/ml 
3.3.4 HWE and Hapmap comparison of genetic data 
Results of the HWE test and the observed vs. Hapmap frequency comparison are shown in Table 
3-5: HWE and Hapmap comparison of genetic data.  The genotype frequencies for CYP2C9 
g.18470G>A were not in HWE (p=0.003).  Also, our SAH population showed different genotype 
frequencies than those reported in the Hapmap CEU population for CYP2C8 g.24879A>T 
(p=0.041), CYP2C9 g.18470G>A (p=0.009), and EPHX2 g.54788T>C (p=0.031) and a trend for 
a difference for CYP2J2 g.14742T>G (p=0.053). 
 
CYP-Eicosanoid Mean Conc. Maximum Conc. Detectable Samples Detectable Patients
Mean ± SEM (ng/ml) Mean ± SEM (ng/ml) N (%) [Total=3151] N (%) [Total=269]
EET 0.073 ± 0.007 0.153 ± 0.018 414 (13.1) 173 (64.3) 
14,15-EET 0.016 ± 0.001 0.037 ± 0.006 140 (4.4) 123 (45.7) 
11,12-EET 0.013 ± 0.001 0.023 ± 0.004 166 (5.3) 87 (32.3) 
8,9-EET 0.044 ± 0.006 0.101 ± 0.015 271 (8.6) 149 (55.4) 
DHET 1.271 ± 0.069 2.462 ± 0.140 3084 (97.9) 266 (98.9) 
14,15-DHET 0.053 ± 0.003 0.114 ± 0.008 2152 (68.3) 241 (89.6) 
11,12-DHET 0.031 ± 0.002 0.078 ± 0.007 1948 (61.8) 189 (70.3) 
8,9-DHET 1.171 ± 0.069 2.329 ± 0.138 3025 (96.0) 264 (98.1) 
5,6-DHET 0.016 ± 0.001 0.048 ± 0.007 382 (12.1) 113 (42.0) 
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Table 3-5: HWE and Hapmap comparison of genetic data 
 
HWE, Hardy-Weinberg Equilibrium; Obs-Hap, observed vs. Hapmap frequency comparison; † Functional SNP; ‡ 
Tagging SNP; *Statistical significance established at p<0.05 
 
3.3.5 CYP eicosanoid levels in genetic groups 
Results comparing CYP eicosanoid CSF levels in genetic groups are shown in Figure 3-1: EET 
CSF levels in genetic groups, Figure 3-2: DHET CSF levels in genetic groups.  CYP2C8*4 
(g.16136G) allele-carriers (n=24) had 44% and 36% lower mean EET and DHET levels when 
compared to CYP2C8*1/*1-carriers (n=197) (p=0.002 and p<0.001), respectively.  Similar results 
were observed when comparing maximum EET and DHET levels in these genotype groups.  
EPHX2 55Arg (g.14861G) allele-carriers (n=38) had 42% and 41% lower mean and maximum 
EET levels (p=0.003 and p=0.049, respectively) and showed a trend for increased maximum 
DHET levels (p=0.094) when compared to EPHX2 55Lys/Lys carriers (n=180).  CYP2C8*1B 
(g.4825A) allele-carriers (n=95) had 23% reduction in maximum DHET levels when compared to 
CYP2C8*1/*1-carriers (n=123) (p=0.044).  Also, CYP2J2*7 (g.4930T) allele-carriers (n=28) had 
36% lower mean DHET levels when compared to CYP2J2*1/*1 carriers (n=193) (p=0.004).  In 
the tSNP analysis, CYP2C8 g.25369T allele-carriers (n=119) had 60% and 93% higher mean and 
maximum EET levels when compared to CYP2C8 g.25369C/C carriers (n=98) (p=0.024 and 
p=0.012), respectively.  CYP2C8 g.36755A allele-carriers (n=104) had 49% and 84% higher mean 
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and maximum EET levels when compared to CYP2C8 g.36755G/G carriers (n=71) (p=0.033 and 
p=0.028), respectively.  CYP2C8 g.24879T allele-carriers (n=101) showed a trend for lower mean 
and maximum EET levels when compared to CYP2C8 g.24879A/A carriers (n=114) (p=091 and 
p=0.094), respectively.  CYP2C8 g.36785G allele-carriers had 22% lower maximum DHET levels 
compared to CYP2C8 g.36785A/A carriers (p=0.044).   
 
 
Figure 3-1: EET CSF levels in genetic groups 
Mean (A) and maximum (B) EET levels in CSF from patients with SAH are compared in genotype groups.  EET CSF 
levels for each patient were calculated and were used to compare the population mean ± SEM of EETs in the variant 
allele-carrier (striped bars) and WT-genotype (solid bars) groups using t-test with Welch’s correction as appropriate.  





Figure 3-2: DHET CSF levels in genetic groups 
Mean (A) and maximum (B) DHET levels in CSF from patients with SAH are compared in genotype groups.  DHET 
CSF levels for each patient were calculated and were used to compare the population mean ± SEM of DHETs in the 
variant allele-carrier (striped bars) and WT-genotype (solid bars) groups using t-test with Welch’s correction as 
appropriate.  Statistical significance established at *p<0.05. 
 
EET and DHET CSF levels in candidate gene haplotypes are shown in Table 3-6: DHET CSF 
levels in CYP2C9 haplotypes, Table 3-7: EET and DHET CSF levels in CYP2C8 haplotypes. The 
most common haplotype (Haplotype 1) for CYP2C8, CYP2C9, CYP2J2 and EPHX2 was GTCAG 
(rs7909236, rs11572133, rs11572139, rs1934953, rs1934952), ATGCGT (rs12772884, 
rs1934967, rs2253635, rs4086116, rs4918766, rs9332104), CT (rs1155002 and rs7515289), and 
TA (rs2071575 and rs7816586) seen in 30.2%, 22.7%, 47.0%, and 39.0% of patients, respectively.  
CYP2C9 Haplotype 4 (ACGCGT) was present in 14.8% of patients and was associated with 0.44 
ng/ml and 1.06 ng/ml higher mean and maximum DHET levels (p=0.028 and p=0.008), 
respectively.   CYP2C8 Haplotype 2 (GATAA) was present 29.1% of patients and was associated 
with 0.03 ng/ml and 0.1 ng/ml higher mean and maximum EET levels (p=0.019 and p=0.006), 
respectively.  Haplotype 2 also showed a trend for 0.25 ng/ml higher mean DHET levels (p=0.072).  
CYP2C8 Haplotype 4 (GACGG) was present 8.3% of patients and was associated with 0.54 ng/ml 
and 1.0 ng/ml higher mean and maximum DHET levels (p=0.010 and p=0.018), respectively.  
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CYP2C8 Haplotype 4 also showed a trend for 0.04 ng/ml higher mean EET levels (p=0.058).  
EPHX2 Haplotype 4 (CA) present in 2.1% of patients was associated with 2.09 ng/ml and 3.84 
ng/ml higher mean and maximum DHET levels (p<0.001).  Similar relationships between CYP 
eicosanoids and haplotypes were observed after controlling for age, sex, and Fisher grade.  There 
were no differences in CYP eicosanoid levels in haplotype groups when compared to the most 
common haplotype for CYP2J2 and EPHX2. 
 
Table 3-6: DHET CSF levels in CYP2C9 haplotypes 
 
§ Multivariate analysis included correction for age, sex, and either Fisher Grade (for acute outcomes) or Hunt & Hess 





Table 3-7: EET and DHET CSF levels in CYP2C8 haplotypes 
 
§ Multivariate analysis included correction for age, sex, and either Fisher Grade (for acute outcomes) or Hunt & Hess 




3.3.6 Outcomes in genetic groups 
Results comparing the genotype and allele frequencies with acute outcomes are shown in Table 
3-8: Acute outcomes in genetic groups.  Carriers of the CYP2C8*4 (g.16136G) allele were ~2.2- 
and 2.5-fold more likely to develop DCI (p=0.041) and CND (p=0.039), respectively.  Conversely, 
patients with CYP2J2 g.30345693C/T genotype were ~1.9-fold less likely to develop CND 




Table 3-8: Acute outcomes in genetic groups 
 
DCI, delayed cerebral ischemia; CND, clinical neurological deterioration; † Functional SNP; ‡ Tagging SNP; § 
Multivariate analysis included correction for age, sex, and Fisher grade; *Statistical significance established at p<0.05. 
 
Figure 3-3: Cumulative incidence of CND in CYP2C8*4 carriers shows patients with the variant 
CYP2C8*4 (g.16136G) allele had a greater cumulative incidence of DCI (53.1%) and a trend for 
greater cumulative incidence of CND (71.8%) over 14 days compared to those with CYP2C8*1/*1 
genotype (35.3% and 54%, p=0.032 and p=0.052, respectively).   These relationships did not 
change after controlling for clinical covariates.   
 
Figure 3-3: Cumulative incidence of CND in CYP2C8*4 carriers 
Gene Genotype CND (+) CND (-) Unadjusted
SNP (rs#) N (%) N (%) P-value OR (95% CI) P-value
CYP2C8 C/C 137 (53.9) 117 (46.1) 0.054 Reference -
g.16136C>G† C/G 23 (71.9) 9 (28.1) 2.48 (1.05-5.89) 0.039*
Ile264Met [*4] G/G 0 (0) 0 (0) - -
(rs1058930) G-carriers 17 (53.1) 15 (46.9) 0.054 2.48 (1.05-5.89) 0.039*
Overall 0.059
CYP2J2 C/C 68 (62.4) 41 (37.6) 0.135 Reference -
g.30345693C>T‡ C/T 69 (50.0) 69 (50.0) 0.53 (0.31-0.92) 0.025*
(rs1155002) T/T 22 (59.5) 15 (40.5) 0.96 (0.42-2.19) 0.922
T-carriers 91 (52.0) 84 (48.0) 0.086 0.60 (0.36-1.02) 0.057
Gene Genotype DCI (+) DCI (-) Unadjusted
SNP (rs#) N (%) N (%) P-value OR (95% CI) P-value
CYP2C8 C/C 90 (35.3) 165 (64.7) 0.049* Reference -
g.16136C>G† C/G 17 (53.1) 15 (46.9) 2.21 (1.03-4.73) 0.041*
Ile264Met [*4] G/G 0 (0) 0 (0) - -






The cumulative incidence of CND and DCI during the inpatient stay is compared in CYP2C8*4-carrier (11.1%) and 
CYP2C8*1/*1 (WT) genotype (88.9%) groups using Kaplan-Meier log rank analysis (n=287).  Statistical significance 
was established at *p<0.05.   
 
Table 3-9: Long-term outcomes in genetic groups shows the results comparing the genotype and 
allele frequencies with long-term outcomes.  Results show that patients with the EPHX2 Thr404del 
(g.50690-50691insGTC) and CYP2C8*1/*2C (g.8633C/T) genotype were ~2.6-, ~2.6-, and 2.0-
fold more likely to have unfavorable outcomes at 3 months (p=0.040, p=0.037, and p=0.045), 
respectively.  Conversely, patients with CYP2C9 g.816G/A, CYP2J2*1/*7 (g.4930G/T) and 
EPHX2 287Arg/Gln (g.30221G/A) genotypes were ~2.1, 3.5, and 2.6-fold less likely develop 
unfavorable outcomes at 3 or 12 months (p=0.048, p=0.048, p=0.027), respectively.  Our haplotype 
analysis showed no differences in outcomes among haplotype groups when compared to the most 




Table 3-9: Long-term outcomes in genetic groups 
 
MRS, Modified Rankin Scale score at 3 and 12 months: Poor (3-6), Good (0-2); † Functional SNP; ‡ Tagging SNP. 
§ Multivariate analysis included correction for age, sex, and Hunt & Hess Score. *Statistical significance established 
at p<0.05. 
 
3.3.7 CYP eicosanoid levels in outcome groups 
Results comparing CYP eicosanoid CSF levels in outcome groups are shown in Figure 3-4: EET 
and DHET CSF levels in outcome groups and Table 3-10:  EET and DHET CSF levels in outcome 
groups.  Mean and maximum EET CSF levels were ~2-fold higher in patients with unfavorable 
outcomes at 3 months (n=67) when compared to those with favorable outcomes (n=115) (p=0.030 
Gene Genotype MRS3 (3-6) MRS3 (0-2) Unadjusted
SNP (rs#) N (%) N (%) P-value OR (95% CI) P-value
CYP2C9 Overall 0.096
g.8633C>T† C/C 39 (25) 117 (75) Reference -
Arg144Cys [*2C] C/T 22 (37) 38 (63) 2.01 (1.01-3.97) 0.045*
(rs1799853) T/T 1 (50) 1 (50) 4.46 (0.23-84.97) 0.32
T-carriers 23 (37) 39 (63) 0.074 2.06 (1.05-4.04) 0.036*
EXPH2 Overall 0.089
g. 50690-50691insGTC† DEL/DEL 51 (26) 145 (74) Reference -
Thr404del DEL/GTC 12 (52) 11 (48) 2.81 (1.12-7.05) 0.028*
(rs71553864) GTC/GTC 0 (0) 2 (100) - 0.999
GTC-carriers 12 (48) 13 (52) 0.022* 2.55 (1.04-6.24) 0.040*
Gene Genotype MRS12 (3-6) MRS12 (0-2) Unadjusted
SNP (rs#) N (%) N (%) P-value OR (95% CI) P-value
CYP2C9 Overall 0.085
g.816A>G‡ A/A 28 (33) 58 (67) 0.034* Reference -
(rs2253635) A/G 17 (18) 78 (82) 0.48 (0.23-0.99) 0.048*
G/G 10 (37) 17 (63) 1.15 (0.44-2.97) 0.78
G-carriers 27 (22) 95 (78) 0.093 0.61 (0.32-1.18) 0.14
CYP2J2 Overall 0.141
g.4930G>T† G/G 55 (29) 133 (71) Reference -
c.-76G>T[*7] G/T 3 (11) 24 (89) 0.28 (0.08-0.99) 0.048*
(rs890293) T/T 1 (100) 0 (0) - 1
T-carriers 4 (14) 24 (86) 0.115 0.36 (0.12-1.14) 0.082
EXPH2 Overall 0.086
g.30221G>A† C/C 51 (32) 109 (68) Reference -
Arg287Gln T/C 8 (15.4) 44 (84.6) 0.38 (0.16-0.89) 0.027*
(rs751141) T/T 0 (0) 2 (100) - 0.999









and p=0.025), respectively.  Similar relationships were observed in the multivariate analysis.  Also, 
there was a trend for increased maximum DHET CSF levels in patients with CND compared 
(n=153) compared to those without CND (n=88) (p=0.056).  No relationship was observed 




Figure 3-4: EET and DHET CSF levels in outcome groups 
Mean EET (A), maximum EET (B), mean DHET (C) and maximum DHET (D) levels in CSF from patients with SAH 
are compared in outcomes groups.  Acute outcomes (solid bars) included the presence or absence of delayed cerebral 
ischemia (DCI) and/or clinical neurological deterioration (CND) up to 14 days after the hemorrhage.  Long-term 
outcomes (stripped bars) were determined by global functional recovery at 3 and 12 months using the Modified Rankin 
Scale (MRS) and were dichotomized into favorable (MRS 0-2) and unfavorable (MRS 3-6) groups.  The mean and 
maximum EET and DHET CSF levels for each patient were calculated and were used to compare the population mean 
± SEM of EET and DHET CSF levels in outcome groups using t-test with Welch’s correction as appropriate.  
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Statistical significance established at *p<0.05. 
 
Table 3-10:  EET and DHET CSF levels in outcome groups 
 
DCI, delayed cerebral ischemia; CND, clinical neurological deterioration; MRS, Modified Rankin Scale score at 3 
and 12 months: Unfavorable (3-6), Favorable (0-2); § Multivariate analysis included correction for age, sex, and either 
Fisher Grade (for acute outcomes) or Hunt & Hess Score (for long-term outcomes); *Statistical significance 
established at p<0.05. 
 
CYP eicosanoid levels in Fisher grade groups are shown in Figure 3-5: EET and DHET CSF levels 
by Fisher grade.  Fisher grade was associated with mean EET levels (p=0.014), maximum EET 
levels (p=0.012), and showed a trend for an association with maximum DHET levels (p=0.084).  
Patients classified as Fisher grade 4 had higher mean and maximum EET levels (0.104 ± 0.021 
ng/ml and 0.227 ± 0.047 ng/ml) compared with those in Fisher grade 2 (0.043 ± 0.003 ng/ml and 
0.071 ± 0.010 ng/ml, p=0.010 and p=0.012, respectively).  Patients classified as Fisher grade 3 
showed a trend for higher maximum DHET levels (2.661 ± 0.196 ng/ml) compared to those in the 





Figure 3-5: EET and DHET CSF levels by Fisher grade 
The mean and maximum EET and DHET CSF levels for each patient were calculated and were used to compare the 
mean ± standard error of the mean (SEM) in Fisher Grade 2 (open bars, 24.1%), Fisher Grade 3 (stripped bars, 53.3%), 
and Fisher Grade 4 (checkerboard bars, 22.6%) using ANOVA with Bonferroni’s post-hoc test (n=257).   Statistical 
significance established at *p<0.05. 
 
3.3.8 Trajectory analysis of CYP eicosanoid levels 
DHET temporal concentration profiles and trajectory patterns are shown in Figure 3-6: DHET 
temporal concentration profiles and trajectory patterns.  The trajectory model evaluating DHET 
CSF levels show three groups of patients with significantly different concentration profiles from 
days 2-11 after SAH (p<0.001).  DHET trajectory groups were not associated with acute or long-
term outcomes.  Concentration values in trajectory groups are presented as geometric mean with 
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95% confidence interval.  Patients in the “low” group (n = 45, 16.7%) have relatively low DHET 
levels that slightly increase over time (day 2: 0.27 ± 1.30 ng/ml; day 11: 0.39 ± 1.26 g/ml).  Patients 
in the “moderate” group (n = 159, 59.1%) have relatively moderate DHET levels that slightly 
decrease over time (day 2: 0.98 ± 1.12 ng/ml; day 11: 0.75 ± 1.09 ng/ml).  Patients in the “high” 
group (n = 65, 24.2%) have relatively high DHET levels that decrease over time (day 2: 3.30 ± 
1.16 ng/ml; day 11: 1.89 ± 1.21 ng/ml).  DHET trajectory groups were not associated with acute 
or long-term outcomes before and after adjusting for clinical covariates (Table 3-11: Outcomes in 





Figure 3-6: DHET temporal concentration profiles and trajectory patterns 
Panel (A) shows raw population values of DHET CSF concentrations (ng/ml) from 269 patients up to 14 days after 
hemorrhage.  Panel (B) shows DHET CSF concentration versus time from hemorrhage (days) in high [filled circles, 
n=65 (24.2%)], moderate [open circles, n=159 (59.1%)], and low [X, n=45 (16.7%)] concentration groups as identified 
by trajectory analysis.   Concentration data are presented as geometric mean with 95% confidence interval. 
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Table 3-11: Outcomes in trajectory groups of DHET CSF levels 
 
DCI, delayed cerebral ischemia; CND, clinical neurological deterioration; MRS, Modified Rankin Scale score at 3 
and 12 months: Unfavorable (3-6), Favorable (0-2); § Multivariate analysis included correction for age, sex, and either 
Fisher Grade (for acute outcomes) or Hunt & Hess Score (for long-term outcomes); *Statistical significance 




This clinical study is the first to investigate the impact of gene variants in the EET metabolic 
pathway on CYP eicosanoid CSF levels, risk for SAH, and subsequent acute/long-term outcomes 
in SAH patients.  We report that patients with CYP2C8*4 showed lowered EET and DHET levels 
in CSF and had a greater likelihood of DCI and CND during the inpatient stay.  Also, patients with 
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the loss-of-function variants CYP2J2*7 and CYP2C8*1B showed lower EET and DHET levels, 
respectively, while those with the CYP2C8 g.25369T allele had higher EET levels.  Patients with 
the gain-of-function EPHX2 55Arg variant had lower EET levels and a trend for increased DHET 
levels.   Patients classified as Fisher grade 4 (ventricular bleed) had increased EET levels compared 
to those in the Fisher grade 2 group (bleed <1mm thick).  DHET CSF levels and trajectory patterns 
were not associated with outcomes.  Patients with EPHX2 404del and CYP2C8*2C variants were 
more likely to have unfavorable long-term outcomes.  Conversely, patients with CYP2J2*7, 
EPHX2 287Gln, and CYP2C9 g.816G>A variants were less likely to develop unfavorable long-
term outcomes.  Furthermore, we identified tSNPs that were not in HWE and showed genotype 
frequencies in our SAH population that were different than those in Hapmap CEU database, which 
may indicate putative genetic markers for SAH risk.   
We observed previously reported relationships between CND, DCI, and MRS scores.764  
Likewise, we observed previously established relationships between HH score, Fisher grade, race, 
and increasing age with acute and/or long-term outcomes.765  Caucasians had better 3-month 
outcomes compared to non-Caucasians as previously reported in patients with SAH and other 
stroke subtypes.261  Collectively, these data suggest that the impact of race and age on EET 
formation/metabolism and outcomes after SAH may warrant further investigation.     
Our genetic analysis showed that that multiple gene variants were associated with altered 
EET and DHET CSF levels.  Patients with the CYP2C8*4 allele (11%) have reduced EET and 
DHET levels in CSF and are ~2.1- to 2.5-fold more likely to develop DCI and CND.  Previous 
studies report that expression of CYP2C8*4 in vitro results in a ~5-fold reduction in protein levels 
and enzymatic activity towards AA to form 14,15-EET.657, 663  CYP2C8*4 enzymes showed 
reduced carbon monoxide binding to the heme moiety and were more sensitive to proteinase K 
digestion indicating improper heme insertion and protein folding.667  Furthermore, human liver 
samples and microsomes from Caucasians harboring CYP2C8*4 or a haplotype containing 
CYP2C8*4 showed reduced protein expression.515, 665 Collectively, these studies suggest that 
CYP2C8*4 is a loss-of-function SNP associated with reduced EET and DHET levels and worse 
outcomes, which is consistent with our results.  
Patients with at least one copy of the variant EPHX2 55Arg had lower mean and maximum 
EET levels and a trend for increased maximum DHET levels.  This reduction in EET concentration 
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is consistent with the findings of Przybyla-Zawislak et al. who demonstrated that this variant 
increases SEH enzyme activity in vitro.676  Similarly, studies report that CYP2J2*7 results in lower 
mRNA transcription in vitro.505  In this study, we did not observe lower EET levels, but we report 
lower mean DHET levels in patients with the variant CYP2J2*7 allele.  These results are expected 
since DHETs are considered surrogate marker for EETs.  We expect worse outcomes in patients 
with CYP2J2*7, but we observed the opposite trend suggesting that other mediators may be 
involved.  Since in vitro expression of CYP2C8*1B results in increased mRNA transcription 
compared to CYP2C8*1, we expect that patients with CYP2C8*1B may have higher EET and 
DHET levels.665  However, CYP2C8*1B was associated with reduced maximum DHET levels in 
our study possibly due to differences in gene regulation in various species.665  Also, CYP2C8 
tSNPs and CYP2C8, CYP2C9, and EPHX2 haplotypes were associated with altered CYP 
eicosanoid levels.  These data suggest that there are multiple SNPs on our candidate genes, 
potentially including SNPs that were not investigated in this study, which may affect EET 
synthesis and metabolism. 
Results revealed that patients heterozygous for CYP2C9*2 (21%) are 2-fold more likely to 
develop unfavorable outcomes at 3 months.  Lundbad et al. reported that expression of CYP2C9*4 
in vitro results in 33% reduced activity towards AA to form EETs and that   incubations of human 
liver microsomes from patients homozygous for CYP2C9*2 and CYP2C8*3 led to a 34% decrease 
in EET formation.404  Moreover, human liver samples from two patients heterozygous for 
CYP2C9*2 showed 5- to 10-fold greater mRNA expression of 144Cys over 144Arg.766   
Collectively, these studies suggest that CYP2C9*2 is a loss-of-function SNP associated with 
reduced EET and DHET levels and worse outcomes.  This hypothesis is consistent with our results 
regarding long-term outcomes.  
We report that patients with the EPXH2 287Gln variant (25%) are ~2.6-fold less likely to 
develop unfavorable outcomes at 12 months.  Previous studies report that in vitro expression of 
the EPHX2 (SEH) 287Gln enzyme resulted in ~5-fold reduction in 14,15-EET hydrolysis, higher 
SEH monomer:dimer ratio, and reduced enzyme stability.676, 678, 679  Rat neuronal cell cultures and 
cardiomyocytes from SEH knockout mice transduced with the EPHX2 287Gln enzyme reduced 
14,15-DHET levels to 34% and ~40% of WT values after administration of excess 14,15-EET and 
reduced ischemic cell death to 80% and 78% of values for untreated cells, respectively.641, 677  
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Moreover, clinical studies report that the EPHX2 287Gln variant was associated with reduced 
epoxyoctadecenoic acid (EpOME) metabolism and higher cholesterol and triglyceride levels in 
plasma.718, 721  These findings suggest that the EPHX2 287Gln variant is a loss-of-function SNP 
associated with reduced EET metabolism and ischemic cell death.  Therefore, it is expected that 
patients with EPHX2 287Gln would have increased EET levels, reduced DHET levels, and 
favorable outcomes.  This hypothesis is consistent with our results regarding long-term outcomes.   
We report that the EPHX2 404del variant was present in 11% of patients and was 
associated with a 2.6- to 3-fold increase in unfavorable outcomes at 3 months.  Although the loss-
of-function EPHX2 402-403ins/del variant (rs2234887)678 was not genotyped, our genetic analysis 
includes rs71553864, which captures the variability in this gene region.  The functional effects of 
this SNPs have not been previously investigated.  Therefore interpretation of these results are 
difficult without further studies.  Although multiple fSNPs and tSNPs were associated with acute 
and long-term outcomes, candidate gene haplotypes were not associated with outcomes.  This 
discrepancy may be due to reduced power when using haplotypes or because the causative variant 
shows different linkage disequilibrium with haplotypes compared to tSNPs.  These data suggest 
that additional studies are needed using a more focused genotype approach and improved 
characterization of candidate gene haplotypes. 
HWE tests show that CYP2C9 g.18470G>A is not in HWE and, similar to other tSNPs in 
our candidate genes, showed genotype frequencies in our SAH population that were different than 
those in the Hapmap CEU population.  Given that our population is enriched for individuals with 
SAH, these results suggest that genetic variation in the EET metabolic pathway may contribute to 
the formation and rupture of intracranial aneurysms.  Support for these results includes numerous 
in vivo studies demonstrate that demonstrate EETs exhibit diverse physiologic functions including 
vasodilation of the cerebrovasculature and anti-hypertensive effects.613, 767  In vitro studies report 
that EETs exhibit proliferative, migratory, angiogenic, fibrinolytic, anti-apoptotic, anti-
inflammatory, and anti-platelet aggregation effects in vascular endothelial cells and inhibit 
migration and apoptosis in vascular smooth muscle cells.355  Based on these reported mechanisms 
of action, it is expected that EETs play an important role in vascular homeostasis and remodeling 
and may impact intracranial aneurysm formation, rupture, or recovery after SAH.   
147 
 
We demonstrated the ability to measure DHET, and to a lesser extent EET, levels in CSF 
from patients with SAH.   The low percentage of samples with detectable EET levels in our study 
may be due to rapid EET metabolism or binding to the collection bag.  As expected, we measured 
a large percentage of CSF samples with 14,15-DHET and 11,12-DHET.  In vitro studies suggest 
that CYP2C8/9 and CYP2J2 produce high, moderate, and low amounts of 14,15-EET, 11,12-EET, 
and 8,9-EET, respectively.768  Based on these data, we expect high, moderate, and low amounts of 
14,15-DHET, 11,12- DHET, and 8,9- DHET in CSF from SAH patients.  As expected, we reported 
a large percentage of samples with 14,15-DHET and 11,12- DHET and low percentage of samples 
with detectable 5,6-DHET.  But, we also reported a large percentage of samples with high 
concentrations of 8,9-DHET.  This may be due to differences in the metabolism of 8,9-EET or 
storage and release of 8,9-DHET compared to other EET regioisomers in brain tissues.769  Thus, 
future studies are needed to identify the factors responsible for the differences in EET and DHET 
regioisomer formation and release in humans and patients with SAH.   
Although EET CSF levels in patients with SAH have not been previously reported in 
clinical studies, our DHET levels were consistent with our previous studies.642, 643  EET and DHET 
CSF levels measured in this study are comparable to EET levels reported to demonstrate 
physiological effects on cerebrovascular tissues.  For example, EETs have been shown to relax 
isolated cerebral arteries and increase the activity of KCa+2 channels in cerebral VSMC at 1 nM 
(0.32 ng/ml).625  It is expected that the CYP eicosanoid levels in the brain will be higher than those 
reported in this study because these compounds act locally in an autocrine/paracrine fashion355 and 
then are diluted in CSF.  In addition, any spikes in concentration will be diluted in the CSF drainage 
bags during the collection period.   
Our analysis of CYP eicosanoids showed that DHET CSF levels and trajectory patterns 
were not associated with acute or long-term outcomes, but increased EET CSF levels were 
associated with unfavorable 3-month outcomes.  This relationship was not expected due to the 
anti-inflammatory, vasodilatory, and neuroprotective properties of EETs.355  On the other hand, 
increased EET levels were associated with Fisher grade 4, which is reported to be strongly 
associated with worse acute and long-term outcomes.765  These data suggest that the degree and 
location of the hemorrhage may affect EET formation and/or release in the brain and possibly 
long-term outcomes.  Red blood cells can release EETs directly from phospholipid membranes or 
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synthesize EETs through the release and subsequent metabolism of AA from phospholipid 
membranes.406  However, it is unknown whether an increase in EET CSF levels are due to EET 
release or synthesis directly from the blood in the CSF or from brain tissues.  Also, it is important 
to note that this relationship was not observed in acute outcomes and 12-month outcomes and that 
the analysis did not include the measurement of vasoconstrictors that may counteract the effects 
of EETs in the brain.  The role of the EET metabolic pathway in SAH has not been previously 
investigated in clinical studies and therefore warrants further study. 
In spite of these novel findings, several limitations of this study should be noted.  The 
analysis of CYP eicosanoid CSF levels were not compared control values due to lack of access to 
control CSF.  Since the CSF samples were taken from drainage bags, which collected CSF over a 
12 hour time period, reported CYP eicosanoid levels represent time-averaged values that may be 
lower than those at the site of action.  Also, there was a significantly lower number of CSF samples 
with EET levels above the quantitation limit when compared to samples with detectable DHET 
levels possibly due EET conversion to DHETs or reduced recovery from the collection bag.  In 
our genetic analysis, some functional genetic variants in the EET metabolic pathway were not 
genotyped.  Many SNPs had allele frequencies that were too low for informative analysis.  Our 
analyses were limited to single fSNP analyses, thus the effects of multiple fSNPs simultaneously 
were not assessed.  It is not possible to determine if our putative genetic markers were causative 
or were in linkage disequilibrium with the causative SNP.  In addition, p-values from significant 
findings did not pass correction criteria for multiple testing.  Furthermore, this study represents 
one of the first reports of a large population of SAH patients for genotype/CYP eicosanoid analysis, 
therefore, a validation cohort is not readily available for confirmation of these genotype findings.  
Future studies that include a focused genotype approach, validation cohort, and/or extensive CYP 
eicosanoid analysis including other vasoconstrictors, such as 20-HETE, are needed.     
 
3.5 CONCLUSIONS 
In summary, EETs have been shown to play an important role in the regulation of cerebrovascular 
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tone and vessel remodeling in vitro and significantly affect CBF and cerebral ischemic injury in 
vivo.  Other studies report that polymorphisms in the genes responsible for the formation or 
metabolism of EETs alter enzyme expression or activity.  This study, involving one of the largest 
SAH cohorts to date, suggests that gene variants involved in EET formation/metabolism are 
associated with the risk for complications after SAH and subsequent acute and long-term 
outcomes.  These results are important to help elucidate the mechanisms involved in the 
pathogenesis and pathophysiology of SAH and possibly identify patients at high risk for 
unfavorable outcomes so that intervention strategies may be implemented earlier or more 
aggressively in these patients.   
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As discussed in Section 1.1, SAH is devastating condition associated with high rates of mortality 
and morbidity that can be attributed in large part to the development of ischemic complications 
such as CND and DCI that typically occur 3-14 days after SAH.  Despite this generous time 
window for therapeutic intervention, strategies to improve outcomes have had limited success in 
part due to the lack of reliable and accurate methods to identify high-risk patients and a poor 
understanding of the underlying mechanisms.  Currently, there are no established predictors for 
the development of acute ischemic complications in the first two weeks after SAH and long-term 
functional outcomes.   
Previous studies report that 20-HETE is formed in multiple brain regions and regulates 
cerebrovascular tone and structure.355  In humans, CYP4F2 and CYP4A11 are the primary 
enzymes responsible for 20-HETE synthesis from AA.356  In the brain, 20-HETE promotes 
vasoconstriction, angiogenesis, inflammation, apoptosis, and platelet aggregation.356  Recent 
evidence suggests that 20-HETE mediates CBF regulation by pericytes and 20-HETE inhibition 
by NO facilitates prostaglandin E2 mediated dilation.
631  Collectively, these studies suggest that 
20-HETE is a critical mediator of CBF by regulating microvascular tone and vascular remodeling.    
Recent evidence implicates 20-HETE in the pathophysiology of cerebral injury due to 
ischemic and hemorrhagic stroke.  Inhibitors of 20-HETE synthesis improve CBF after SAH and 
reduce infarct size after temporary focal ischemia while 20-HETE agonists reduce baseline CBF 
in rats.589, 590  Also, 20-HETE formation is reduced by NO, a known mediator of SAH 
pathophysiology.317, 356 Currently, no studies have evaluated the role of 20-HETE in a large SAH 
cohort.  Therefore, we hypothesized that loss-of-function polymorphisms in 20-HETE synthesis 
genes (CYP4A11 and CYP4F2) will be associated with decreased 20-HETE concentrations in CSF 
resulting and decreased risk for ischemic complications and unfavorable long-term functional 
outcomes in patients with SAH.  Furthermore, we compared genotype frequencies in our SAH 
population with those reported in the general population using the Hapmap database to identify 







4.2.1 Design and participants 
The study design and participants for this section are identical to those described in Section 3.2.1.  
Briefly, the study included 363 adult patients with SAH classified as Fisher grade >1.  CSF was 
available from 269 patients for 20-HETE quantitation and blood samples were taken from 304 
Caucasians for genotyping.  All patients received standard medical care.760   
 
4.2.2 Analysis of 20-HETE CSF levels  
Analysis of 20-HETE levels in CSF from SAH patients was performed in the manner described in 
Section 2.2.  Briefly, samples were withdrawn from collection bags on external ventricular drains 
approximately every 12 hours for up to 14 days.  We previously demonstrated stability of 20-
HETE assessment from sample collection bags.643  CSF samples of 2-3 ml were processed using 
SPE and reconstituted in 50 l of 80:20 MeOH:dH20.  Quantitation of CYP-eicosanoids was 
performed using a published UPLC-MS/MS method with minor modifications.643  20-HETE 
concentrations were determined from the standard curve of the ratio of their peak area to IS peak 
areas of 20-HETE-d6 over a linear range of 0.014-8.88 ng/ml.  EET and DHET concentrations 




4.2.3 Analysis of gene variants in 20-HETE synthesis pathway 
 
Candidate genes associated with 20-HETE synthesis include CYP4A11 and CYP4F2.  Tagging 
single nucleotide polymorphisms (tSNPs) were selected using the CEU population from Hapmap 
database (Release 27; www.hapmap.org) and criteria included r2 > 0.8 and minor allele frequency 
≥ 20% while functional SNPs (fSNPs) were defined as those previously reported to affect mRNA 
transcription, protein expression, or enzyme activity in vitro.  Our genetic analysis excluded SNPs 
with variant genotype frequencies <1% in our SAH population.  Our genetic analysis included five 
tSNPs (CYP4A11-g.13414C>G, CYP4F2-g.4593T>C, CYP4F2-g.4211A>T, CYP4F2-
g.8575T>C, CYP4F2-g.16162A>G), six fSNPs (CYP4A11-g.4207A>G, CYP4A11-
g.13661G>A, CYP4F2-g.7222002G>A, CYP4F2-g.5416G>C, CYP4F2-g.5373T>C CYP4F2-
g.5497T>C), and one fSNP/tSNP (CYP4F2-g.14389C>T) as shown in Table 4-1: Candidate gene 
variants in 20-HETE pathway included in the analysis.  Genotyping was performed using Taqman 
allele discrimination assay with ABI Prism 7000 Sequence Detection System (Applied Bioscience, 
Carlsbad, CA, USA) for rs3093105, sequencing with BigDye and ABI 3730xl (Applied 
Bioscience, Carlsbad, CA, USA) for rs1126742, and iPLEX MassArray (Sequenom, San Diego, 
CA) for all other SNPs.  Consistency and integrity of genotyping data was checked by inclusion 
of duplicate CEPH controls on each plate for internal as well as plate-to-plate consistency, using 
genotype call rate criteria of >85%, comparing the observed and Hapmap Caucasian (CEU) 
frequencies, and performing checks for Hardy-Weinberg Equilibrium (HWE) consistency.  
Analyses of genetic data included both genotype groups (codominant) and presence or absence of 
the variant allele (dominant) groups.  SNPstats software was used to assign haplotypes for 




Table 4-1: Candidate gene variants in 20-HETE pathway included in the analysis 
 
 
4.2.4 Outcomes assessment 
Outcomes were assessed as described in Section 3.2.4.  Briefly, acute outcomes included the 
presence or absence of CND and/or DCI during the inpatient stay (up to 14 days).762  Long-term 
outcomes were determined by global functional recovery at 3 and 12 months using the Modified 
Rankin score (MRS) obtained during face-to-face interview or phone call with the patient or their 
surrogate.  
4.2.5 Statistical analysis 
Statistical analysis was performed as described in Section 3.2.5.  Statistical significance was 
determined at *p-values<0.05.  Bonferroni’s multiple comparison correction was used in analyses 
involving genetic and biomarker concentration data (**p<0.0042 and **p<0.0167, respectively). 
Gene rs# Genomic cDNA Protein CYP
(fSNP/tSNP)  Nomenclature
rs9332978 (†) g.4207A>G c.-825A>G NA NA
rs1126742 (†) g.13661G>A c.1301G>A 434Phe>Ser NA
rs3890011 (‡) g.13414C>G c.1223-24C>G NA NA
rs2108622 (†‡) g.14389C>T c.1297C>T 433Val>Met CYP4F2*3
rs2189784 (†) g.7222002G>A NA NA NA
rs3093100 (†) g.5416G>C c.-48G>C NA NA
rs3093098 (†) g.5373T>C c.-91T>C NA NA
rs3093105 (†) g.5497T>C c.34T>G 12Trp>Arg CYP4F2*2
rs3093089 (‡) g.4593T>C c.-458T>C NA NA
rs3093156 (‡) g.4211A>T c.648-106A>T NA NA
rs3093168 (‡) g.8575T>C c.1115+489T>C NA NA






4.3.1 Quantitation of 20-HETE CSF samples 
Table 4-1: Candidate gene variants in 20-HETE pathway included in the analysis shows the 
concentrations of CYP eicosanoids in CSF from SAH patients along with the percentage of 
samples and patients with detectable levels.  Detectable 20-HETE, EET, and DHET levels were 
found in 71.6%, 13.1%, and 97.9% of samples (n=3151) and 98.5%, 64.3%, and 98.9% of patients 
(n=269), respectively.   
 
 
Figure 4-1: Quantitation of CYP eicosanoids in CSF samples 
Detectable Concentration ≥ 0.014 ng/ml 
 
4.3.2 20-HETE CSF levels in Fisher grade groups 
A comparison of 20-HETE CSF levels SAH patients by Fisher grade is shown in Figure 4-2: 20-
HETE CSF levels by Fisher grade.  20-HETE was higher in patients classified as Fisher grade 4 
when compared to Fisher grade 2/3.   
CYP-Eicosanoid Mean Conc. Maximum Conc. Detectable Samples Detectable Patients
Mean ± SEM (ng/ml) Mean ± SEM (ng/ml) N (%) [Total=3151] N (%) [Total=269]
20-HETE 0.099 ± 0.012 0.307 ± 0.038 2255 (71.6) 265 (98.5) 
EET 0.073 ± 0.007 0.153 ± 0.018 414 (13.1) 173 (64.3) 
14,15-EET 0.016 ± 0.001 0.037 ± 0.006 140 (4.4) 123 (45.7) 
11,12-EET 0.013 ± 0.001 0.023 ± 0.004 166 (5.3) 87 (32.3) 
8,9-EET 0.044 ± 0.006 0.101 ± 0.015 271 (8.6) 149 (55.4) 
DHET 1.271 ± 0.069 2.462 ± 0.140 3084 (97.9) 266 (98.9) 
14,15-DHET 0.053 ± 0.003 0.114 ± 0.008 2152 (68.3) 241 (89.6) 
11,12-DHET 0.031 ± 0.002 0.078 ± 0.007 1948 (61.8) 189 (70.3) 
8,9-DHET 1.171 ± 0.069 2.329 ± 0.138 3025 (96.0) 264 (98.1) 




Figure 4-2: 20-HETE CSF levels by Fisher grade 
The mean and maximum 20-HETE CSF levels for each patient were calculated and were used to compare the mean ± 
standard error of the mean (SEM) in Fisher grade 2 (open bars, 24.1%), Fisher grade 3 (stripped bars, 53.3%), and 
Fisher grade 4 (checkerboard bars, 22.6%) using ANOVA with Bonferroni’s post-hoc test (n=257).   Statistical 
significance established at *p<0.05. 
4.3.3 20-HETE CSF levels in outcome groups 
20-HETE CSF levels in acute and long-term outcomes groups is shown in Figure 4-3: 20-HETE 
CSF levels in outcome groups.  Patients with CND had ~2.2- and 2.6-fold higher mean and 
maximum 20-HETE levels, respectively, when compared to those without CND (p=0.001).  
Patients with unfavorable 3-month outcomes had ~2.7- and 2.6-fold higher mean and maximum 
20-HETE levels when compared to those with favorable outcomes (p=0.009 and p=0.010), 
respectively.  Patients with unfavorable 12-month outcomes showed a trend for a 2.2- and 1.6-fold 
increase in mean and maximum 20-HETE levels when compared to those with favorable outcomes 
(p=0.052 and p=0.063), respectively.  Similar relationships were observed between 20-HETE:EET 
and 20-HETE:DHET CSF levels and outcomes (Figure 4-3: 20-HETE CSF levels in outcome 
groups and Table 4-2: 20-HETE CSF levels and ratios in outcome groups).  Also, adjusting for 
covariates did not significantly change the relationship between 20-HETE, 20-HETE:EET, and 





Figure 4-3: 20-HETE CSF levels in outcome groups   
Mean (panel A) and maximum (panel B) 20-HETE levels in CSF from patients with SAH are compared in outcomes 
groups.  Acute outcomes (solid bars) included the presence or absence of clinical neurological deterioration (CND) 
and/or delayed cerebral ischemia (DCI) up to 14 days after the hemorrhage.  Long-term outcomes (stripped bars) were 
determined by global functional recovery at 3 and 12 months using the Modified Rankin Scale (MRS) and were 
dichotomized into favorable (MRS 0-2) and unfavorable (MRS 3-6) groups.  The mean and maximum 20-HETE CSF 
levels for each patient (n=269) were calculated and were used to compare the mean ± SEM of the CYP eicosanoid 
levels in outcome groups using t-test with Welch’s correction as appropriate.  Statistical significance established at 






Figure 4-4: 20-HETE:EET and 20-HETE:DHET CSF levels in outcome groups 
Mean 20-HETE:EET (panel A), maximum 20-HETE:EET (panel B), mean 20-HETE:DHET (panel C), and maximum 
20-HETE:DHET (panel D) levels CSF in patients with SAH are compared in outcomes groups.  Acute outcomes (solid 
bars) included the presence or absence of delayed cerebral ischemia (DCI) and/or clinical neurological deterioration 
(CND) up to 14 days after the hemorrhage.  Long-term outcomes (stripped bars) were determined by global functional 
recovery at 3 and 12 months using the Modified Rankin Scale (MRS) and were dichotomized into good (MRS 0-2) 
and poor (MRS 3-6) groups.  The mean and maximum 20-HETE CSF levels for each patient (n=269) were calculated 
and were used to compare the mean ± SEM of the CYP eicosanoid levels in outcome groups using t-test with Welch’s 





Table 4-2: 20-HETE CSF levels and ratios in outcome groups 
 
DCI, delayed cerebral ischemia; CND, clinical neurological deterioration; MRS, Modified Rankin Scale score at 3 
and 12 months: Poor (3-6), Good (0-2); § Multivariate analysis included correction for age, sex, race, and either Fisher 
Grade (for acute outcomes) or Hunt & Hess score (for long-term outcomes); *Statistical significance established at 
*p<0.05 or **p<0.0167 (for multiple comparison correction)  
 
4.3.4 20-HETE temporal concentration profiles and trajectory patterns 
20-HETE temporal concentration profiles and trajectory patterns are shown in Figure 4-5: 20-
HETE temporal concentration profiles and trajectory patterns.  The trajectory model evaluating 
20-HETE CSF levels identified three groups of patients with concentration profiles categorized 
“low”, “moderate”, and “high” (p<0.001).  A comparison of 20-HETE trajectory patterns with 
acute and long-term outcomes is shown in Table 4-3: Outcomes in trajectory groups of 20-HETE 
CSF levels.  20-HETE trajectory groups showed an association with CND, 3-month MRS, and 12-
Outcome Group N Mean Unadjusted Adjusted§  Max. Unadjusted Adjusted§
20-HETE (ng/ml) P-value P-value 20-HETE (ng/ml) P-value P-value
(-) 88 0.054 ± 0.007 0.153 ± 0.037
(+) 153 0.116 ± 0.017 0.399 ± 0.061
(-) 139 0.088 ± 0.015 0.281 ± 0.060
(+) 103 0.100 ± 0.017 0.343 ± 0.053
Low (0-2) 115 0.069 ± 0.011 0.203 ± 0.036
High (3-6) 67 0.189 ± 0.043 0.532 ± 0.119
Low (0-2) 117 0.077 ± 0.012 0.239 ± 0.040
High (3-6) 61 0.167 ± 0.044 0.383 ± 0.074
Outcome Group N Mean Unadjusted Adjusted§  Max. Unadjusted Adjusted§
20-HETE:DHET P-value P-value 20-HETE:DHET P-value P-value
(-) 88 0.082 ± 0.010 0.225 ± 0.037
(+) 153 0.186 ± 0.039 0.818 ± 0.267
(-) 139 0.152 ± 0.041 0.630 ± 0.288
(+) 103 0.142 ± 0.018 0.558 ± 0.096
Low (0-2) 115 0.103 ± 0.016 0.375 ± 0.078
High (3-6) 67 0.381 ± 0.131 1.550 ± 0.656
Low (0-2) 117 0.108 ± 0.016 0.352 ± 0.072
High (3-6) 61 0.314 ± 0.116 0.974 ± 0.337
Outcome Group N Mean Unadjusted Adjusted§  Max. Unadjusted Adjusted§
20-HETE:EET P-value P-value 20-HETE:EET P-value P-value
(-) 88 1.155 ± 0.140 3.449 ± 0.849
(+) 153 2.844 ± 0.465 9.848 ± 1.348
(-) 139 2.140 ± 0.479 6.532 ± 1.292
(+) 103 2.334 ± 0.297 8.775 ± 1.301
Low (0-2) 115 1.753 ± 0.275 5.303 ± 0.948
High (3-6) 67 4.505 ± 1.357 12.762 ± 2.919
Low (0-2) 117 1.841 ± 0.282 5.844 ± 0.984







MRS12 0.093 0.125 0.080
MRS3 0.051 0.165 0.017* 0.029*
DCI 0.752 0.915 0.232
CND 0.001** 0.003** <0.001** 0.005**
MRS12 0.084 0.074 0.076
MRS3 0.039* 0.045* 0.080 0.062
DCI 0.838 0.565 0.835
CND 0.010** 0.008** 0.029* 0.002**
MRS12 0.052 0.087 0.063
MRS3 0.009** 0.033* 0.010** 0.012**
DCI 0.619 0.817 0.459
CND 0.001** 0.019* 0.001** 0.009**
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month MRS (p=0.012, p=0.001, and p=0.046, respectively).  The cumulative incidence of CND 
over 14 days in 20-HETE trajectory groups are shown in Figure 4-6: Cumulative incidence of 
CND and DCI in 20-HETE trajectory groups.  Patients in moderate/high 20-HETE trajectory 
groups were 2.1-, 2.5-, and 2.1-fold more likely to have CND and unfavorable 3- and 12-month 






Figure 4-5: 20-HETE temporal concentration profiles and trajectory patterns 
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Panel (A) shows raw population values of 20-HETE CSF concentrations from 269 patients up to 14 days after 
hemorrhage.  Panel (B) shows 20-HETE CSF concentration versus time from hemorrhage (days) in high [filled circles, 
n=21 (7.8%)], moderate [open circles, n=75 (27.9%), and low [X, n=173 (64.3%)] concentration groups as identified 
by trajectory analysis.   Concentration data are presented as geometric mean with 95% confidence interval (CI).  
4.3.5 Outcomes in 20-HETE trajectory groups 
 
Table 4-3: Outcomes in trajectory groups of 20-HETE CSF levels 
 
 
20-HETE CND (-) CND (+) Unadjusted
Trajectory N (% ) N (% ) P-value OR (95%  CI) P-value
Overall 0.047*
Low 68 (43) 90 (57) Reference -
Moderate 17 (25.8) 49 (74.2) 1.98 (1.02 - 3.82) 0.043*
High 3 (17.6) 14 (82.4) 3.07 (0.82 - 11.47) 0.096
Moderate/High 20 (24.1) 63 (75.9) 0.004** 2.14 (1.16 - 3.96) 0.015**
20-HETE DCI (-) DCI (+) Unadjusted
Trajectory N (% ) N (% ) P-value OR (95%  CI) P-value
Overall 0.342
Low 97 (61) 62 (39) Reference -
Moderate 34 (51.5) 32 (48.5) 1.46 (0.81 - 2.66) 0.208
High 8 (47.1) 9 (52.9) 1.66 (0.59 - 4.66) 0.334
Moderate/High 42 (50.6) 41 (49.4) 0.120 1.50 (0·87 - 2.61) 0.148
20-HETE MRS3 (0-2) MRS3 (3-6) Unadjusted
Trajectory N (% ) N (% ) P-value OR (95%  CI) P-value
Overall 0.011**
Low 85 (71.4) 34 (28.6) Reference -
Moderate 25 (55.6) 20 (44.4) 1.88 (0.88 - 4.03) 0.105
High 5 (27.8) 13 (72.2) 5.33 (1.65 - 17.22) 0.005**
Moderate/High 30 (47.6) 33 (52.4) 0.002** 2.49 (1.16 - 4.93) 0.009**
20-HETE MRS12 (0-2) MRS12 (3-6) Unadjusted
Trajectory N (% ) N (% ) P-value OR (95%  CI) P-value
Overall 0.111
Low 83 (72.2) 32 (27.8) Reference -
Moderate 26 (55.3) 21 (44.7) 2.08 (0.99 - 4.38) 0.053
High 8 (50) 8 (50) 2.00 (0.65 - 6.15) 0.224












Figure 4-6: Cumulative incidence of CND and DCI in 20-HETE trajectory groups 
The cumulative incidence of clinical neurological deterioration (CND) in 153 patients (panel A) and delayed cerebral 
ischemia (DCI) in 103 patients (panel B) was compared in trajectory groups using Kaplan-Meier log-rank analysis.  
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For the analysis, the time to develop CND and DCI was rounded up to the nearest day and the trajectory groups were 
defined in Figure 4-5: 20-HETE temporal concentration profiles and trajectory patterns.  Cox regression was used to 
control for age, sex, race, and Fisher grade or Hunt and Hess (HH) score. 
 
4.3.6 20-HETE:EET and 20-HETE:DHET trajectory patterns and relation to 
outcomes 
 
Temporal concentration profiles for 20-HETE:EET and 20-HETE:DHET ratios are shown in 
Figure 4-7: Temporal concentration profiles and trajectory patterns for 20-HETE:EET and 20-
HETE:DHET.  Similar relationships were observed when comparing 20-HETE:EET and 20-
HETE:DHET CSF trajectory groups showed similar relationships to outcomes as the 20-HETE 
trajectory groups (Table 4-4: Outcomes in 20-HETE:EET CSF level trajectory groups and Table 





Figure 4-7: Temporal concentration profiles and trajectory patterns for 20-HETE:EET and 20-HETE:DHET 
Panels (A) and (C) show the raw population values of 20-HETE:EET and 20-HETE:DHET CSF concentrations from 
269 patients up to 14 days after hemorrhage, respectively.  Panels (B) and (D) shows 20-HETE:EET and 20-
HETE:DHET CSF concentration versus time from hemorrhage (days) in high (filled circles), moderate (open circles), 
and low (X) concentration groups as identified by trajectory analysis, respectively.  Concentration data are presented 




Table 4-4: Outcomes in 20-HETE:EET CSF level trajectory groups 
 
DCI, delayed cerebral ischemia; CND, clinical neurological deterioration; MRS, Modified Rankin Scale score at 3 
and 12 months: Poor (3-6), Good (0-2); § Multivariate analysis included correction for age, sex, race, and either Fisher 
Grade (for acute outcomes) or Hunt & Hess score (for long-term outcomes); *Statistical significance established at 
*p<0.05 or **p<0.0167 (for multiple comparison correction)  
 
 
20-HETE:EET CND (-) CND (+) Unadjusted
 Trajectory Group N (%) N (%) P-value O R (95% CI) P-value
Overall 0.008**
Low 34 (51.5) 32 (48.5) Reference -
Moderate 45 (33.1) 91 (66.9) 2.21 (1.18 - 4.13) 0.013**
High 9 (23.1) 30 (76.9) 3.66 (1.46 - 9.16) 0.006**
Moderate/High 54 (30.9) 121 (69.1) 0.003** 2.45 (1.34 - 4.48) 0.004**
20-HETE:EET DCI (-) DCI (+) Unadjusted
 Trajectory Group N (%) N (%) P-value O R (95% CI) P-value
Overall 0.006**
Low 49 (74.2) 17 (25.8) Reference -
Moderate 71 (51.8) 66 (48.2) 2.73 (1.42 - 5.30) 0.009**
High 19 (48.7) 20 (51.3) 3.13 (1.34 - 7.32) 0.003**
Moderate/High 90 (51.1) 86 (48.9) 0.001** 2.82 (1.49 - 5.32) 0.001**
20-HETE:EET MRS3 (0-2) MRS3 (3-6) Unadjusted
 Trajectory Group N (%) N (%) P-value O R (95% CI) P-value
Overall 0.092
Low 40 (76.9) 12 (23.1) Reference -
Moderate 59 (57.8) 43 (42.2) 2.53 (1.1 - 5.83) 0.029*
High 16 (57.1) 12 (42.9) 2.14 (0.72 - 6.4) 0.173
Moderate/High 75 (57.7) 55 (42.3) 0.015** 2.44 (1.08 - 5.51) 0.031*
20-HETE:EET MRS12 (0-2) MRS12 (3-6) Unadjusted
 Trajectory Group N (%) N (%) P-value O R (95% CI) P-value
Overall 0.028*
Low 43 (81.1) 10 (18.9) Reference -
Moderate 59 (59) 41 (41) 3.12 (1.35 - 7.21) 0.008**
High 15 (60) 10 (40) 2.47 (0.82 - 7.48) 0.109











Table 4-5: Outcomes in 20-HETE:DHET CSF level trajectory groups 
 
DCI, delayed cerebral ischemia; CND, clinical neurological deterioration; MRS, Modified Rankin Scale score at 3 
and 12 months: Poor (3-6), Good (0-2); § Multivariate analysis included correction for age, sex, race, and either Fisher 
Grade (for acute outcomes) or Hunt & Hess score (for long-term outcomes); *Statistical significance established at 
*p<0.05 or **p<0.0167 (for multiple comparison correction)  
 
The time-to-maximum 20-HETE concentration was compared to the time-to-CND in Figure 4-8: 
Time to maximum 20-HETE CSF levels vs. time to CND.  There was a weak and moderate 
correlation between time-to-maximum 20-HETE concentrations and time-to-CND in all patients 
(r=0.274, p<0.001) and those with moderate/high trajectory groups, respectively (r=0.439, 
p<0.001).   
 
20-HETE:DHET CND (-) CND (+) Unadjusted
 Trajectory Group N (%) N (%) P-value O R (95% CI) P-value
Overall 0.046*
Low 25 (50) 25 (50) Reference -
Moderate 48 (37.5) 80 (62.5) 1.62 (0.81 - 3.24) 0.173
High 15 (23.8) 48 (76.2) 2.92 (1.25 - 6.83) 0.013**
Moderate/High 63 (33) 128 (67) 0.026* 1.92 (0.98 - 3.74) 0.056
20-HETE:DHET DCI (-) DCI (+) Unadjusted
 Trajectory Group N (%) N (%) P-value O R (95% CI) P-value
Overall 0.037*
Low 37 (74) 13 (26) Reference -
Moderate 67 (51.9) 62 (48.1) 2.62 (1.25 - 5.48) 0.011**
High 35 (55.6) 28 (44.4) 1.96 (0.85 - 4.53) 0.114
Moderate/High 102 (53.1) 90 (46.9) 0.008** 2.4 (1.18 - 4.88) 0.016**
20-HETE:DHET MRS3 (0-2) MRS3 (3-6) Unadjusted
 Trajectory Group N (%) N (%) P-value O R (95% CI) P-value
Overall 0.207
Low 30 (78.9) 8 (21.1) Reference -
Moderate 63 (62.4) 38 (37.6) 1.76 (0.69 - 4.5) 0.234
High 22 (51.2) 21 (48.8) 2.6 (0.9 - 7.48) 0.076
Moderate/High 85 (59) 59 (41) 0.024* 1.98 (0.8 - 4.9) 0.139
20-HETE:DHET MRS12 (0-2) MRS12 (3-6) Unadjusted
 Trajectory Group N (%) N (%) P-value O R (95% CI) P-value
Overall 0.168
Low 31 (81.6) 7 (18.4) Reference -
Moderate 64 (64) 36 (36) 2.33 (0.9 - 6.05) 0.082
High 22 (55) 18 (45) 2.63 (0.89 - 7.75) 0.080












Figure 4-8: Time to maximum 20-HETE CSF levels vs. time to CND 
The time to reach maximum 20-HETE levels in CSF was compared to the time to reach CND in all patients (panel A, 
n=148) and in patients with high/moderate trajectory patterns (panel B, n=60) as identified in Figure 4-5: 20-HETE 
temporal concentration profiles and trajectory patterns.  Comparison was performed using Pearson correlation 
coefficient (r) and statistical significance established at *p<0.05. 
 
 
4.3.7 Evaluation of genotype frequency data 
 
Table 4-6: HWE and observed vs. Hapmap comparison shows a comparison of the observed 
genotype frequencies in this study with the expected frequencies based on the Hapmap CEU 
population data.  Multiple CYP4F2 gene variants were not in HWE including g.5416G>C 
(p<0.001), g.5373T>C (p=0.023), g.14389C>T(*3) (p<0.001), g.7222002G>A (p=0.001), 
g.4593T>C (p=0.013) and g.16162A>G (p=0.002).  Also, our SAH population showed different 
allele frequencies than those reported in the Hapmap CEU population for CYP4F2 gene variants 
including g.14389C>T(*3), g.7222002G>A, g.16162A>G (p<0.001) and a trend for a difference 




Table 4-6: HWE and observed vs. Hapmap comparison 
 
HWE, Hardy-Weinberg Equilibrium; Obs, observed frequency in SAH cohort; Hap, expected frequency based on 
Hapmap CEU population. 
 
4.3.8 Acute and long-term outcomes in genetic groups 
 
A comparison of the acute outcomes in genetic groups is shown in Table 4-7: Acute and Long-
term outcomes in genetic groups.  In the multivariate analysis, patients with CYP4F2-g.4593C/C 
genotype were 2.3-fold less likely to develop CND compared to CYP4F2-g.4593T/T carriers 
(p=0.047).  CYP4A11-g.13414C allele-carriers were ~2-fold more likely to have unfavorable 3- 
and 12-month MRS (p=0.019 and p=0.042), respectively.  Also, patients with the variant CYP4F2-
g.4211T allele or CYP4F2-g.8575T/T genotype were ~2.4-fold less likely and ~3.3-fold more 
likely to have unfavorable outcomes at 3 months (p=0.016 and p=0.017), respectively.   
 
Gene Genotype Observed Hapmap HWE Obs-Hap
SNP (rs#) N (% ) N (% ) P-value P-value
CYP4F2 GG 194 (65.8) 244 (82.6)
g.5416G>C CG 96 (32.5) 51 (17.4)
(rs3093100)† CC 5 (1.7) 0 (0)
 CYP4F2 TT 199 (66.3) 228 (76.1)
g.5373T>C CT 96 (32) 66 (22.1)
(rs3093098)† CC 5 (1.7) 5 (1.8)
CYP4F2 CC 147 (51.4) 174 (60.7)
g.14389C>T [*3] CT 137 (47.9) 92 (32.1)
(rs2108622)†‡ TT 2 (0.7) 20 (7.1)
CYP4F2 GG 90 (30.1) 111 (37.2)
g.7222002G>A GA 178 (59.5) 135 (45.1)
(rs2189784)‡ AA 31 (10.4) 53 (17.7)
CYP4F2 TT 134 (47.5) 117 (41.6)
g.4593T>C TC 107 (37.9) 127 (45.1)
(rs3093089)‡ CC 41 (14.5) 38 (13.3)
  CYP4F2 AA 125 (41.7) 151 (50.4)
g.16162A>G AG 155 (51.7) 112 (37.2)









Table 4-7: Acute and Long-term outcomes in genetic groups 
 
† Functional SNP; ‡ Tagging SNP, DCI, delayed cerebral ischemia; CND, clinical neurological deterioration; MRS, 
Modified Rankin Scale score at 3 and 12 months: Unfavorable (3-6), Favorable (0-2); § Multivariate analysis included 
correction for age, sex, race, and either Fisher grade (for acute outcomes) or Hunt & Hess score (for long-term 
outcomes); *Statistical significance established at *p<0.05 or **p<0.0042 (for multiple comparison correction)  
 
4.3.9 20-HETE levels in genetic groups 
A comparison of 20-HETE CSF levels in acute and long-term outcome groups is shown in Figure 
Gene Genotype CND (+) CND (-) Unadjusted
SNP (rs#) N (% ) N (% ) P-value OR (95%  CI) P-value
Overall 0.138
CYP4F2 TT 77 (60.6) 50 (39.4) Reference -
g.4593T>C TC 59 (56.7) 45 (43.3) 0.82 (0.46-1.44) 0.482
(rs3093089)‡ CC 16 (44.4) 20 (55.6) 0.44 (0.20-0.99) 0.047*
C-carriers 75 (53.6) 65 (46.4) 0.245 0.70 (0.41-1.17) 0.175
Gene Genotype MRS3 (3-6) MRS3 (0-2) Unadjusted
SNP (rs#) N (% ) N (% ) P-value OR (95%  CI) P-value
Overall 0.025*
CYP4A11 GG 31 (23) 106 (77) Reference -
g.13414G>C GC 31 (42) 43 (58) 2.43 (1.28-4.62) 0.007*
(rs3890011)‡ CC 0 (0) 6 (100) - 0.999
C-carriers 31 (39) 49 (61) 0.011* 2.12 (1.13-3.99) 0.019*
Overall 0.055
CYP4F2 AA 22 (40) 33 (60) Reference -
g.4211A>T TA 25 (23) 82 (77) 0.42 (0.2-0.89) 0.023*
(rs3093156)‡ TT 15 (27) 41 (73) 0.44 (0.19-1.03) 0.059
T-carriers 40 (25) 123 (75) 0.028* 0.43 (0.21-0.85) 0.016*
Overall 0.055
CYP4F2 CC 23 (25) 69 (75) Reference -
g.8575C>T CT 26 (26) 74 (74) 1.21 (0.61-2.41) 0.579
(rs3093168)‡ TT 12 (46) 14 (54) 3.30 (1.23-8.83) 0.017*
T-carriers 38 (30) 88 (70) 0.402 1.51 (0.8-2.88) 0.206
Gene Genotype MRS12 (3-6) MRS12 (0-2) Unadjusted
SNP (rs#) N (% ) N (% ) P-value OR (95%  CI) P-value
Overall 0.067
CYP4A11 GG 29 (21) 108 (79) Reference -
g.13414G>C GC 27 (40) 41 (61) 2.22 (1.13-4.34) 0.020*
(rs3890011)‡ CC 0 (0) 5 (100) - 0.999











4-9: 20-HETE CSF levels in acute and long-term outcome groups.  CYP4A11-g.4207G allele-
carriers had 43% lower mean 20-HETE levels when compared to CYP4A11-g.4207A/A carriers 
(p=0.005).  20-HETE levels were not associated with genotype in the codominant model.  The 
most common CYP4F2 haplotype (Haplotype 1) was CTCAC (31.9%) for rs3093089, rs3093156, 
rs3093168, rs3093207, and rs2108622, respectively.  Compared to Haplotype 1, haplotype 4 
(TTCGT, 9.5%) was associated with 0.26 ng/ml lower 20-HETE (p=0.034), but there were no 
differences in other haplotype groups.   
 
 
Figure 4-9: 20-HETE CSF levels in acute and long-term outcome groups 
Mean (panel A) and maximum (panel B) 20-HETE levels in CSF from patients with SAH are compared in outcomes 
groups.  Acute outcomes (solid bars) included the presence or absence of clinical neurological deterioration (CND) 
and/or delayed cerebral ischemia (DCI) up to 14 days after the hemorrhage.  Long-term outcomes (stripped bars) were 
determined by global functional recovery at 3 and 12 months using the Modified Rankin Scale (MRS) and were 
dichotomized into favorable (MRS 0-2) and unfavorable (MRS 3-6) groups.  The mean and maximum 20-HETE CSF 
levels for each patient (n=269) were calculated and were used to compare the mean ± SEM of the CYP eicosanoid 
levels in outcome groups using t-test with Welch’s correction as appropriate.  Statistical significance established at 





This clinical study is the first to investigate the relationship between SNPs in 20-HETE synthesis 
genes, 20-HETE CSF levels, and acute/long-term outcomes in a large SAH cohort.  We report that 
higher 20-HETE CSF levels and trajectory patterns were associated with unfavorable acute and 
long-term outcomes before and after controlling for age, sex, race, and Fisher grade or HH score.  
Also, SNPs in 20-HETE synthesis genes were associated with long-term outcomes and showed 
different frequencies compared to control populations in Hapmap.  Collectively, these results 
demonstrate the translational importance of 20-HETE in pathophysiology of SAH.   
Growing evidence suggests that 20-HETE contributes to the pathophysiology of SAH 
along with other biomarkers.317   We observed that CYP-eicosanoids are present in SAH patients 
at concentrations reported to affect cerebrovascular function.  20-HETE constricts isolated cat and 
rat cerebral arteries at 0.1 nM (0.032 ng/ml) and 10 nM (3.2 ng/ml) concentrations, respectively.590, 
614 A dog model of SAH-induced DCI was associated with 20-HETE CSF levels of ~1.2 nM.620  
Our clinical study reports maximum 20-HETE, EET, and DHET CSF concentration of ~1.0, 0.5, 
and 7.3 nM, respectively, which are comparable to levels reported to alter cerebrovascular tone.  
Moreover, it is expected that CYP-eicosanoid levels in the cerebrovasculature are higher than those 
in CSF.356  These results suggest that CYP-eicosanoids are present at physiologically relevant 
levels in the brain after SAH in humans.  
We observed that elevated 20-HETE CSF levels and temporal concentration profiles were 
associated with CND, but not DCI, both before and after adjustment for covariates.  Patients with 
high/moderate 20-HETE trajectory patterns developed CND earlier and to a greater extent than 
those in the low group.  20-HETE generally reached maximum levels before the onset of CND in 
first few days after SAH, suggesting that 20-HETE may contribute to secondary ischemic insults.  
The terms used to describe the delayed onset of cerebral ischemia and neurological deterioration 
after SAH are inconsistent and often used interchangeably in clinical studies.160  Roman et al. 
reported that nine SAH patients with angiographic vasospasm and neurological deficits had 
elevated 20-HETE CSF levels compared to controls.620  Similarly, our lab reported that detectable 
20-HETE in CSF was associated with DCI in a smaller SAH cohort.642, 762  In these studies, 
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multivariate analyses were not performed and 20-HETE was measured in fresh CSF using a less 
sensitive quantitation method with dichotomization of patients into detectible and non-detectible 
groups.  Also, growing evidence suggests that cerebral vasospasm in large arteries plays a limited 
role in DCI after SAH.216  20-HETE is a primary regulator of cerebral microvasculature tone356 
and therefore may affect CND to a greater extent than DCI after SAH.224  Future studies are needed 
to delineate the temporal relationships between 20-HETE CSF levels, 
microvascular/macrovascular tone, and regional CBF after SAH.  
We observed that increased 20-HETE CSF levels were associated with unfavorable long-
term outcomes.  Since CND is a strong prognostic factor for unfavorable long-term outcomes after 
SAH150, it is possible that 20-HETE is a causative factor in this relationship.  Conversely, the 
effects of 20-HETE on long-term outcomes may be mediated through inflammation, vascular 
remodeling, or other mechanisms that occur at various time periods after SAH.355  Future studies 
are needed to elucidate the mechanisms involved in the relationship between 20-HETE and long-
term outcomes after SAH.    
We observed previously established relationships between Fisher grade, HH score, and 
increasing age with acute and/or long-term outcomes.765, 770  20-HETE was associated with 
ventricular hemorrhage but not the severity of hemorrhage. Since 20-HETE is released from white 
blood cells and vascular tissue356, it is difficult to determine the source of 20-HETE in CSF.  
Nevertheless, the multivariate analysis showed that 20-HETE CSF levels/trajectory groups 
remained strong predictors of outcomes with comparable prognostic ability as Fisher grade and 
HH score, respectively.  Collectively, these studies suggest that 20-HETE may serve as a potential 
biomarker of acute and long-term outcomes in patients with SAH.  
Our genetic integrity tests show that multiple gene variants on CYP4F2 violated HWE 
conditions possibly due to enrichment in the SAH population.  Many of the SNPs that violated 
HWE conditions also showed genotype frequencies in our SAH population that were different than 
those in the Hapmap CEU population, suggesting putative genetic markers for the formation and 
rupture of intracranial aneurysms.  Previous studies report a strong link between hypertension and 
vascular remodeling with the incidence of SAH.124  20-HETE elicits a wide array of effects 
including regulation of blood pressure, CBF, and vascular remodeling.355, 356  Thus, it is expected 
that CYP4F2 variants that lead to alterations in 20-HETE may impact the occurrence of SAH 
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possibly through its effects on blood pressure, cerebrovascular tone, and vascular homeostasis.   
The CYP4F2 putative genetic markers for SAH identified in this study were not associated 
with altered 20-HETE CSF levels, but previous in vitro studies associated the CYP4F2 variants 
g.14389C>T [*3], g.5373T>C, and g.5416G>C with reduced enzymatic activity, reduced 
transcriptional activity, and increased transcriptional activity, respectively.648, 649, 651  Interpretation 
of our results is difficult because of the discrepant in vitro/in vivo findings on the effect of 
CYP4F3*3 on 20-HETE levels and 20-HETE levels on vascular remodeling.355, 682  Also, it is 
possible that the genotype frequencies observed in our SAH population were different than those 
in the Hapmap CEU population due to differences in genotyping methods. Thus, the effects of 
CYP4F2 gene variants and 20-HETE on the formation and rupture of intracranial aneurysms 
warrants further investigation.    
Our genetic analysis showed that patients with the variant g.4207G-allele located in the 
promoter region of CYP4A11 showed 43% lower mean 20-HETE CSF levels.  In-silico models 
predicted that this SNP will lower CYP4A11 transcriptional activity.771  When the CYP4A11 
g.4207G/G (c.-825G/G) mutant construct was expressed in vitro, CYP4A11 transcriptional 
activity was reduced by ~30% compared to the WT-construct.646  Based on these studies, we expect 
that patients with the variant CYP4A11 g.4207G-allele would have decreased 20-HETE CSF 
levels, which is consistent with our results.   
Multiple tSNPs in CYP4F2 and CYP4A11 were associated with acute and long-term 
outcomes.  Patients with the variant CYP4F2 g.4593C/C genotype were 2.3-fold less likely to 
develop CND compared to those with g.4593T/T genotype in the multivariate analysis.  In a study 
of Chinese hypertensive patients, no association was observed between the CYP4F2 g.4593T>C 
polymorphism and both urinary 20-HETE levels and hypertension.683  Thus factors other than 20-
HETE may mediate the lower risk to develop CND in patients with the variant CYP4F2 g.4593C/C 
genotype.  We report that CYP4A11 g.13414C allele-carriers were ~2-fold more likely to develop 
unfavorable outcomes at 3 and 12 months.  Also, patients with the variant CYP4F2 g.4211T allele 
or CYP4F2 g.8575T/T genotype were ~2.4-fold less likely and ~3.3-fold more likely to have 
unfavorable outcomes at 3 months, respectively.  These tSNPs are located at the intron regions of 
CYP4A11 or CYP4A11 and are not likely to alter enzyme expression or activity.  However, these 
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tSNPs may be linkage disequilibrium with fSNPs or contribute to haplotype constructs and thus 
may serve as surrogate genetic markers for clinical phenotypes.   
We also note some limitations of our results.  First, our biomarker assessment was 
performed only in patients with ventricular drains that commonly have more significant 
hemorrhage than those without ventricular drains.  20-HETE CSF levels represent time-averaged 
values during the 12hr collection period.  20-HETE levels in the cerebrovasculature were not 
measured but are expected to be higher than CSF levels.  Also, our findings implicate regions of 
association and not necessarily causative genetic variation. 
4.5 CONCLUSIONS 
In summary, 20-HETE has been shown to play an important role in the regulation of 
cerebrovascular tone and vessel remodeling in vitro and significantly affect CBF and cerebral 
ischemic injury in vivo.  Our study, involving one of the largest SAH cohorts to date, implicates 
20-HETE and CYP4F2 gene variants in the risk for SAH and subsequent acute and long-term 
outcomes.  These results are important to help elucidate the mechanisms involved in the 
pathophysiology of SAH and possibly identify patients at high risk for unfavorable outcomes; 




5.0  CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1 CONCLUSIONS 
5.1.1 Summary of research goals 
The primary goal of this research was to investigate the role of CYP eicosanoids in the 
pathophysiology of SAH.  This was achieved by investigating key polymorphisms in the genes 
responsible for CYP eicosanoid synthesis and metabolism and their relationship to CYP eicosanoid 
levels in CSF, ischemic complications during the inpatient stay, and long-term functional 
outcomes at 3 and 12 months in a large SAH cohort.  Similarly, the relationship between CYP 
eicosanoid CSF levels and acute/long-term outcomes was also determined.  In order to accomplish 
these goals, we first set out to develop and validate a sensitive analytical method to measure CYP 
eicosanoid levels in CSF and then modified this assay in order to improve our ability to evaluate 
temporal concentration profiles.  Key findings from this research are summarized below.   
5.1.2 Key research findings 
In the first part of this research, we developed and validated a rapid, sensitive, and specific UPLC-
MS/MS method for measuring CYP eicosanoids in CSF from SAH patients.  Linear calibration 
curves ranged from 0.208-33.3 ng/ml and the matrix did not affect the accuracy or precision of the 
assay.  Then, we modified this method to lower detection limits from 0.208 ng/ml to 0.028 ng/ml, 
thus significantly improving our ability to develop temporal concentration profiles.  Modifications 
included utilizing larger volumes of CSF available in the drainage bags and modifications to our 
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sample processing methods.  We also established room temperature stability of the CYP 
eicosanoids over the 12 hour collection period and measured the recovery from the collection bags.  
These findings were critical to accomplish the other goals of our research.   
Next, we investigated the relationships between key polymorphisms in the genes 
responsible for EET synthesis and metabolism, EET and DHET CSF levels, acute ischemic 
complications (CND and DCI), and long-term functional outcomes as determined by MRS at 3 
and 12 months.  We report that patients with the CYP2C8*4 allele had 44% and 36% lower EET 
and DHET CSF levels and were 2.2- and 2.5-fold more likely to develop DCI and CND, 
respectively.  We identified a few candidate gene variants that were associated with altered EET 
and/or DHET CSF levels and favorable or unfavorable outcomes.  Many of these polymorphisms 
were previously reported to affect gene expression, protein levels or activity in vitro and our 
results generally agreed with the expected impact of these gene variants on CYP eicosanoid CSF 
levels and outcomes in our SAH cohort.  Also, EET levels were associated with the 
severity/location of the hemorrhage and poor 3-month outcomes, but DHET levels and trajectory 
patterns were not associated with outcomes.  These are the first clinical data demonstrating the 
association between the EET biosynthesis/metabolic pathway and the pathophysiology of SAH. 
Finally, we investigated the relationships between key polymorphisms in the genes 
responsible for 20-HETE synthesis, 20-HETE CSF levels, acute ischemic complications (CND 
and DCI), and long-term functional outcomes as determined by MRS at 3 and 12 months.  
Patients with CND and unfavorable 3-month MRS had ~2.2- and 2.7-fold higher mean 20-HETE 
CSF levels, respectively. 20-HETE CSF levels were described by three trajectory groups with 
decreasing concentrations over time.  Patients in high/moderate 20-HETE trajectory groups were 
2.1-, 2.5-, and 2.1-fold more likely to have CND and unfavorable MRS at 3 and 12 months after 
controlling for age, sex, race, and Fisher grade or Hunt & Hess score.  We identified a few 
candidate gene variants that were associated with altered 20-HETE CSF levels and favorable or 
unfavorable outcomes.  Many of these polymorphisms were previously reported to affect gene 
expression, protein levels or activity in vitro and our results generally agreed with the expected 
impact of these gene variants on CYP eicosanoid CSF levels and outcomes in our SAH cohort.  
Furthermore, several CYP4F2 genotype frequencies in our SAH population differed from the 
Hapmap CEU database indicating putative genetic markers for SAH risk.  These findings in 
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SAH patients support the emerging role of 20-HETE in cerebral microvascular dysregulation 
after a neurovascular hemorrhage and implicates this pathway as a target for future intervention. 
5.2 FUTURE DIRECTIONS 
5.2.1 Future Studies and Potential Areas for Improvement 
The source of CYP eicosanoids in CSF after SAH has not been studied extensively.  Recently, 
Alkayed et al. reported that SAH patients with DCI had low EET CSF levels that increased over 
14 days.772 These results suggest that EETs may be produced and secreted into CSF following 
SAH in humans.  Conversely, the same study reported that 20-HETE CSF levels were high early 
after SAH and decreased over 14 days in SAH patients with DCI.772  Our study reported a similar 
trends with 20-HETE CSF levels over time.  These temporal concentration profiles suggest that 
20-HETE could be released directly from the vascular tissue at aneurysm rupture, extravasated 
blood, or the breakdown of blood after SAH.  In addition, preclinical studies have shown that 20-
HETE is released from white blood cells and vascular tissue.356   On the other hand, evidence from 
this study shows that 20-HETE CSF levels were not associated with the severity of hemorrhage as 
determined by Fisher grade.  Although the Fisher Scale is the most commonly used clinical grading 
method used to predict vasospasm after SAH, disadvantages of the Fisher Scale includes scoring 
criteria developed using old imaging technology, unclear and subjective classifications, and 
exclusion of certain characteristics of the bleed such as clot density and clearance rate.278  Thus, 
Fisher grade has limited ability to accurately measure the amount and location of blood over time.  
These limitations make it difficult to determine the relationship of CYP eicosanoid levels with 
hemorrhagic factors and limit our ability to determine source of CYP eicosanoids in CSF after 
SAH.   
In order to further investigate the source of CYP eicosanoids in CSF after SAH in humans, 
it may be valuable to measure the concentration of blood constituents and blood breakdown 
products to assess the degree of bleed more accurately than Fisher grade.  Levels of blood 
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constituents such as red blood cells, white blood cells, and platelets can be measured using standard 
blood count panels.  Blood breakdown products such as bilirubin, oxyhemoglobin, and 
methemoglobin can be measured using spectrophotometry.  These spectrophotometry methods are 
commonly used to diagnose SAH by quantify the level of xanthochromia (yellow appearance) in 
CSF due to the presence of blood breakdown products.  If these methods were employed in this 
clinical study, the relationship between the temporal concentration profiles of blood constituents 
and blood breakdown products in CSF from SAH patients and CYP eicosanoid levels could be 
investigated.  These investigations may help elucidate the primary source of CYP eicosanoid 
release in CSF after SAH in humans.   
Until recently, there were no published clinical studies investigating the relationship of 
CYP eicosanoid levels over time with outcomes after SAH.  A few months ago, Alkayed et al. 
published a study that showed similar trends in 20-HETE CSF levels over time when compared to 
our study.772  Although our study showed limited ability to measure EETs, the stable EET 
metabolites 11,12-DHET and 14,15-DHET, but not 8,9-DHET, appeared to show similar temporal 
concentration profiles to those reported by Alkayed et al.  Since the 8,9-DHET levels were 
significantly higher than those of the other DHET regioisomers, the overall DHET temporal 
concentration profiles appeared to parallel those of 8,9-DHET.  However, our study did not 
perform trajectory analysis of the individual CYP eicosanoid regioisomers. Thus, the analysis of 
our study should be extended to include an evaluation of the CYP eicosanoid regioisomer 
concentration over time and their relationship to clinical outcomes.   
Despite our significant efforts to develop robust experimental methods and analyses, 
numerous areas of our research project can be modified and evaluated for potential improvements.  
For instance, other studies have reported alternative methods of CSF collection and preparation.  
Alkayed et al. collected 3ml of CSF directly from the ventricles instead of the drainage bags and 
measured CYP eicosanoids using our method with minor modifications to the sample 
preparation.772  An evaluation of these methods may be beneficial since a significant number of 
CSF samples from SAH patients showed quantifiable EET levels in this study.772  In order to 
further address our limited ability to measure EETs in CSF from SAH patients, we could add an 
SEH inhibitor to the CSF sample immediately after collection in an effort to limit the conversion 
of EETs to DHETs.  Currently, it was unknown whether increased DHET concentrations are the 
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result of increased EET availability or increased SEH expression after SAH.  In order to address 
this issue, previous studies have measured 9,10-epoxyoctadecenoic acid (9,10-EpOME) and 9,10-
Dihydroxyoctadecenoate (9,10-DiHOME) as surrogate markers of EETs and DHETs and 
evaluated the changes in 9,10-DiHOME/9,10-EpOME ratio after SAH.773  This study also 
measured 9,10-EpOME and 9,10-DiHOME in a subset of our SAH cohort, but further analysis has 
not yet been completed. Since we did not have access to control CSF, we were not able to compare 
control levels of CYP eicosanoids to those of SAH patients.  However, others reported that CYP 
eicosanoids were below LLQ for all control CSF samples.620, 772 In a similar fashion, we could 
genotype control patients with similar demographic factors (age, sex, race, etc.) to our SAH 
patients instead of using genetic data from the Caucasian (CEU) population in the Hapmap 
database for our analyses.  Furthermore, we could perform full sequencing of our candidate genes 
instead of limiting our study to include the analysis of only functional and tagging SNPs.  Finally, 
we can improve the clinical utility of our studies by expanding our analysis to include an 
assessment and evaluation of concomitant medications and medical conditions and their 
relationship with CYP eicosanoid levels and outcomes in SAH patients.  In summary, limitations 
of this clinical study can be potentially be addressed or improved with modifications to our 
experimental methods and additional analyses.   
5.2.2 Pharmacological agents targeting the CYP eicosanoid pathway 
Drug candidates targeting the EET metabolic pathway show promise for the treatment of SAH and 
CVD in general.  Hammock et al. provides an excellent review discussing the history, rationale, 
and status of the development of pharmaceutical agents targeting the EET metabolic pathway.609  
The beneficial actions of EETs can be enhanced or increased by utilizing EET agonists or SEH 
inhibitors to inhibit of EET metabolism.  The potential benefits of an EET agonist includes the 
initiation of biological action in the absence of endogenous EETs, extended half-life when 
compared to endogenous EETs, and the flexibility to attain supraphysiological levels and 
responses if desired.  Advantages of SEH inhibitors include the extended half-life of endogenous 
EETs present in the stereo- and regio-specific EET isomers unique to each tissue.  Also, the 
biological effects of SEH inhibitors are limited by the level of endogenous EETs thus reducing the 
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risk for potential side effects.  On the other hand, disadvantages of using EET agonists include 
differences between endogenous stereo- and regio-specific EET isomer formation and differences 
in tissue specific levels when compared to endogenous EET formation.  Disadvantages of SEH 
inhibitors include a limited biological response and increase in alternative metabolic pathways 
such as -oxidation.  Currently, there are no FDA approved SEH inhibitors or EET agonists, 
however numerous compounds are in various stages of development.  Based on the wide 
therapeutic index presented by SEH inhibitors, it is likely that one of these compounds will be 
approved for the prevention or treatment of chronic vascular conditions such as hypertension or 
ischemic complications after SAH.   
Candidates targeting 20-HETE synthesis appear less promising compared to SEH 
inhibitors.  For instance, many inhibitors of 20-HETE synthesis, such as DDMS and 17-ODYA, 
have limited potency and selectivity.  These compounds along with the 20-HETE antagonist 
WIT002 are highly protein bound and have minimal bioavailability when delivered systemically.  
HET0016 is a potent and selective 20-HETE synthesis inhibitor, but has a short half-life with 
limited solubility.  Among the -hydrolase inhibitors, TS-011 demonstrates superior potency and 
selectivity along with sufficient bioavailability and half-life in preclinical studies.589  Therefore, 
TS-011 appears to be one of the most promising 20-HETE synthesis inhibitors for clinical 
development.  Currently, phase I clinical trials for the use of TS-011 in acute ischemic stroke 
patients is underway.  
Numerous factors must be considered when targeting CYP eicosanoid pathways for 
pharmacological intervention.  Since AA is metabolized by multiple enzymatic pathways, it is 
possible that inhibition of one enzymatic pathway may lead to shunting to another pathway through 
increased substrate availability.  To illustrate, a few studies reported that inhibition of COX 
enzymes leads to shunting of AA metabolism to CYP and LOX pathways.  Ren et al. reported that 
administration of the COX inhibitor indomethacin to isolated rabbit afferent arterioles led to an 
increase in 20-HETE levels.774  Similarly, Hammock et al. reported that oral administration of the 
selective COX-2 inhibitor rofecoxib (Vioxx) to mice for 3 months resulted in a 120-fold increase 
in 20-HETE levels in plasma and shorter bleeding times.775  Based on these data, it is also expected 
that inhibition of CYP enzymes responsible for 20-HETE and EET formation may lead to 
increased COX and LOX metabolites through shunting of AA metabolism.  Therefore, the impact 
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of CYP eicosanoid inhibition on the formation of COX and LOX metabolites warrants further 
clinical investigation.   
Similarly, a wide variety of endogenous substrates and drugs are metabolized by CYP 
eicosanoid enzymes and thus inhibition of these enzymes may lead to considerable side effects.  
As discussed in Section 1.5.3, CYP eicosanoid enzymes are responsible for the metabolism of 
medium chain (C10-C16) and long chain (C16-C26) fatty acids leading a wide array of metabolites 
that exhibit diverse biological actions and play important roles in numerous diseases.776  For 
example, one of the primary endogenous substrates of CYP4F2 is leukotriene B4 (LTB4), which is 
a chemotactic agent involved in inflammation.777 Thus, inhibition of CYP4F2 would be expected 
to alter the termination of the inflammatory response mediated by CYP4F2.  In addition, numerous 
FDA approved drugs are metabolized by CYP eicosanoid enzymes.  CYP2C8 and CYP2C9 are 
responsible for the metabolic clearance of up to 5% and 15%-20%, respectively, of all drugs 
undergoing Phase I metabolism.458, 559, 560  Therefore, it is possible that pre- or post-admission use 
of medications may impact endogenous CYP eicosanoid formation.  Alternatively, inhibition of 
the CYP eicosanoid pathway may also lead to potentially important drug-drug interactions.  As a 
result, the benefit of pharmacological agents targeting the CYP eicosanoid pathway should be 
compared to the potential side effects or drug-drug interactions associated with these target 
enzymes.   
Alternatively, altered CYP eicosanoid levels may be achieved through dietary -3 
supplementation.  Enzymes involved in the synthesis of CYP eicosanoids have recently been 
reported to preferentially metabolize -3 polyunsaturated fatty acids (PUFAs) such as 
eicosapentanoic acid (EPA) and docosahexaenoic acid (DHA) over AA.778  EPA and DHA 
promote vasodilation and reduce inflammation, thrombosis, and triglycerides and diets rich in -
3 PUFAs have been associated with protection against CVD.779  The mechanisms of -3 PUFA 
action on CVD are not fully understood, but some have argued that the reduction in -6 eicosanoid 
biosynthesis due to competitive inhibition of COX, LOX, and CYP enzymes by -3 PUFAs 
substrates plays an important role.778, 780, 781 The effect of -3 PUFAs on cerebrovascular tone and 
CBF regulation have not been studied extensively, but it is reported that 17(R),18(S)-EEQ, an 
epoxide metabolite of EPA, is a more potent vasodilator of rat cerebral arteries than 11(R),12(S)-
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EET.782  Therefore, it is expected that administration of -3 supplements may reduce the risk for 
SAH and improve outcomes in SAH patients by reducing the formation of -6 PUFAs.  
 
 
5.2.3 Expected trends and research focused on SAH 
It is expected that advances in the treatment of SAH will continue to focus on CND and DCI due 
to their strong associations with outcomes, the time window for therapeutic intervention, the 
reversible nature of these conditions, the marginal efficacy of existing pharmacotherapies, and the 
high risk presented by aggressive treatments.  As explained in Section 1.1.3, AHA recommends 
the administration of oral nimodipine to all SAH patients and induction of hypertension in patients 
that develop DCI.  These therapies can significantly affect cerebral hemodynamics and are 
effective in preventing or treating the development of the delayed onset of ischemic complications.  
However, recent evidence suggests that the efficacy of induced hypertension in SAH patients with 
DCI is closely linked to their autoregulatory status.783  Therefore, future studies are needed to 
individualize treatment modalities based on autoregulatory status and other factors.   
It is also expected that future experimental and clinical studies of SAH will focus on the 
cerebral microcirculation.  As explained in section 1.1.4, growing evidence suggests that 
vasospasm in large cerebral arteries plays a limited role in the development of DCI after SAH.216  
Some studies suggest that microvasculature plays a predominant role in regulating CBF 
regulation222, 223, especially after SAH224, and imaging technologies provide direct evidence of 
microvascular vasospasm in humans after SAH225, 226.  Moreover, the definition of DCI should 
account for clinically relevant alterations in both macrocirculation and microcirculation that lead 
to ischemia.160  Thus, the relative contribution of the microcirculation and macrocirculation to the 
regulation of CBF after SAH has not been well studied and thus presents a promising area of future 
research.   
Moreover, CBF regulation after SAH is a complex process involving the interaction 
between mechanical factors presented by the hemorrhage, altered metabolic needs of brain tissue, 
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loss of cerebral autoregulation due to altered myogenic response and neurovascular coupling, 
structural alterations of cells by edema, inflammation, and oxidative stress, and cell death by 
necrosis and apoptotic mechanisms.  However, few clinical studies have investigated the 
interaction of these factors.  Therefore, it is likely that future studies will combine multiple 
structural and physiological measurements with clinical findings. 
It is expected that clinical grading scales will continue to be the most clinically relevant 
prognostic indicators of acute and long-term outcomes after SAH.  As discussed in Section 1.1.7, 
advantages of clinical grading scales include history of use, simple grading criteria, and moderate 
sensitivity and specificity as prognostic indicators. Disadvantages presented by clinical grading 
scales includes poor inter-rater reliability due to subjective and broad grading criteria and 
inconsistent timing of use.  A genetic marker would be an ideal prognostic factor based on 
consistent genotyping results, inexpensive methods, and the ability to apply the predictive tool at 
any time before or after the injury.  However, no genetic markers have demonstrated sensitive and 
specific prediction of DCI in large and/or diverse SAH cohorts.  Potential advantages presented 
by biomarkers include the ability to elucidate the pathogenic mechanisms, identify early indicators 
of complications, and evaluate the temporal effects of the biomarker levels over the clinical course 
of SAH injury.  However, biochemical markers would not be expected to be a clinically relevant 
prognostic indicator because the cost and time required for the assessment and the difficulty in 
determining if the biomarker is a causal factor or indicator of injury.  In order for any of these 
potential prognostic factors to be widely accepted in the clinic, their predictive ability would need 
to be classified and validated according to criteria previously described in studies evaluating 
genetic784, 785, biomarker318, 786, 787, clinical grading scales788, and combinations of prognostic 
factors and other clinical criteria789-791. 
Currently, there is a lack of understanding of the underlying mechanisms by which CYP 
eicosanoids are synthesized/metabolized and affect CBF and injury after SAH.  For instance, the 
source of CYP eicosanoids in CSF after SAH is currently unknown.  Likewise, there is a lack of 
understanding of the mechanisms leading to the altered CYP eicosanoid synthesis by the release 
of plasmogens from blood in the CSF after SAH.   The interaction of CYP eicosanoids with other 
vasoactive compounds and their relative contribution to the pathophysiology of SAH should be 
further investigated.  In addition, the predominant metabolite of 20-HETE has not been identified 
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and it is unknown if 20-HETE elicits its vasoconstrictive effects directly or through further 
metabolism to COX metabolites.621, 792  More importantly, the 20-HETE and EET receptors should 
be identified and targeted for pharmacological intervention after SAH.  Further investigation in 
these areas would greatly enhance our understanding of the biological mechanisms of CYP 
eicosanoids in SAH.  
5.2.4 Focus on Translational Research  
The development of a drug is a costly and high-risk process with high failure rates.  The average 
length of time from target discovery to approval of a new drug currently averages about 13 years, 
the failure rate exceeds 95%, and the cost per successful drug exceeds $1 billion, after adjusting 
for all of the failures.793  Recently, the National Institute of Health (NIH) formed the National 
Center for Advancing Translational Sciences (NCATS) in order to address common barriers to 
clinical and translational research, develop innovative and effective therapies, and transform 
healthcare.  One of the key elements of the NCATS approach is to develop and support innovative 
collaborations across traditionally separate scientific disciplines and convene teams with diverse 
expertise to reduce, remove or bypass significant bottlenecks in translational sciences.794  The 
clinical project discussed in this dissertation utilized this key NCATS element of diverse 
collaboration by including a team of researchers with expertise in biomarker analysis, genetics, 
statistics, neuroscience and neurosurgery, nursing and critical care medicine, and stroke research 
and outcomes assessments.  On the other hand, the NCATS approach would most likely identify 
the limited number of promising drug candidates for the treatment of DCI after SAH as a barrier 
to translational sciences.  In addition, the NCATS approach would likely identify the modifiable 
risk factors for SAH as a key target for the prevention SAH.  In summary, the strategies and 
methods presented by NCATS can be used to identify barriers to clinical research focused on SAH 




APPENDIX A: EFFECT OF PROCESSING MODIFICATIONS ON UPLC-MS/MS 
PEAK RESPONSE TO MEASURE CYP EICOSANOIDS 
 
Peak response was expressed as mean peak area ± SD and data were normalized to the values 
observed using our published method (1 ml load volume and 125 µl reconstitution volume). 
Load Volume 1 ml 1 ml 3 ml 3 ml
Reconstitution Volume 125 ml 50 ml 125 ml 50 ml
Theoretical Fold 
Increase
- 2.5 3 7.5
20-HETE-d6 1.00 ± 0.04 2.46 ± 0.15 2.81 ± 0.20 7.08 ± 0.47
20-HETE 1.00 ± 0.11 3.30 ± 0.27 3.60 ± 0.39 10.00 ± 0.59
14,15-EET 1.00 ± 0.06 3.01 ± 0.31 3.66 ± 0.33 9.35 ± 1.06
11,12-EET 1.00 ± 0.12 2.67 ± 0.50 3.42 ± 0.51 9.06 ± 1.02
8,9-EET 1.00 ± 0.19 3.46 ± 0.83 3.96 ± 0.75 11.62 ± 2.52
14,15-DHET 1.00 ± 0.05 2.69 ± 0.22 3.07 ± 0.23 8.96 ± 0.75
11,12-DHET 1.00 ± 0.07 2.70 ± 0.14 2.91 ± 0.29 8.07 ± 0.80
8,9-DHET 1.00 ± 0.14 2.86 ± 0.30 3.12 ± 0.38 8.41 ± 1.02
5,6-DHET 1.00 ± 0.04 2.52 ± 0.18 2.85 ± 0.12 7.54 ± 0.51
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APPENDIX B: 20-HETE CSF LEVELS IN GENETIC GROUPS 
 
Gene rs# Genotype N
Mean 20-HETE 
(ng/ml)
P-value Max. 20-HETE (ng/ml) P-value
g.4207AA 185 0.117 ± 0.018 0.346 ± 0.053
g.4207G-carriers 35 0.061 ± 0.008 0.228 ± 0.060
g.13661G>A 5 0.080 ± 0.042 0.418 ± 0.322
g.13661A-carriers 172 0.114 ± 0.018 0.3273 ± 0.052
g.13414CC 132 0.117 ± 0.019 0.361 ± 0.066
g.13414G-carriers 84 0.099 ± 0.026 0.275 ± 0.058
g.14389CC 113 0.110 ± 0.022 0.352 ± 0.073
g.14389T-carriers 95 0.090 ± 0.014 0.286 ± 0.054
g.7222002GG 68 0.105 ± 0.023 0.319 ± 0.061
g.7222002A-carriers 150 0.112 ± 0.019 0.338 ± 0.061
g.5416GG 149 0.112 ± 0.02 0.330 ± 0.060
g.5416C-carriers 67 0.099 ± 0.022 0.311 ± 0.066
g.5373TT 152 0.112 ± 0.019 0.338 ± 0.060
g.5373C-carriers 68 0.100 ± 0.022 0.31 ± 0.065
g.5497T>C 159 0.110 ± 0.017 0.346 ± 0.057
g.5497C-carriers 60 0.093 ± 0.023 0.252 ± 0.050
g.4593TT 94 0.103 ± 0.022 0.293 ± 0.053
g.4593C-carriers 113 0.122 ± 0.023 0.380 ± 0.077
g.4211AA 58 0.129 ± 0.034 0.390 ± 0.081
g.4211T-carriers 160 0.103 ± 0.017 0.313 ± 0.056
g.8575TT 90 0.102 ± 0.020 0.332 ± 0.087
g.8575C-carriers 128 0.113 ± 0.022 0.328 ± 0.049
g.16162AA 100 0.126 ± 0.028 0.383 ± 0.083
g.16162G-carriers 120 0.095 ± 0.015 0.286 ± 0.047
*Statistical significance established at *p<0.05 
rs3093168 (‡) 0.721 0.968
rs3093207 (‡) 0.307 0.293
rs3093089 (‡) 0.554 0.37
rs3093156 (‡) 0.462 0.46
rs3093098 (†) 0.712 0.774
rs3093105 (†) 0.581 0.348CYP4F2
rs2108622 (†‡) 0.455 0.482
rs2189784 (†) 0.841 0.85
rs3093100 (†) 0.713 0.842
CYP4A11
rs9332978 (†) 0.005* 0.347
rs1126742 (†) 0.747 0.772
rs3890011 (‡) 0.561 0.364
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APPENDIX C: EET CSF LEVELS IN GENETIC GROUPS  
 
Gene rs# Genotype N Max. EET P-value Mean EET P-value
Mean ± SEM Mean ± SEM
(ng/ml) (ng/ml)
g.35506T/T 175 0.155 ± 0.024 0.076 ± 0.009
g.35506C-carriers 46 0.166 ± 0.036 0.077 ± 0.013
g.16136C/C 197 0.166 ± 0.022 0.080 ± 0.009
g.16136G-carriers 24 0.082 ± 0.021 0.045 ± 0.007
g.4825G/G 123 0.155 ± 0.023 0.077 ± 0.011
g.4825T-carriers 95 0.176 ± 0.038 0.078 ± 0.012
g.24879A/A 114 0.201 ± 0.036 0.091 ± 0.014
g.24879T-carriers 101 0.127 ± 0.019 0.063 ± 0.007
g.25369C/C 98 0.107 ± 0.017 0.057 ± 0.006
g.25369T-carriers 119 0.207 ± 0.035 0.091 ± 0.013
g.36755G/G 71 0.116 ± 0.021 0.061 ± 0.008
g.36755A-carriers 104 0.214 ± 0.039 0.099 ± 0.018
g.36785A/A 100 0.149 ± 0.024 0.069 ± 0.008
g.36785G-carriers 117 0.178 ± 0.034 0.085 ± 0.013
g.8633C/C 166 0.155 ± 0.025 0.076 ± 0.010
g.8633T-carriers 52 0.195 ± 0.038 0.082 ± 0.012
g.47639A/A 190 0.158 ± 0.022 0.076 ± 0.009
g.47639C-carriers 24 0.208 ± 0.069 0.090 ± 0.024
g.723T/T 72 0.149 ± 0.026 0.070 ± 0.009
g.723A-carriers 145 0.173 ± 0.029 0.082 ± 0.011
g.48012C/C 128 0.136 ± 0.019 0.067 ± 0.007
g.48012T-carriers 92 0.193 ± 0.042 0.090 ± 0.016
g.816A/A 85 0.136 ± 0.022 0.066 ± 0.008
g.816G-carriers 128 0.183 ± 0.032 0.083 ± 0.012
g.13788C/C 140 0.150 ± 0.027 0.076 ± 0.011
g.13788T-carriers 77 0.185 ± 0.032 0.076 ± 0.009
g.18470G/G 117 0.180 ± 0.034 0.086 ± 0.013
g.18470A-carriers 101 0.146 ± 0.022 0.068 ± 0.008
g.5276T/T 127 0.177 ± 0.029 0.080 ± 0.011
g.5276C-carriers 88 0.142 ± 0.031 0.072 ± 0.012
g.4930G/G 193 0.167 ± 0.023 0.078 ± 0.009
g.4930T-carriers 28 0.139 ± 0.038 0.075 ± 0.018
g.30345693C/C 87 0.179 ± 0.034 0.093 ± 0.017
g.30345693T-carriers 132 0.154 ± 0.027 0.067 ± 0.007
g.14742T/T 121 0.177 ± 0.032 0.078 ± 0.010
g.14742G-carriers 98 0.142 ± 0.024 0.073 ± 0.012
g.14861A/A 180 0.168 ± 0.024 0.081 ± 0.009
g.14861G-carriers 38 0.099 ± 0.025 0.047 ± 0.006
g.30221C/C 169 0.163 ± 0.024 0.076 ± 0.009
g.30221T-carriers 51 0.139 ± 0.039 0.078 ± 0.019
404Thr/Thr 202 0.164 ± 0.022 0.077 ± 0.008
404del-carriers 20 0.145 ± 0.048 0.076 ± 0.020
g.54788T/T 111 0.164 ± 0.028 0.079 ± 0.012
g.54788C-carriers 110 0.162 ± 0.031 0.075 ± 0.011
g.25690G/G 72 0.164 ± 0.036 0.080 ± 0.015
g.25690A/C-carriers 143 0.168 ± 0.027 0.078 ± 0.010
EET, epoxyeicosatrienoic acids; SEM, standard error of the mean; Max, maximum; 
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APPENDIX D: DHET CSF LEVELS IN GENETIC GROUPS  
 
Gene rs# Genotype N Max. DHET P-value Mean DHET P-value
Mean ± SEM Mean ± SEM
(ng/ml) (ng/ml)
g.35506T/T 175 2.601 ± 0.188 1.331 ± 0.090
g.35506C-carriers 46 2.518 ± 0.316 1.326 ± 0.180
g.16136C/C 197 2.658 ± 0.178 1.384 ± 0.089
g.16136G-carriers 24 1.968 ± 0.289 0.891 ± 0.107
g.4825G/G 123 2.920 ± 0.221 1.451 ± 0.113
g.4825T-carriers 95 2.253 ± 0.241 1.217 ± 0.116
g.24879A/A 114 2.736 ± 0.241 1.424 ± 0.117
g.24879T-carriers 101 2.514 ± 0.226 1.287 ± 0.115
g.25369C/C 98 2.429 ± 0.244 1.213 ± 0.119
g.25369T-carriers 119 2.779 ± 0.223 1.443 ± 0.111
g.36755G/G 71 2.448 ± 0.281 1.330 ± 0.150
g.36755A-carriers 104 2.862 ± 0.244 1.455 ± 0.124
g.36785A/A 100 2.942 ± 0.244 1.430 ± 0.124
g.36785G-carriers 117 2.294 ± 0.210 1.246 ± 0.103
g.8633C/C 166 2.616 ± 0.194 1.334 ± 0.093
g.8633T-carriers 52 2.673 ± 0.301 1.397 ± 0.167
g.47639A/A 190 2.610 ± 0.177 1.344 ± 0.088
g.47639C-carriers 24 2.881 ± 0.510 1.460 ± 0.245
g.723T/T 72 2.478 ± 0.261 1.359 ± 0.149
g.723A-carriers 145 2.650 ± 0.203 1.317 ± 0.094
g.48012C/C 128 2.803 ± 0.213 1.420 ± 0.108
g.48012T-carriers 92 2.292 ± 0.251 1.212 ± 0.120
g.816A/A 85 2.759 ± 0.262 1.412 ± 0.137
g.816G-carriers 128 2.464 ± 0.209 1.273 ± 0.098
g.13788C/C 140 2.626 ± 0.216 1.339 ± 0.106
g.13788T-carriers 77 2.612 ± 0.250 1.339 ± 0.125
g.18470G/G 117 2.751 ± 0.246 1.383 ± 0.116
g.18470A-carriers 101 2.488 ± 0.212 1.310 ± 0.114
g.5276T/T 127 2.603 ± 0.220 1.327 ± 0.106
g.5276C-carriers 88 2.708 ± 0.253 1.405 ± 0.131
g.4930G/G 193 2.680 ± 0.175 1.402 ± 0.089
g.4930T-carriers 28 2.083 ± 0.438 0.892 ± 0.145
g.30345693C/C 87 2.558 ± 0.237 1.308 ± 0.120
g.30345693T-carriers 132 2.663 ± 0.223 1.372 ± 0.109
g.14742T/T 121 2.722 ± 0.226 1.400 ± 0.111
g.14742G-carriers 98 2.428 ± 0.237 1.249 ± 0.117
g.14861A/A 180 2.460 ± 0.168 1.293 ± 0.089
g.14861G-carriers 38 3.184 ± 0.493 1.483 ± 0.198
g.30221C/C 169 2.631 ± 0.187 1.377 ± 0.098
g.30221T-carriers 51 2.450 ± 0.332 1.186 ± 0.128
404Thr/Thr 202 2.653 ± 0.170 1.371 ± 0.086
404del-carriers 20 2.038 ± 0.523 0.984 ± 0.189
g.54788T/T 111 2.486 ± 0.209 1.307 ± 0.115
g.54788C-carriers 110 2.708 ± 0.251 1.362 ± 0.114
g.25690G/G 72 2.587 ± 0.290 1.256 ± 0.129
g.25690A/C-carriers 143 2.587 ± 0.195 1.354 ± 0.100
DHET, dihydroxyeicosatetraenoic acid (DHET); SEM, standard error of the mean; Max, maximum; 
c






































x-axis: DHET levels (ng/ml); y-axis: frequency of CSF samples  
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